The University of Chicago Header Logo

George Bakris

TitleProfessor
InstitutionUniversity of Chicago
DepartmentMedicine-Endocrinology
AddressChicago IL 60637
Phone+1 (773) 702-7936
Email
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Director, ASH Comprehensive Hypertension Center

    Collapse Biography 
    Collapse awards and honors
    2014Astra Zeneca Award for Innovation in Therapeutics, International Society of Hypertension
    2009Honorary Doctorate Degree, University of Thessaloniki Greece
    2012 - 2015Top Doctors in USA, Castle Connelly
    2019 - 2019Irvine Page-Alva Bradley Lifetime Achievement Award-Am Heart Assoc. BP , Am Heart Assoc. BP Council
    2021 - 20212021 National Kidney Foundation of Illinois Lifetime Service-Achievement Award, National Kidney Foundation
    2023 - 2023Luminary in Cardiometabolic Medicine Award-, Heart in Diabetes Group
    2023 - 2023Honorary Doctorate Degree, University of Athens, GREECE
    2023 - 2023Hippokrates Lifetime Academic Contribution Award, University of Athens School of Medicine
    2015 - 2023Top Doctors in USA, Castle Connelly
    2015 - 2015Hypertension Lecturer of the Year- , Belgium Hypertension Society

    Collapse Research 
    Collapse research activities and funding
    U01DK048643     (BAKRIS, GEORGE LOUIS)Aug 15, 1994 - Jun 30, 2008
    NIH
    AASK Cohort Study
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Bakris G, Lin PP, Xu C, Chen C, Ashton V, Singhal M. Prediction of cardiovascular and renal risk among patients with apparent treatment-resistant hypertension in the United States using machine learning methods. J Clin Hypertens (Greenwich). 2024 Mar 24. PMID: 38523465.
      Citations:    Fields:    
    2. Rivera FB, Lumbang GNO, Gaid DRM, Cruz LLA, Magalong JV, Bantayan NRB, Lara-Breitinger KM, Gulati M, Bakris G. Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression. Diabetes Obes Metab. 2024 Mar 20. PMID: 38505997.
      Citations:    Fields:    
    3. Bansal S, Canziani MEF, Birne R, Anker SD, Bakris GL, Filippatos G, Rossing P, Ruilope LM, Farjat AE, Kolkhof P, Lage A, Brinker M, Pitt B. Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials. BMJ Open. 2024 Mar 19; 14(3):e076444. PMID: 38508632; PMCID: PMC10952937.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    4. Bakris GL, Saxena M, Gupta A, Chalhoub F, Lee J, Stiglitz D, Makarova N, Goyal N, Guo W, Zappe D, Desai AS, KARDIA-1 Study Group. RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial. JAMA. 2024 03 05; 331(9):740-749. PMID: 38363577; PMCID: PMC10873804.
      Citations:    Fields:    Translation:Humans
    5. Bakris G, Chen C, Campbell AK, Ashton V, Haskell L, Singhal M. Real-world Impact of Blood Pressure Control in Patients With Apparent Treatment-Resistant or Difficult-to-control Hypertension and Stages 3 and 4 Chronic Kidney Disease. Am J Hypertens. 2024 Mar 04. PMID: 38436491.
      Citations:    Fields:    
    6. Stavas J, Silva AL, Wooldridge TD, Aqeel A, Saad T, Prakash R, Bakris G. Rilparencel (Renal Autologous Cell Therapy-REACT®) for Chronic Kidney Disease and Type 1 and 2 Diabetes: Phase 2 Trial Design Evaluating Bilateral Kidney Dosing and Re-Dosing Triggers. Am J Nephrol. 2024 Feb 29. PMID: 38423000.
      Citations:    Fields:    
    7. Bakris GL, Weber MA. Overview of the Evolution of Hypertension: From Ancient Chinese Emperors to Today. Hypertension. 2024 Apr; 81(4):717-726. PMID: 38507509.
      Citations:    Fields:    Translation:Humans
    8. Pitt B, Bakris GL. Resistant hypertension: cardiorenal protection with mineralocorticoid receptor blockade. Eur Heart J. 2024 Jan 07; 45(2):136-138. PMID: 37224444.
      Citations:    Fields:    Translation:Humans
    9. Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S, Lawatscheck R, Rohwedder K, Ruilope LM, Rossing P, Pitt B, Filippatos G, Anker SD, Bakris GL, FIDELIO-DKD and FIGARO-DKD Investigators. Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis. Ann Intern Med. 2023 12; 176(12):1606-1616. PMID: 38048573.
      Citations: 3     Fields:    Translation:Humans
    10. Ahmed A, Anker SD, Butler J, Bakris GL, Bhatt DL, Fonarow GC, Packer M. Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial. Lancet Diabetes Endocrinol. 2023 Dec; 11(12):892-894. PMID: 37996192.
      Citations:    Fields:    Translation:Humans
    11. Neuen BL, Heerspink HJL, Vart P, Claggett BL, Fletcher RA, Arnott C, de Oliveira Costa J, Falster MO, Pearson SA, Mahaffey KW, Neal B, Agarwal R, Bakris G, Perkovic V, Solomon SD, Vaduganathan M, Neuen BL, Heerspink HJL, Vart P, Claggett BL, Fletcher RA, Arnott C, de Oliveira Costa J, Falster MO, Pearson SA, Mahaffey KW, Neal B, Agarwal R, Bakris G, Perkovic V, Solomon SD, Vaduganathan M. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. Circulation. 2024 02 06; 149(6):450-462. PMID: 37952217.
      Citations: 1     Fields:    Translation:Humans
    12. Al Dhaybi O, Bakris GL. Albuminuria is Your Guide to Assessing Future GFR Slope. Kidney Int Rep. 2024 Feb; 9(2):194-196. PMID: 38344724; PMCID: PMC10851060.
      Citations:    
    13. Razaghizad A, Aziz H, Zhang GK, Ferreira JP, White WB, Mehta CR, Bakris GL, Zannad F, Sharma A, Ferreira JP, White WB, Mehta CR, Bakris GL, Zannad F. Pathophysiological Sex Differences in Heart Failure Progression After Acute Coronary Syndrome: Insights From the EXAMINE Trial. J Card Fail. 2023 Nov 07. PMID: 37939897.
      Citations:    Fields:    
    14. Heerspink HL, Jongs N, Schloemer P, Little DJ, Brinker M, Tasto C, Karpefors M, Wheeler DC, Bakris G, Perkovic V, Nkulikiyinka R, Rossert J, Gasparyan SB, Heerspink HJL. Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression. J Am Soc Nephrol. 2023 12 01; 34(12):2025-2038. PMID: 37872654; PMCID: PMC10703083.
      Citations:    Fields:    Translation:Humans
    15. Kalantar-Zadeh K, Forfang D, Bakris G, Martin KJ, Moe SM, Sprague SM, Kalantar-Zadeh K, Forfang D, Bakris G, Martin KJ, Moe SM, Sprague SM. Managing Phosphate Burden in Patients Receiving Dialysis: Beyond Phosphate Binders and Diet. Kidney360. 2023 11 01; 4(11):1650-1656. PMID: 37870525; PMCID: PMC10695651.
      Citations:    Fields:    Translation:Humans
    16. Bakris GL, Yang YF, McCabe JM, Liu JR, Tan XJ, Benn VJ, Pitt B. Efficacy and Safety of Ocedurenone: Subgroup Analysis of the BLOCK-CKD Study. Am J Hypertens. 2023 Oct 13; 36(11):612-618. PMID: 37471468; PMCID: PMC10570658.
      Citations: 1     Fields:    
    17. Desai AS, Sweetser MT, Bakris GL. Zilebesiran for Hypertension. Reply. N Engl J Med. 2023 Oct 12; 389(15):1439-1440. PMID: 37819965.
      Citations:    Fields:    Translation:Humans
    18. Perakakis N, Bornstein SR, Birkenfeld AL, Linkermann A, Demir M, Anker SD, Filippatos G, Pitt B, Rossing P, Ruilope LM, Kolkhof P, Lawatscheck R, Scott C, Bakris GL, FIDELIO-DKD and FIGARO-DKD investigators. Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysis. Diabetes Obes Metab. 2024 Jan; 26(1):191-200. PMID: 37814928.
      Citations:    Fields:    Translation:Humans
    19. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Lernmark Å, Metzger BE, Nathan DM, Kirkman MS. Executive Summary: Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. Diabetes Care. 2023 10 01; 46(10):1740-1746. PMID: 37471272; PMCID: PMC10516242.
      Citations:    Fields:    Translation:Humans
    20. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Lernmark Å, Metzger BE, Nathan DM, Kirkman MS. Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. Diabetes Care. 2023 10 01; 46(10):e151-e199. PMID: 37471273; PMCID: PMC10516260.
      Citations: 7     Fields:    Translation:Humans
    21. Flack JM, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Adler SG, Fried L, Jamerson K, Toto R, Brinker M, Farjat AE, Kolkhof P, Lawatscheck R, Joseph A, Bakris GL, FIDELIO-DKD and FIGARO-DKD Investigators. Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials. Kidney Med. 2023 Dec; 5(12):100730. PMID: 38046911; PMCID: PMC10692708.
      Citations:    
    22. Naaman SC, Bakris GL. Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression. Diabetes Care. 2023 09 01; 46(9):1574-1586. PMID: 37625003; PMCID: PMC10547606.
      Citations: 8     Fields:    Translation:Humans
    23. Rossing P, Burgess E, Agarwal R, Anker SD, Filippatos G, Pitt B, Ruilope LM, Gillard P, MacIsaac RJ, Wainstein J, Joseph A, Brinker M, Roessig L, Scott C, Bakris GL, FIDELIO-DKD Investigators . Erratum. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care 2022;45:888-897. Diabetes Care. 2023 Sep 01; 46(9):1721. PMID: 37310695; PMCID: PMC10465986.
      Citations:    Fields:    
    24. Baeres FMM, Bosch-Traberg H, Gislum M, Gough SCL, Idorn T, Lawson J, Mersebach H, Rossing P, Bakris G, Mahaffey KW, Mann JFE, Perkovic V, Tuttle K, Pratley R. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2023 08 31; 38(9):2041-2051. PMID: 36651820; PMCID: PMC10469096.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    25. Heerspink HJL, Vart P, Jongs N, Neuen BL, Bakris G, Claggett B, Vaduganathan M, McCausland F, Docherty KF, Jhund PS, Solomon SD, Perkovic V, McMurray JJV. Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials. Diabetes Obes Metab. 2023 11; 25(11):3327-3336. PMID: 37580309.
      Citations: 3     Fields:    Translation:Humans
    26. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Lernmark Å, Metzger BE, Nathan DM, Sue Kirkman M. Executive Summary: Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. Clin Chem. 2023 08 02; 69(8):777-784. PMID: 37562009.
      Citations: 1     Fields:    Translation:Humans
    27. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Lernmark Å, Metzger BE, Nathan DM, Kirkman MS. Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. Clin Chem. 2023 08 02; 69(8):808-868. PMID: 37473453.
      Citations: 1     Fields:    Translation:Humans
    28. Agarwal R, Pitt B, Rossing P, Anker SD, Filippatos G, Ruilope LM, Kovesdy CP, Tuttle K, Vaduganathan M, Wanner C, Bansilal S, Gebel M, Joseph A, Lawatscheck R, Bakris GL. Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone. JAMA Cardiol. 2023 08 01; 8(8):732-741. PMID: 37314801; PMCID: PMC10267848.
      Citations: 3     Fields:    Translation:Humans
    29. Rosas SE, Ruilope LM, Anker SD, Pitt B, Rossing P, Bonfanti AAC, Correa-Rotter R, González F, Munoz CFJ, Pergola P, Umpierrez GE, Scalise A, Scott C, Lawatscheck R, Joseph A, Bakris GL, FIDELIO-DKD and FIGARO-DKD investigators. Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY Analysis. Kidney Med. 2023 Oct; 5(10):100704. PMID: 37745646; PMCID: PMC10514441.
      Citations:    
    30. Blazek O, Bakris GL. Slowing the Progression of Diabetic Kidney Disease. Cells. 2023 07 31; 12(15). PMID: 37566054; PMCID: PMC10417620.
      Citations: 2     Fields:    Translation:Humans
    31. Desai AS, Webb DJ, Taubel J, Casey S, Cheng Y, Robbie GJ, Foster D, Huang SA, Rhyee S, Sweetser MT, Bakris GL. Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. N Engl J Med. 2023 Jul 20; 389(3):228-238. PMID: 37467498.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    32. Bakris G, Chen C, Campbell AK, Ashton V, Haskell L, Singhal M. Association of uncontrolled blood pressure in apparent treatment-resistant hypertension with increased risk of major adverse cardiovascular events plus. J Clin Hypertens (Greenwich). 2023 08; 25(8):737-747. PMID: 37461262; PMCID: PMC10423765.
      Citations: 1     Fields:    Translation:Humans
    33. Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, Billings LK, Green JB, Koya D, Mosenzon O, Pantalone KM, Ahlers C, Lage A, Lawatscheck R, Scalise A, Bakris GL. The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study. Diabetes Obes Metab. 2023 10; 25(10):2989-2998. PMID: 37402696.
      Citations: 3     Fields:    Translation:Humans
    34. Usman MS, Siddiqi TJ, Anker SD, Bakris GL, Bhatt DL, Filippatos G, Fonarow GC, Greene SJ, Januzzi JL, Khan MS, Kosiborod MN, McGuire DK, Piña IL, Rosenstock J, Vaduganathan M, Verma S, Zieroth S, Butler J. Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations. J Am Coll Cardiol. 2023 06 27; 81(25):2377-2387. PMID: 37344038.
      Citations: 8     Fields:    Translation:Humans
    35. Fletcher RA, Arnott C, Rockenschaub P, Schutte AE, Carpenter L, Vaduganathan M, Agarwal R, Bakris G, Chang TI, Heerspink HJL, Jardine MJ, Mahaffey KW, Neal B, Pollock C, Jun M, Rodgers A, Perkovic V, Neuen BL. Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials. J Am Heart Assoc. 2023 07 04; 12(13):e028516. PMID: 37345834; PMCID: PMC10356084.
      Citations: 2     Fields:    Translation:Humans
    36. Charytan DM, Mahaffey KW, Jardine MJ, Cannon CP, Neal B, Lambers Heerspink HJ, Agarwal R, Bakris GL, de Zeeuw D, Levin A, Pollock C, Zhang H, Zinman B, Rosenthal N, Perkovic V, Di Tanna GL, Yu J, Rogers K, Arnott C, Wheeler DC. Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering. BMJ Open Diabetes Res Care. 2023 06; 11(3). PMID: 37311602; PMCID: PMC10277062.
      Citations:    Translation:Humans
    37. Michos ED, Bakris GL, Rodbard HW, Tuttle KR. Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection. Am J Prev Cardiol. 2023 Jun; 14:100502. PMID: 37313358; PMCID: PMC10258236.
      Citations: 4     
    38. Kang A, Smyth B, Neuen BL, Heerspink HJL, Di Tanna GL, Zhang H, Arnott C, Hockham C, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Mahaffey KW, Perkovic V, Jardine MJ. The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials. Diabetes Obes Metab. 2023 08; 25(8):2151-2162. PMID: 37161691.
      Citations: 1     Fields:    Translation:Humans
    39. Heerspink HJL, Jongs N, Neuen BL, Schloemer P, Vaduganathan M, Inker LA, Fletcher RA, Wheeler DC, Bakris G, Greene T, Chertow GM, Perkovic V. Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials. Kidney Int. 2023 07; 104(1):181-188. PMID: 37119876.
      Citations: 3     Fields:    Translation:Humans
    40. Bansal N, Artinian NT, Bakris G, Chang T, Cohen J, Flythe J, Lea J, Vongpatanasin W, Chertow GM, American Heart Association Council on the Kidney in Cardiovascular Disease; Council on Cardiovascula. Hypertension in Patients Treated With In-Center Maintenance Hemodialysis: Current Evidence and Future Opportunities: A Scientific Statement From the American Heart Association. Hypertension. 2023 06; 80(6):e112-e122. PMID: 37092336.
      Citations: 3     Fields:    Translation:Humans
    41. Schlaich MP, Bellet M, Weber MA, Bakris GL, Wang JG, PRECISION investigators. Fluid retention and heart failure in the PRECISION trial - Authors' reply. Lancet. 2023 04 22; 401(10385):1335-1336. PMID: 37087163.
      Citations:    Fields:    Translation:Humans
    42. Bhatt DL, Bakris GL. Key questions regarding the SYMPLICITY HTN-3 trial - Authors' reply. Lancet. 2023 04 22; 401(10385):1337-1338. PMID: 37087166.
      Citations:    Fields:    Translation:Humans
    43. Daugherty A, Lu HS, Bakris GL. Angiotensinogen in Sex and Hypertension: New Insights From the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol. 2023 04 04; 81(13):1260-1262. PMID: 36990545.
      Citations:    Fields:    Translation:Humans
    44. Kahn SE, Anderson CAM, Atkinson MA, Bakris GL, Buse JB, Hu FB, Rich SS, Riddle MC, Selvin E. Reducing Bias in Academic Publishing: The Diabetes Care Approach. Diabetes Care. 2023 04 01; 46(4):665-666. PMID: 36952610; PMCID: PMC10985280.
      Citations:    Fields:    Translation:Humans
    45. Green JB, Bakris G, Heerspink HJL, Mann JFE, McGill JB, Rossing P, Scott C, Gay A, Agarwal R, Mottl AK, Nangaku M. Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE). Nephrol Dial Transplant. 2023 03 31; 38(4):894-903. PMID: 35700142; PMCID: PMC10064838.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    46. Sarafidis P, Agarwal R, Pitt B, Filippatos G, Boletis J, Tuttle KR, Ruilope LM, Rossing P, Toto R, Liu ZH, Joseph A, Ahlers C, Brinker M, Lawatscheck R, Bakris G, FIDELIO-DKD and FIGARO-DKD Investigators, Wanner C, Anker SD. Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis. Clin J Am Soc Nephrol. 2023 Mar 17. PMID: 36927680; PMCID: PMC10278789.
      Citations: 5     Fields:    
    47. de Zeeuw D, Wheeler DC, CREDENCE Trial Investigators, Yi TW, Smyth B, Di Tanna GL, Arnott C, Cardoza K, Kang A, Pollock C, Agarwal R, Bakris G, Charytan DM, Heerspink HJL, Neal B, Cannon CP, Zhang H, Zinman B, Perkovic V, Levin A, Mahaffey KW, Jardine M. Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial. Am J Kidney Dis. 2023 07; 82(1):84-96.e1. PMID: 36889425.
      Citations: 3     Fields:    Translation:Humans
    48. McGill JB, Agarwal R, Anker SD, Bakris GL, Filippatos G, Pitt B, Ruilope LM, Caramori ML, Brinker M, Joseph A, Lawatscheck R, Scott C, Rossing P, FIDELIO-DKD and FIGARO-DKD investigators, Birkenfeld AL, Lage A. Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline. Diabetes Obes Metab. 2023 06; 25(6):1512-1522. PMID: 36722675.
      Citations: 2     Fields:    Translation:Humans
    49. Ruilope LM, Pitt B, Rossing P, Kovesdy CP, Pecoits-Filho R, Pergola P, Joseph A, Mentenich N, Scheerer MF, Bakris GL, Anker SD, Lage A. Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study. Nephrol Dial Transplant. 2023 02 13; 38(2):372-383. PMID: 35451488; PMCID: PMC9923706.
      Citations: 7     Fields:    Translation:Humans
    50. Blazek O, Bakris GL. Novel Therapies on the Horizon of Hypertension Management. Am J Hypertens. 2023 02 13; 36(2):73-81. PMID: 36201204.
      Citations:    Fields:    Translation:HumansCells
    51. Koshino A, Oshima M, Arnott C, Fletcher RA, Bakris GL, Jardine M, Mahaffey KW, Perkovic V, Pollock C, Heerspink HJL, Neuen BL. Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial. Diabetes Obes Metab. 2023 05; 25(5):1413-1418. PMID: 36655422.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    52. Laffin LJ, Briasoulis A, Bakris GL. Newer alternatives for resistant hypertension: Beyond 2022 paradigms. Hellenic J Cardiol. 2023 Mar-Apr; 70:75-77. PMID: 36739976.
      Citations:    Fields:    Translation:HumansPHPublic Health
    53. Filippatos G, August P, Coats AJS, Januzzi JL, Mankovsky B, Rossing P, Ruilope LM, Pitt B, Teerlink JR, Kapelios CJ, Gebel M, Brinker M, Joseph A, Bakris G, Agarwal R, Anker SD, Sarafidis P, Lage A. Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis. Eur Heart J Cardiovasc Pharmacother. 2023 02 02; 9(2):183-191. PMID: 36639130; PMCID: PMC9892867.
      Citations: 7     Fields:    Translation:Humans
    54. Khan MS, Shahid I, Fonarow GC, Fudim M, Hall ME, Hernandez A, Morris AA, Shafi T, Weir MR, Bakris GL, Butler J, Anker SD, Zannad F. Albuminuria and Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2023 01 24; 81(3):270-282. PMID: 36653095.
      Citations: 8     Fields:    Translation:Humans
    55. Handelsman Y, Butler J, Bakris GL, DeFronzo RA, Fonarow GC, Green JB, Grunberger G, Januzzi JL, Klein S, Kushner PR, McGuire DK, Michos ED, Morales J, Pratley RE, Weir MR, Wright E, Fonseca VA. Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications. 2023 02; 37(2):108389. PMID: 36669322.
      Citations: 4     Fields:    Translation:Humans
    56. Filippatos G, Pitt B, McGuire DK, Rossing P, Ruilope LM, Butler J, Jankowska EA, Michos ED, Farmakis D, Farjat AE, Kolkhof P, Scalise A, Joseph A, Bakris GL, Agarwal R, Anker SD. Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease. Eur Heart J Cardiovasc Pharmacother. 2022 12 15; 9(1):85-93. PMID: 36251465; PMCID: PMC9753093.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    57. Agarwal R, Ruilope LM, Ruiz-Hurtado G, Haller H, Schmieder RE, Filippatos G, Pitt B, Rossing P, Lambelet M, Nowack C, Kolkhof P, Joseph A, Bakris GL, Anker SD. Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes. J Hypertens. 2023 02 01; 41(2):295-302. PMID: 36583355; PMCID: PMC9799031.
      Citations: 9     Fields:    Translation:Humans
    58. de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, Rosas SE, Rossing P, Bakris G. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022 12 01; 45(12):3075-3090. PMID: 36189689; PMCID: PMC9870667.
      Citations: 82     Fields:    Translation:Humans
    59. Rossing P, Filippatos G, Pitt B, Ruilope LM, McGill JB, Rosas SE, Joseph A, Gebel M, Roberts L, Scheerer MF, Bakris GL, Agarwal R, FIDELIO-DKD and FIGARO-DKD Investigators, Anker SD, Birkenfeld AL. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis. Diabetes Care. 2022 12 01; 45(12):2991-2998. PMID: 35972218; PMCID: PMC9862372.
      Citations: 25     Fields:    Translation:Humans
    60. Rossing P, Garweg JG, Osonoi T, Pitt B, Rosas SE, Ruilope LM, Zhu D, Brinker M, Finis D, Leal S, Schmelter T, Bakris G, Anker SD. Effect of finerenone on the occurrence of vision-threatening complications in patients with non-proliferative diabetic retinopathy: Pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFineDR). Diabetes Obes Metab. 2023 03; 25(3):894-898. PMID: 36331803; PMCID: PMC10100268.
      Citations: 3     Fields:    Translation:Humans
    61. Schlaich MP, Bellet M, Weber MA, Danaietash P, Bakris GL, Flack JM, Dreier RF, Sassi-Sayadi M, Haskell LP, Narkiewicz K, Wang JG, PRECISION investigators. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022 12 03; 400(10367):1927-1937. PMID: 36356632.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    62. Rossing P, Agarwal R, Filippatos G, Pitt B, Ruilope LM, Fonseca V, Umpierrez GE, Caramori ML, Joseph A, Lambelet M, Lawatscheck R, Bakris GL, FIDELIO-DKD and FIGARO-DKD Investigators, Anker SD. Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use. Diabetes Obes Metab. 2023 02; 25(2):407-416. PMID: 36193847; PMCID: PMC10092103.
      Citations: 6     Fields:    Translation:Humans
    63. Sarraju A, Bakris G, Cannon CP, Cherney D, Damaraju CV, Figtree GA, Gogate J, Greene T, Heerspink HJL, Januzzi JL, Neal B, Jardine MJ, Blais J, Kosiborod M, Levin A, Lingvay I, Weir MR, Perkovic V, Mahaffey KW. Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria. J Am Coll Cardiol. 2022 11 01; 80(18):1721-1731. PMID: 36302584.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    64. Agarwal R, Pitt B, Palmer BF, Kovesdy CP, Burgess E, Filippatos G, Malyszko J, Ruilope LM, Rossing P, Pecoits-Filho R, Joseph A, Lawatscheck R, Wilson D, Gebel M, Bakris GL, Rossignol P, Anker SD. A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease. Clin Kidney J. 2023 Feb; 16(2):293-302. PMID: 36864892; PMCID: PMC9972517.
      Citations: 7     
    65. Bakris GL, Filippatos G, Pitt B, Rossing P, Fried L, Roy-Chaudhury P, Sarafidis P, Ahlers C, Brinker M, Joseph A, Lawatscheck R, Agarwal R, FIDELIO-DKD and FIGARO-DKD Investigators, Ruilope LM, Anker SD. A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes. Kidney Int. 2023 01; 103(1):196-206. PMID: 36367466.
      Citations: 7     Fields:    Translation:Humans
    66. Khan MS, Ahmed A, Greene SJ, Fiuzat M, Kittleson MM, Butler J, Bakris GL, Fonarow GC. Managing Heart Failure in Patients on Dialysis: State-of-the-Art Review. J Card Fail. 2023 01; 29(1):87-107. PMID: 36243339.
      Citations: 5     Fields:    Translation:Humans
    67. Mistry N, Bakris GL. The changing trajectory of diabetic kidney disease. Curr Opin Nephrol Hypertens. 2023 01 01; 32(1):98-102. PMID: 36250469.
      Citations: 1     Fields:    Translation:HumansAnimals
    68. Ruilope LM, Agarwal R, Filippatos G, Pitt B, Rossing P, Sarafidis P, Schmieder RE, Joseph A, Rethemeier N, Nowack C, Bakris GL, FIDELIO-DKD Investigators, Anker SD. Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes. Hypertension. 2022 12; 79(12):2685-2695. PMID: 36252131; PMCID: PMC9640256.
      Citations: 7     Fields:    Translation:Humans
    69. Filippatos G, Pitt B, Rossing P, Joseph A, Kolkhof P, Lambelet M, Lawatscheck R, Bakris GL, Agarwal R, Anker SD, Ruilope LM. Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes. JACC Heart Fail. 2022 11; 10(11):860-870. PMID: 36328655.
      Citations: 10     Fields:    Translation:Humans
    70. Bakris GL, Jaisser F. Aldosterone excess and cardiorenal risk: more common than appreciated. Eur Heart J. 2022 10 11; 43(38):3792-3793. PMID: 36219774.
      Citations: 1     Fields:    Translation:Humans
    71. de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, Rosas SE, Rossing P, Bakris G. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2022 11; 102(5):974-989. PMID: 36202661.
      Citations: 31     Fields:    Translation:Humans
    72. Razaghizad A, Sharma A, Ni J, White WB, Mehta CR, Bakris GL, Ferreira JP, Zannad F. External validation and extension of the TIMI risk score for heart failure in diabetes for patients with recent acute coronary syndrome: An analysis of the EXAMINE trial. Diabetes Obes Metab. 2023 01; 25(1):229-237. PMID: 36082521.
      Citations: 1     Fields:    Translation:Humans
    73. Salvador VD, Bakris GL. Novel antihypertensive agents for resistant hypertension: what does the future hold? Hypertens Res. 2022 12; 45(12):1918-1928. PMID: 36167808.
      Citations: 2     Fields:    Translation:Animals
    74. Bhatt DL, Vaduganathan M, Kandzari DE, Leon MB, Rocha-Singh K, Townsend RR, Katzen BT, Oparil S, Brar S, DeBruin V, Fahy M, Bakris GL, SYMPLICITY HTN-3 Steering Committee Investigators. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Lancet. 2022 10 22; 400(10361):1405-1416. PMID: 36130612.
      Citations: 24     Fields:    Translation:Humans
    75. Kolkhof P, Filippatos G, Bakris GL, Lawatscheck R. Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone-Translational Aspects and Clinical Perspectives across Multiple Organ Systems. Int J Mol Sci. 2022 Aug 17; 23(16). PMID: 36012508; PMCID: PMC9408839.
      Citations: 6     Fields:    Translation:Humans
    76. Stergiou G, MacDonald T, Kyriakoulis KG, Bursztyn M, Khan N, Bakris G, Kollias A, Menti A, Muntner P, Orias M, Poulter N, Shimbo D, Williams B, Adeoye AM, Damasceno A, Korostovtseva L, Li Y, Zhang Y, Mancia G, Tomaszewski M, Brunström M, Muxfeldt E, Kreutz R. Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension. J Hypertens. 2022 10 01; 40(10):1847-1858. PMID: 35983870.
      Citations: 11     Fields:    Translation:Humans
    77. Smeijer JD, Koomen JV, Kohan DE, McMurray JJV, Bakris GL, Hou FF, Kitzman DW, Makino H, Mayer G, Nowicki M, Perkovic V, Rossing P, Tobe S, Parving HH, de Zeeuw D, Heerspink HJL, Correa-Rotter R. Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response to Atrasentan in Patients With Diabetic Kidney Disease. Clin Pharmacol Ther. 2022 Nov; 112(5):1098-1107. PMID: 35892316.
      Citations: 1     Fields:    Translation:Humans
    78. Li JW, Arnott C, Heerspink HJL, MBiostat QL, Cannon CP, Wheeler DC, Charytan DM, Barraclough J, Figtree GA, Agarwal R, Bakris G, de Zeeuw D, Greene T, Levin A, Pollock C, Zhang H, Zinman B, Mahaffey KW, Perkovic V, Neal B, Jardine MJ. Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial. J Am Heart Assoc. 2022 08 16; 11(16):e025045. PMID: 35929472; PMCID: PMC9496296.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    79. Blazek O, Bakris GL. The evolution of "pillars of therapy" to reduce heart failure risk and slow diabetic kidney disease progression. Am Heart J Plus. 2022 Jul; 19:100187. PMID: 38558865; PMCID: PMC10978322.
      Citations:    
    80. Toto R, Bakris G. Correction to: The FIDELIO Study Podcast. Diabetes Ther. 2022 Aug; 13(8):1571. PMID: 35780229; PMCID: PMC9309103.
      Citations:    
    81. Iyer NN, Shah S, Ganz ML, Dang-Tan T, Gamble C, Mehanna S, Bakris G, Li Q. Glucose-lowering treatment patterns in patients with diabetic kidney disease. Am J Manag Care. 2022 08 01; 28(8):e301-e307. PMID: 35981131.
      Citations:    Fields:    Translation:Humans
    82. Riddle MC, with and on behalf of Associate Editors Vanita Aroda, Bakris G, Blonde L, Boulton AJM, Castle J, DiMeglio L, Gonder-Frederick L, Hu F, Kahn S, Kaul S, Moses R, Rich S, Rosenstock J, Selvin E, Vella A, Wylie-Rosett J. Editorial Cycles and Continuity of Diabetes Care. Diabetes Care. 2022 07 07; 45(7):1493-1494. PMID: 35796770.
      Citations:    Fields:    Translation:Humans
    83. Bakris G. Use of SGLT-2 Inhibitors to Treat Chronic Kidney Disease in Primary Care. J Fam Pract. 2022 07; 71(6 Suppl):S88-S93. PMID: 35960952.
      Citations:    Fields:    Translation:Humans
    84. Agarwal R, Filippatos G, Pitt B, Rossing P, Ruilope LM, Boletis J, Toto R, Umpierrez GE, Wada T, Scott C, Joseph A, Ogbaa I, Roberts L, Scheerer MF, Bakris GL, Anker SD, Wanner C. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results. Nephrol Dial Transplant. 2022 06 23; 37(7):1261-1269. PMID: 34850173; PMCID: PMC9217637.
      Citations: 11     Fields:    Translation:Humans
    85. Bakris GL, Weir MR. Initial Drops in Glomerular Filtration Rate with Certain Drug Classes Retard Kidney Disease Progression. Am J Nephrol. 2022; 53(7):513-515. PMID: 35691290.
      Citations: 2     Fields:    Translation:Humans
    86. Tuttle KR, Agarwal R, Alpers CE, Bakris GL, Brosius FC, Kolkhof P, Uribarri J. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int. 2022 08; 102(2):248-260. PMID: 35661785.
      Citations: 60     Fields:    Translation:Humans
    87. Young TK, Toussaint ND, Di Tanna GL, Arnott C, Hockham C, Kang A, Schutte AE, Perkovic V, Mahaffey KW, Agarwal R, Bakris GL, Charytan DM, Heerspink HJL, Levin A, Pollock C, Wheeler DC, Zhang H, Jardine MJ. Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial. J Diabetes Res. 2022; 2022:9998891. PMID: 35677742; PMCID: PMC9168808.
      Citations: 1     Fields:    Translation:Humans
    88. Agarwal R, Bakris G, Filippatos G, Pitt B, Rossing P, Ruilope L, Gebel M, Kolkhof P, Nowack C, Joseph A, FIDELIO-DKD and FIGARO-DKD Investigators, Anker SD. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. Nephrol Dial Transplant. 2022 05 25; 37(6):1014-1023. PMID: 33280027; PMCID: PMC9130026.
      Citations: 26     Fields:    Translation:HumansAnimals
    89. Filippatos G, Pitt B, Agarwal R, Farmakis D, Ruilope LM, Rossing P, Bauersachs J, Mentz RJ, Kolkhof P, Scott C, Joseph A, Bakris GL, FIDELIO-DKD Investigators, Anker SD. Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial. Eur J Heart Fail. 2022 06; 24(6):996-1005. PMID: 35239204; PMCID: PMC9541504.
      Citations: 8     Fields:    Translation:Humans
    90. Smeijer JD, Koomen J, Kohan DE, McMurray JJV, Bakris GL, Hou FF, Januzzi JL, Kitzman DW, Kolansky DM, Makino H, Perkovic V, Tobe S, Parving HH, de Zeeuw D, Heerspink HJL, Correa-Rotter R. Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure. JACC Heart Fail. 2022 07; 10(7):498-507. PMID: 35772861.
      Citations: 4     Fields:    Translation:Humans
    91. Khan MS, Bakris GL, Shahid I, Weir MR, Butler J. Potential Role and Limitations of Estimated Glomerular Filtration Rate Slope Assessment in Cardiovascular Trials: A Review. JAMA Cardiol. 2022 05 01; 7(5):549-555. PMID: 34985495.
      Citations: 5     Fields:    Translation:Humans
    92. Cohen S, Sternlicht H, Bakris GL. Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists. Curr Diab Rep. 2022 05; 22(5):213-218. PMID: 35441935.
      Citations: 2     Fields:    Translation:Humans
    93. Lerma E, White WB, Bakris G. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease. Postgrad Med. 2023 Apr; 135(3):224-233. PMID: 35392754.
      Citations: 4     Fields:    Translation:Humans
    94. DeFronzo RA, Bakris GL. Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes. Diabetes Obes Metab. 2022 07; 24(7):1197-1205. PMID: 35302284; PMCID: PMC9323420.
      Citations: 6     Fields:    Translation:Humans
    95. Khan MS, Bakris GL, Packer M, Shahid I, Fonarow GC, Weir MR, Butler J, Anker SD, Wanner C, Zannad F. Kidney function assessment and endpoint ascertainment in clinical trials. Eur Heart J. 2022 04 06; 43(14):1379-1400. PMID: 34966917.
      Citations: 3     Fields:    Translation:Humans
    96. Rossing P, Burgess E, Agarwal R, Filippatos G, Pitt B, Ruilope LM, Gillard P, MacIsaac RJ, Wainstein J, Joseph A, Brinker M, Roessig L, Scott C, Bakris GL, FIDELIO-DKD Investigators, Anker SD. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care. 2022 04 01; 45(4):888-897. PMID: 35061867; PMCID: PMC9271031.
      Citations: 7     Fields:    Translation:Humans
    97. Toto R, Bakris G. The FIDELIO Study Podcast. Diabetes Ther. 2022 May; 13(5):823-828. PMID: 35325360; PMCID: PMC9076781.
      Citations:    
    98. Chiu N, Aggarwal R, Bakris GL, Pitt B, Bhatt DL. Generalizability of FIGARO-DKD and FIDELIO-DKD Trial Criteria to the US Population Eligible for Finerenone. J Am Heart Assoc. 2022 04 05; 11(7):e025079. PMID: 35311349; PMCID: PMC9075441.
      Citations: 2     Fields:    Translation:Humans
    99. van Kleef MEAM, Devireddy CM, van der Heyden J, Bates MC, Bakris GL, Stone GW, Williams B, Spiering W, CALM-FIM Investigators. Treatment of Resistant Hypertension With Endovascular Baroreflex Amplification: 3-Year Results From the CALM-FIM Study. JACC Cardiovasc Interv. 2022 02 14; 15(3):321-332. PMID: 35144789.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    100. Liao J, Kang A, Xia C, Young T, Di Tanna GL, Arnott C, Pollock C, Krishnan AV, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Heerspink HJL, Levin A, Neal B, Wheeler DC, Zhang H, Zinman B, Mahaffey KW, Perkovic V, Jardine MJ, Smyth B. The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial. Diabetes Metab. 2022 07; 48(4):101331. PMID: 35172198.
      Citations: 3     Fields:    Translation:Humans
    101. Agarwal R, Filippatos G, Pitt B, Rossing P, Bakris GL, FIDELIO-DKD and FIGARO-DKD investigators, Anker SD, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022 Feb 10; 43(6):474-484. PMID: 35023547; PMCID: PMC8830527.
      Citations: 136     Fields:    Translation:HumansCTClinical Trials
    102. Yu J, Jardine MJ, Cannon CP, Agarwal R, Bakris G, Greene T, Levin A, Pollock C, Powe NR, Arnott C, CREDENCE study investigators, Charytan DM, Mahaffey KW. Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial. Clin J Am Soc Nephrol. 2022 03; 17(3):361-373. PMID: 35063969; PMCID: PMC8975029.
      Citations: 1     Fields:    Translation:Humans
    103. Stavas J, Gerber D, Coca SG, Silva AL, Johns A, Jain D, Bertram T, Bakris G, Díaz-González de Ferris M. Novel Renal Autologous Cell Therapy for Type 2 Diabetes Mellitus Chronic Diabetic Kidney Disease: Clinical Trial Design. Am J Nephrol. 2022; 53(1):50-58. PMID: 35034024.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    104. Salvador VD, Bakris GL. Identifying Resistant Hypertension in the Population: The Devil Is in the Details. Can J Cardiol. 2022 05; 38(5):555-556. PMID: 35033633.
      Citations:    Fields:    Translation:Humans
    105. Bakris GL, Kolkhof P, Kintscher U. Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br J Pharmacol. 2022 07; 179(13):3220-3234. PMID: 34811750.
      Citations: 28     Fields:    Translation:Humans
    106. American Diabetes Association Professional Practice Committee. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S185-S194. PMID: 34964887.
      Citations: 49     Fields:    Translation:Humans
    107. American Diabetes Association Professional Practice Committee. 16. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S244-S253. PMID: 34964884.
      Citations: 58     Fields:    Translation:Humans
    108. American Diabetes Association Professional Practice Committee. Summary of Revisions: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S4-S7. PMID: 34964881.
      Citations: 16     Fields:    
    109. American Diabetes Association Professional Practice Committee. 3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S39-S45. PMID: 34964876.
      Citations: 36     Fields:    Translation:Humans
    110. American Diabetes Association Professional Practice Committee. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S17-S38. PMID: 34964875.
      Citations: 605     Fields:    Translation:Humans
    111. American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S175-S184. PMID: 34964873.
      Citations: 105     Fields:    Translation:Humans
    112. American Diabetes Association Professional Practice Committee. 1. Improving Care and Promoting Health in Populations: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S8-S16. PMID: 34964872.
      Citations: 27     Fields:    Translation:Humans
    113. American Diabetes Association Professional Practice Committee. 7. Diabetes Technology: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S97-S112. PMID: 34964871.
      Citations: 75     Fields:    Translation:Humans
    114. American Diabetes Association Professional Practice Committee. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S46-S59. PMID: 34964869; PMCID: PMC8935396.
      Citations: 56     Fields:    Translation:Humans
    115. American Diabetes Association Professional Practice Committee. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S83-S96. PMID: 34964868.
      Citations: 187     Fields:    Translation:Humans
    116. American Diabetes Association Professional Practice Committee. 5. Facilitating Behavior Change and Well-being to Improve Health Outcomes: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S60-S82. PMID: 34964866.
      Citations: 91     Fields:    Translation:Humans
    117. American Diabetes Association Professional Practice Committee. 14. Children and Adolescents: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S208-S231. PMID: 34964865.
      Citations: 53     Fields:    Translation:Humans
    118. American Diabetes Association Professional Practice Committee. 15. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S232-S243. PMID: 34964864.
      Citations: 62     Fields:    Translation:Humans
    119. American Diabetes Association Professional Practice Committee. 13. Older Adults: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S195-S207. PMID: 34964847; PMCID: PMC8935395.
      Citations: 61     Fields:    Translation:Humans
    120. American Diabetes Association Professional Practice Committee. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S113-S124. PMID: 34964843.
      Citations: 58     Fields:    Translation:Humans
    121. American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S125-S143. PMID: 34964831.
      Citations: 275     Fields:    Translation:Humans
    122. American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 01 01; 45(Suppl 1):S144-S174. PMID: 34964815.
      Citations: 137     Fields:    Translation:Humans
    123. Neuen BL, Oshima M, Perkovic V, Agarwal R, Arnott C, Bakris G, Cannon CP, Charytan DM, Edwards R, Jardine MJ, Levin A, Neal B, De Nicola L, Pollock C, Rosenthal N, Wheeler DC, Mahaffey KW, Heerspink HJL, Górriz JL. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. Eur Heart J. 2021 12 21; 42(48):4891-4901. PMID: 34423370.
      Citations: 36     Fields:    Translation:Humans
    124. Shaman AM, Bain SC, Bakris GL, Buse JB, Mahaffey KW, Mann JFE, Rossing P, Zinman B, Perkovic V, Idorn T, Nauck MA, Rasmussen S, Wolthers B. Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. Circulation. 2022 02 22; 145(8):575-585. PMID: 34903039; PMCID: PMC8860212.
      Citations: 43     Fields:    Translation:Humans
    125. Handelsman Y, Anderson JE, Bakris GL, Ballantyne CM, Beckman JA, Bhatt DL, Bloomgarden ZT, Bozkurt B, Budoff MJ, Butler J, Dagogo-Jack S, de Boer IH, DeFronzo RA, Eckel RH, Einhorn D, Fonseca VA, Green JB, Grunberger G, Guerin C, Inzucchi SE, Jellinger PS, Kosiborod MN, Kushner P, Lepor N, Mende CW, Michos ED, Plutzky J, Taub PR, Umpierrez GE, Vaduganathan M, Weir MR. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications. 2022 02; 36(2):108101. PMID: 34922811.
      Citations: 6     Fields:    Translation:Humans
    126. Bakris G, Mehta C, White WB, Ferreira JP, Rossignol P, Zannad F. Blood and Urine Biomarkers Predicting Worsening Kidney Function in Patients with Type 2 Diabetes Post-Acute Coronary Syndrome: An Analysis from the EXAMINE Trial. Am J Nephrol. 2021; 52(12):969-976. PMID: 34872085.
      Citations: 2     Fields:    Translation:Humans
    127. Salvador VD, Bakris GL. Taking a step back: Making sense of evidence on diastolic blood pressure in the context of targets for older adults. Am Heart J Plus. 2022 Jan; 13:100079. PMID: 38560062; PMCID: PMC10978199.
      Citations:    
    128. Waijer SW, Gansevoort RT, Bakris GL, Hou FF, Kohan DE, Kitzman DW, Makino H, McMurray JJV, Perkovic V, Tobe S, Parving HH, de Zeeuw D, Heerspink HJL, Correa-Rotter R. The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Randomized Trial. Clin J Am Soc Nephrol. 2021 12; 16(12):1824-1832. PMID: 34853062; PMCID: PMC8729501.
      Citations: 6     Fields:    Translation:Humans
    129. Filippatos G, Agarwal R, Ruilope LM, Rossing P, Bakris GL, Tasto C, Joseph A, Kolkhof P, Pitt B, FIGARO-DKD Investigators, Anker SD, Lage A. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. Circulation. 2022 02 08; 145(6):437-447. PMID: 34775784; PMCID: PMC8812430.
      Citations: 43     Fields:    Translation:HumansCTClinical Trials
    130. Agarwal R, Joseph A, Filippatos G, Rossing P, Ruilope LM, Pitt B, Kolkhof P, Scott C, Lawatscheck R, Wilson DJ, Bakris GL, FIDELIO-DKD Investigators, Anker SD. Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. J Am Soc Nephrol. 2022 01; 33(1):225-237. PMID: 34732509; PMCID: PMC8763180.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    131. Kaneko H, Yano Y, Itoh H, Morita K, Kiriyama H, Kamon T, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Nishiyama A, Node K, Bakris G, Miura K, Muntner P, Viera AJ, Oparil S, Lloyd-Jones DM, Yasunaga H, Komuro I. Untreated Hypertension and Subsequent Incidence of Colorectal Cancer: Analysis of a Nationwide Epidemiological Database. J Am Heart Assoc. 2021 11 16; 10(22):e022479. PMID: 34724797; PMCID: PMC8751953.
      Citations: 6     Fields:    Translation:Humans
    132. Bakris GL, Barrera-Chimal J, Lima-Posada I, Jaisser F. Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects. Nat Rev Nephrol. 2022 01; 18(1):56-70. PMID: 34675379.
      Citations: 38     Fields:    Translation:Humans
    133. Pitt B, Jaisser F, Bakris G. An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension. Expert Opin Investig Drugs. 2021 Oct; 30(10):1017-1023. PMID: 34595995.
      Citations: 7     Fields:    Translation:Humans
    134. Rossing P, Filippatos G, Agarwal R, Pitt B, Ruilope LM, Chan JCN, Kooy A, McCafferty K, Schernthaner G, Joseph A, Scheerer MF, Scott C, Bakris GL, FIDELIO-DKD Investigators, Anker SD, Wanner C. Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy. Kidney Int Rep. 2022 Jan; 7(1):36-45. PMID: 35005312; PMCID: PMC8720648.
      Citations: 26     
    135. Salvador VD, Bakris GL. Longitudinal Blood Pressure Patterns and Chronic Kidney Disease Progression: An Evolving Paradigm. Hypertension. 2021 11; 78(5):1365-1367. PMID: 34644175.
      Citations:    Fields:    Translation:Humans
    136. Rossing P, Agarwal R, Filippatos G, Pitt B, Ruilope LM, Amod A, Joseph A, Scott C, Bakris GL, FIDELIO-DKD Investigators, Anker SD, Marre M, Lage A. Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial. Diabetes Obes Metab. 2022 01; 24(1):125-134. PMID: 34580995; PMCID: PMC9293162.
      Citations: 24     Fields:    Translation:Humans
    137. Zemke AM, Rodby RA, Hertl M, Waleed A, Bakris GL. Successful treatment of refractory hypertension with bilateral nephrectomy in a patient with chronic kidney disease stage 3. Clin Kidney J. 2022 Feb; 15(2):347-350. PMID: 35145649; PMCID: PMC8824767.
      Citations:    
    138. Heerspink HJL, Xie D, Bakris G, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Perkovic V, Rossing P, Parving HH, de Zeeuw D, on behalf on the SONAR Investigators, Correa-Rotter R. Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial. J Am Soc Nephrol. 2021 11; 32(11):2900-2911. PMID: 34551995; PMCID: PMC8806086.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    139. Bakris G, Mehta C, White WB, Ferreira JP, Rossignol P, Zannad F. Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial. Cardiovasc Diabetol. 2021 09 14; 20(1):187. PMID: 34521390; PMCID: PMC8442423.
      Citations: 2     Fields:    Translation:Humans
    140. Filippatos G, Agarwal R, Bakris G, FIDELIO-DKD Committees and Investigators, Anker S. Response by Filippatos et al to Letter Regarding Article, "Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes". Circulation. 2021 09 14; 144(11):e202-e203. PMID: 34516303.
      Citations:    Fields:    Translation:Humans
    141. FIGARO-DKD Investigators, Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021 12 09; 385(24):2252-2263. PMID: 34449181.
      Citations: 261     Fields:    Translation:HumansCTClinical Trials
    142. Kandzari DE, Townsend RR, Bakris G, Basile J, Bloch MJ, Cohen DL, East C, Ferdinand KC, Fisher N, Kirtane A, Lee DP, Puckrein G, Rader F, Vassalotti JA, Weber MA, Willis K, Secemsky E. Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by SCAI and NKF. Catheter Cardiovasc Interv. 2021 09; 98(3):416-426. PMID: 34343406.
      Citations: 11     Fields:    Translation:Humans
    143. Laffin LJ, Bakris GL. Approach to Resistant Hypertension from Cardiology and Nephrology Standpoints: Tailoring Therapy. Cardiol Clin. 2021 Aug; 39(3):377-387. PMID: 34247751.
      Citations:    Fields:    Translation:Humans
    144. Laffin LJ, Bakris GL. Intersection Between Chronic Kidney Disease and Cardiovascular Disease. Curr Cardiol Rep. 2021 07 16; 23(9):117. PMID: 34269921.
      Citations: 10     Fields:    Translation:Humans
    145. Al Dhaybi O, Bakris GL. Mineralocorticoid Receptor Antagonists-Evidence for Kidney Protection, Trials With Novel Agents. Adv Chronic Kidney Dis. 2021 07; 28(4):371-377. PMID: 34922693.
      Citations: 1     Fields:    Translation:Humans
    146. Bakris GL, Mikami H, Hirata M, Nakajima A, Cressman MD. A Non-purine Xanthine Oxidoreductase Inhibitor Reduces Albuminuria in Patients with DKD: A Randomized Controlled Trial. Kidney360. 2021 08 26; 2(8):1240-1250. PMID: 35369650; PMCID: PMC8676384.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    147. Pulipati VP, Mares JW, Bakris GL. Optimizing Blood Pressure Control Without Adding Anti-Hypertensive Medications. Am J Med. 2021 10; 134(10):1195-1198. PMID: 34197786.
      Citations:    Fields:    Translation:Humans
    148. Brook RD, Kaciroti N, Bakris G, Pitt B, Velazquez E, Weber MA, Jamerson KA, Dahlöf B. Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension. Am J Hypertens. 2021 05 22; 34(5):531-539. PMID: 33216879.
      Citations: 1     Fields:    Translation:Humans
    149. Filippatos G, Bakris GL, Pitt B, Agarwal R, Rossing P, Ruilope LM, Butler J, Lam CSP, Kolkhof P, Roberts L, Tasto C, Joseph A, FIDELIO-DKD Investigators, Anker SD. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. J Am Coll Cardiol. 2021 07 13; 78(2):142-152. PMID: 34015478.
      Citations: 36     Fields:    Translation:HumansCTClinical Trials
    150. Polonsky TS, Bakris GL. Systolic Blood Pressure During Exercise Testing: Where the Valley Means More Than the Peak. Hypertension. 2021 06; 77(6):1915-1917. PMID: 33979181.
      Citations:    Fields:    
    151. Bakris G, Pergola PE, Delgado B, Genov D, Doliashvili T, Vo N, Yang YF, McCabe J, Benn V, Pitt B, BLOCK-CKD Study Group. Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study. Hypertension. 2021 07; 78(1):74-81. PMID: 33966452; PMCID: PMC8189259.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    152. Morgan ES, Tami Y, Hu K, Brambatti M, Mullick AE, Geary RS, Bakris GL, Tsimikas S. Antisense Inhibition of Angiotensinogen With IONIS-AGT-LRx: Results of Phase 1 and Phase 2 Studies. JACC Basic Transl Sci. 2021 Jun; 6(6):485-496. PMID: 34222719; PMCID: PMC8246029.
      Citations: 9     
    153. Rossello X, Caimari F, Sharma A, Mehta C, Bakris G, Cannon CP, White WB, Ferreira JP, Lamiral Z, Zannad F. Influence of sex, age and race on coronary and heart failure events in patients with diabetes and post-acute coronary syndrome. Clin Res Cardiol. 2021 Oct; 110(10):1612-1624. PMID: 33929598.
      Citations: 6     Fields:    Translation:Humans
    154. Arnott C, Li JW, Cannon CP, de Zeeuw D, Neuen BL, Heerspink HJL, Charytan DM, Agarwal A, Huffman MD, Figtree GA, Bakris G, Chang TI, Feng K, Rosenthal N, Zinman B, Jardine MJ, Perkovic V, Neal B, Mahaffey KW. The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial. Diabetes Obes Metab. 2021 07; 23(7):1652-1659. PMID: 33769679.
      Citations: 2     Fields:    Translation:Humans
    155. Bakris G, Mehta C, White WB, Ferreira JP, Lamiral Z, Zannad F. Red cell distribution width in patients with diabetes and myocardial infarction: An analysis from the EXAMINE trial. Diabetes Obes Metab. 2021 07; 23(7):1580-1587. PMID: 33687751.
      Citations: 9     Fields:    Translation:HumansCells
    156. Bakris GL, Agarwal R, Filippatos G, FIDELIO-DKD Study Group. Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes. Reply. N Engl J Med. 2021 03 18; 384(11):e42. PMID: 33730470.
      Citations: 2     Fields:    Translation:Humans
    157. Bakris G, Sternlicht H. Time in Therapeutic Range: Redefining "Optimal" Blood Pressure Control. J Am Coll Cardiol. 2021 03 16; 77(10):1300-1301. PMID: 33706871; PMCID: PMC8091295.
      Citations: 4     Fields:    Translation:Humans
    158. Bakris GL, Woods SD, Alvarez PJ, Arthur SP, Kumar R. Hyperkalemia Management in Older Adults With Diabetic Kidney Disease Receiving Renin-Angiotensin-Aldosterone System Inhibitors: A Post Hoc Analysis of the AMETHYST-DN Clinical Trial. Kidney Med. 2021 May-Jun; 3(3):360-367.e1. PMID: 34136782; PMCID: PMC8178474.
      Citations: 1     
    159. Jardine M, Zhou Z, Lambers Heerspink HJ, Hockham C, Li Q, Agarwal R, Bakris GL, Cannon CP, Charytan DM, Greene T, Levin A, Li JW, Neuen BL, Neal B, Oh R, Oshima M, Pollock C, Wheeler DC, de Zeeuw D, Zhang H, Zinman B, Mahaffey KW, Perkovic V. Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis. Clin J Am Soc Nephrol. 2021 03 08; 16(3):384-395. PMID: 33619120; PMCID: PMC8011002.
      Citations: 16     Fields:    Translation:Humans
    160. Prischl FC, Rossing P, Bakris G, Mayer G, Wanner C. Major adverse renal events (MARE): a proposal to unify renal endpoints. Nephrol Dial Transplant. 2021 02 20; 36(3):491-497. PMID: 31711188.
      Citations: 7     Fields:    Translation:Humans
    161. Ye N, Jardine MJ, Oshima M, Hockham C, Heerspink HJL, Agarwal R, Bakris G, Schutte AE, Arnott C, Chang TI, Cannon CP, Charytan DM, de Zeeuw D, Levin A, Mahaffey KW, Neal B, Pollock C, Wheeler DC, Luca Di Tanna G, Cheng H, Perkovic V, Neuen BL, Górriz JL. Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial. Circulation. 2021 05 04; 143(18):1735-1749. PMID: 33554616.
      Citations: 22     Fields:    Translation:Humans
    162. Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, Zannad F. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021 01 07; 42(2):152-161. PMID: 33099609; PMCID: PMC7813624.
      Citations: 108     Fields:    Translation:Humans
    163. Koomen JV, Stevens J, Bakris G, Hou FF, Kitzman DW, Kohan DE, Makino H, McMurray JJV, Parving HH, Perkovic V, Tobe SW, de Zeeuw D, Heerspink HJL, Correa-Rotter R. Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease. Clin Pharmacol Ther. 2021 06; 109(6):1631-1638. PMID: 33338269; PMCID: PMC8246733.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    164. Riddle MC, Bakris G, Blonde L, Boulton AJM, D'Alessio D, DiMeglio LA, Gonder-Frederick L, Hood KK, Hu FB, Kahn SE, Kaul S, Leiter LA, Moses RG, Rich SS, Rosenstock J, Wylie-Rosett J. A Lesson From 2020: Public Health Matters for Both COVID-19 and Diabetes. Diabetes Care. 2021 01; 44(1):8-10. PMID: 33571952.
      Citations: 2     Fields:    
    165. Sarraju A, Li J, Cannon CP, Chang TI, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Greene T, Heerspink HJL, Levin A, Neal B, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Perkovic V, Jardine M, Mahaffey KW. Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. Am Heart J. 2021 03; 233:141-148. PMID: 33358942.
      Citations: 15     Fields:    Translation:Humans
    166. Hanrahan JP, de Boer IH, Bakris GL, Wilson PJ, Wakefield JD, Seferovic JP, Chickering JG, Chien YT, Carlson K, Cressman MD, Currie MG, Milne GT, Profy AT. Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial. Clin J Am Soc Nephrol. 2020 12 31; 16(1):59-69. PMID: 33328269; PMCID: PMC7792638.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    167. Aggarwal R, Lu K, Chiu N, Bakris GL, Bhatt DL. U.S. Prevalence of Individuals With Diabetes and Chronic Kidney Disease Indicated for SGLT-2 Inhibitor Therapy. J Am Coll Cardiol. 2020 12 15; 76(24):2907-2910. PMID: 33303081.
      Citations: 1     Fields:    Translation:Humans
    168. Oshima M, Jardine MJ, Agarwal R, Bakris G, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Levin A, Lim SK, Mahaffey KW, Neal B, Pollock C, Rosenthal N, Wheeler DC, Zhang H, Zinman B, Perkovic V, Heerspink HJL. Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. Kidney Int. 2021 04; 99(4):999-1009. PMID: 33316282.
      Citations: 32     Fields:    Translation:Humans
    169. Koomen JV, Stevens J, Bakris G, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Parving HH, Perkovic V, Tobe SW, de Zeeuw D, Heerspink HJL, Correa-Rotter R. Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial. Diabetes Obes Metab. 2021 02; 23(2):561-568. PMID: 33184931; PMCID: PMC7839558.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    170. Oshima M, Mahaffey KW, Agarwal R, Cannon CP, Capuano G, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Neal B, Oh R, Pollock C, Rosenthal N, Wheeler DC, Zhang H, Zinman B, Jardine MJ, Perkovic V, Bakris G. Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial. Clin J Am Soc Nephrol. 2020 12 07; 15(12):1705-1714. PMID: 33214158; PMCID: PMC7769025.
      Citations: 40     Fields:    Translation:Humans
    171. Filippatos G, Agarwal R, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Schloemer P, Tornus I, Joseph A, Bakris GL, FIDELIO-DKD Investigators, Anker SD. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation. 2021 02 09; 143(6):540-552. PMID: 33198491; PMCID: PMC7864612.
      Citations: 87     Fields:    Translation:HumansCTClinical Trials
    172. Weir MR, Bakris GL, Mattheus M, Cherney DZI, Sattar N, Heerspink HJL, Ritter I, Zinman B, Inzucchi SE, Kraus BJ, von Eynatten M, Wanner C, Koitka-Weber A. Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int. 2021 03; 99(3):750-762. PMID: 33181154.
      Citations: 43     Fields:    Translation:Humans
    173. Itano S, Yano Y, Nagasu H, Tomiyama H, Kanegae H, Makino H, Higashi Y, Kobayashi Y, Sogawa Y, Satoh M, Suzuki K, Townsend RR, Budoff M, Bakris G, Kashihara N. Association of Arterial Stiffness With Kidney Function Among Adults Without Chronic Kidney Disease. Am J Hypertens. 2020 11 03; 33(11):1003-1010. PMID: 32530466; PMCID: PMC7750955.
      Citations: 4     Fields:    Translation:Humans
    174. Oshima M, Neuen BL, Jardine MJ, Bakris G, Edwards R, Levin A, Mahaffey KW, Neal B, Pollock C, Rosenthal N, Wada T, Wheeler DC, Perkovic V, Heerspink HJL. Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. Lancet Diabetes Endocrinol. 2020 11; 8(11):903-914. PMID: 33065060.
      Citations: 34     Fields:    Translation:Humans
    175. Ali W, Nathan S, Funaki B, Eggener S, Bakris G. An Unusual Case of Resistant Hypertension Secondary to Fibromuscular Dysplasia. JACC Case Rep. 2020 Dec; 2(15):2460-2464. PMID: 34317194; PMCID: PMC8304536.
      Citations:    
    176. FIDELIO-DKD Investigators, Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 03; 383(23):2219-2229. PMID: 33264825.
      Citations: 503     Fields:    Translation:HumansCTClinical Trials
    177. Ali W, Bakris GL. How to Manage Hypertension in People With Diabetes. Am J Hypertens. 2020 10 21; 33(10):935-943. PMID: 32307510.
      Citations: 1     Fields:    Translation:Humans
    178. Bakris G. Stemming the Progression of Diabetic Kidney Disease: The Role of the Primary Care Clinician. J Fam Pract. 2020 09; 69(7 Suppl):S81-S86. PMID: 33104113.
      Citations:    Fields:    Translation:Humans
    179. Sharma A, Mehta C, Bakris G, White WB, Ferreira JP, Rossignol P, Zannad F. Multi-proteomic approach to predict specific cardiovascular events in patients with diabetes and myocardial infarction: findings from the EXAMINE trial. Clin Res Cardiol. 2021 Jul; 110(7):1006-1019. PMID: 32789678.
      Citations: 11     Fields:    Translation:Humans
    180. Elharram M, Sharma A, White W, Bakris G, Mehta C, Rossignol P, Ferreira JP, Zannad F. Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus. Am Heart J. 2020 11; 229:40-51. PMID: 32916607.
      Citations: 1     Fields:    Translation:Humans
    181. Sarafidis P, Bakris G. Diastolic Blood Pressure Does Not Influence Cardiovascular Outcomes in Type 2 Diabetes; or Does It? Diabetes Care. 2020 08; 43(8):1684-1686. PMID: 32669408.
      Citations: 1     Fields:    Translation:Humans
    182. Ali W, Bakris G. Evolution of Patiromer Use: a Review. Curr Cardiol Rep. 2020 07 09; 22(9):94. PMID: 32648072.
      Citations: 5     Fields:    Translation:Humans
    183. Sternlicht HK, Bakris GL. Reductions in albuminuria with SGLT2 inhibitors: a marker for improved renal outcomes in patients without diabetes? Lancet Diabetes Endocrinol. 2020 07; 8(7):553-555. PMID: 32559465.
      Citations: 2     Fields:    Translation:Humans
    184. Sarafidis PA, Loutradis C, Karpetas A, Tzanis G, Bikos A, Raptis V, Syrgkanis C, Liakopoulos V, Papagianni A, Bakris G, Parati G. The association of interdialytic blood pressure variability with cardiovascular events and all-cause mortality in haemodialysis patients. Nephrol Dial Transplant. 2020 07 01; 35(7):1277. PMID: 30239875.
      Citations: 2     Fields:    
    185. Bakris G, Yang YF, Pitt B. Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease: BLOCK-CKD Trial. Hypertension. 2020 07; 76(1):144-149. PMID: 32520623.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    186. Butler J, Pitt B, Kosiborod M, Lund LH, Bakris GL, Weir MR, Ferreira JP, Rossignol P, Anker SD, Zannad F. Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 06 09; 75(22):2836-2850. PMID: 32498812.
      Citations: 43     Fields:    Translation:Humans
    187. Al Dhaybi O, Bakris GL. Factitious acidosis and severe hypoalbuminemia caused by unsuspected assay interference. Clin Kidney J. 2021 Mar; 14(3):1023-1024. PMID: 34840734; PMCID: PMC8612138.
      Citations:    
    188. Jardine MJ, Zhou Z, Mahaffey KW, Oshima M, Agarwal R, Bakris G, Bajaj HS, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Di Tanna GL, Greene T, Heerspink HJL, Levin A, Neal B, Pollock C, Qiu R, Sun T, Wheeler DC, Zhang H, Zinman B, Rosenthal N, Perkovic V, CREDENCE Study Investigators. Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. J Am Soc Nephrol. 2020 05; 31(5):1128-1139. PMID: 32354987; PMCID: PMC7217416.
      Citations: 51     Fields:    Translation:Humans
    189. Al Dhaybi O, Bakris GL. Non-steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease. Diabetes Obes Metab. 2020 04; 22 Suppl 1:69-76. PMID: 32267074.
      Citations: 6     Fields:    Translation:Humans
    190. Bakris GL, Josephson MA. Improvement of Cardiovascular Functional Reserve After Kidney Transplant-Has the CAPER Been Solved? JAMA Cardiol. 2020 04 01; 5(4):430-431. PMID: 32022826.
      Citations:    Fields:    Translation:HumansAnimals
    191. Ali WE, Bakris GL. Fear of Lowering Cardiovascular Risk by Achieving Blood Pressure Goals: The Irrationality of Combination Therapy Avoidance. Hypertension. 2020 04; 75(4):943-944. PMID: 32148130.
      Citations:    Fields:    Translation:Humans
    192. Idzerda NMA, Clegg LE, Hernandez AF, Bakris G, Penland RC, Boulton DW, Bethel MA, Holman RR, Heerspink HJL. Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL. Diabetes Obes Metab. 2020 05; 22(5):798-806. PMID: 31912603; PMCID: PMC7187441.
      Citations: 8     Fields:    Translation:Humans
    193. Ali W, Gao G, Bakris GL. Improved Sleep Quality Improves Blood Pressure Control among Patients with Chronic Kidney Disease: A Pilot Study. Am J Nephrol. 2020; 51(3):249-254. PMID: 31982868.
      Citations: 2     Fields:    Translation:Humans
    194. Butler J, Handelsman Y, Bakris G, Verma S. Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure. Eur J Heart Fail. 2020 04; 22(4):604-617. PMID: 31926059.
      Citations: 18     Fields:    Translation:Humans
    195. Vaduganathan M, Liu Y, Bakris GL, Cannon CP, White WB, Sharma A, Ferreira JP, Zannad F. Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial. J Am Heart Assoc. 2020 01 07; 9(1):e012797. PMID: 31902327; PMCID: PMC6988143.
      Citations: 11     Fields:    Translation:Humans
    196. Polonsky TS, Bakris GL. Paradoxical Cardiorenal Responses Following Acute Vasodilator/Natriuretic Treatment in Presystolic Heart Failure: Should We Be Surprised? JACC Basic Transl Sci. 2019 Dec; 4(8):973-975. PMID: 31909769; PMCID: PMC6938987.
      Citations:    
    197. Alexandrou ME, Papagianni A, Tsapas A, Loutradis C, Boutou A, Piperidou A, Papadopoulou D, Ruilope L, Bakris G, Sarafidis P. Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2019 12; 37(12):2307-2324. PMID: 31688290.
      Citations: 30     Fields:    Translation:Humans
    198. Bethel MA, Mentz RJ, Merrill P, Buse JB, Chan JC, Goodman SG, Iqbal N, Jakuboniene N, Katona B, Lokhnygina Y, Lopes RD, Maggioni AP, Ohman P, Tankova T, Bakris GL, Hernandez AF, Holman RR. Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. Diabetes Care. 2020 02; 43(2):446-452. PMID: 31757838; PMCID: PMC7411285.
      Citations: 31     Fields:    Translation:Humans
    199. Cannon CP, Perkovic V, Agarwal R, Baldassarre J, Bakris G, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Jardine MJ, Levin A, Li JW, Neal B, Pollock C, Wheeler DC, Zhang H, Zinman B, Mahaffey KW. Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial. Circulation. 2020 02 04; 141(5):407-410. PMID: 31707795.
      Citations: 38     Fields:    Translation:Humans
    200. Ruilope LM, Agarwal R, Bakris GL, Filippatos G, Nowack C, Kolkhof P, Joseph A, Mentenich N, Pitt B, Anker SD, FIGARO-DKD study investigators. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. Am J Nephrol. 2019; 50(5):345-356. PMID: 31665733; PMCID: PMC6889917.
      Citations: 58     Fields:    Translation:HumansCTClinical Trials
    201. Bakris GL, Agarwal R, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Schloemer P, Filippatos G, Anker SD, Ferreira AC, on behalf of the FIDELIO-DKD study investigators, FIDELIO-DKD study investigators. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. Am J Nephrol. 2019; 50(5):333-344. PMID: 31655812; PMCID: PMC6888890.
      Citations: 46     Fields:    Translation:HumansCTClinical Trials
    202. Koyner J, Bakris G. Kidney injury is not prevented by hydration alone. Eur Heart J. 2019 10 07; 40(38):3179-3181. PMID: 31263876.
      Citations:    Fields:    Translation:Humans
    203. Baliga RR, Bossone E, Bakris GL. Hypertensive Heart Failure: Sprinting to the Finish Line to Prevent End-Organ Damage. Heart Fail Clin. 2019 10; 15(4):xiii-xv. PMID: 31472892.
      Citations:    Fields:    
    204. Bakris G. Chronic Kidney Disease in Type 2 Diabetes: Optimizing Glucose-Lowering Therapy. J Fam Pract. 2019 10; 68(8):S1-S6. PMID: 31697796.
      Citations:    Fields:    Translation:Humans
    205. Bakris GL, Berglund LF, Hivert MF, Horton ES, Kalyani RR, Murad MH, Rosenzweig JL, Vergès BL. Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2019 Sep 01; 104(9):3939-3985. PMID: 31365087.
      Citations: 17     Fields:    
    206. Burnier M, Bakris G, Williams B. Redefining diuretics use in hypertension: why select a thiazide-like diuretic? J Hypertens. 2019 08; 37(8):1574-1586. PMID: 30882593; PMCID: PMC6615933.
      Citations: 23     Fields:    Translation:Humans
    207. Polonsky TS, Bakris GL. Heart Failure and Changes in Kidney Function: Focus on Understanding, Not Reacting. Heart Fail Clin. 2019 Oct; 15(4):455-461. PMID: 31472881.
      Citations: 2     Fields:    Translation:Humans
    208. Mahaffey KW, Jardine MJ, Bompoint S, Cannon CP, Neal B, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Capuano G, de Zeeuw D, Greene T, Levin A, Pollock C, Sun T, Wheeler DC, Yavin Y, Zhang H, Zinman B, Rosenthal N, Brenner BM, Perkovic V. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. Circulation. 2019 08 27; 140(9):739-750. PMID: 31291786; PMCID: PMC6727954.
      Citations: 91     Fields:    Translation:HumansPHPublic Health
    209. Bakris GL. Major Advancements in Slowing Diabetic Kidney Disease Progression: Focus on SGLT2 Inhibitors. Am J Kidney Dis. 2019 11; 74(5):573-575. PMID: 31262591.
      Citations: 9     Fields:    Translation:Humans
    210. Bakris G, Ali W, Parati G. ACC/AHA Versus ESC/ESH on Hypertension Guidelines: JACC Guideline Comparison. J Am Coll Cardiol. 2019 06 18; 73(23):3018-3026. PMID: 31196460.
      Citations: 91     Fields:    Translation:Humans
    211. Bakris GL, Laffin LJ. Assessing Wide Pulse Pressure Hypertension: Data Beyond the Guidelines. J Am Coll Cardiol. 2019 06 11; 73(22):2856-2858. PMID: 31171091; PMCID: PMC7111461.
      Citations: 5     Fields:    Translation:Humans
    212. Ali W, Bakris G. The Management of Hypertension in 2018: What Should the Targets Be? Curr Hypertens Rep. 2019 04 25; 21(6):41. PMID: 31025203.
      Citations: 7     Fields:    Translation:Humans
    213. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW, CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 06 13; 380(24):2295-2306. PMID: 30990260.
      Citations: 1673     Fields:    Translation:Humans
    214. Heerspink HJL, Parving HH, Andress DL, Bakris G, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D, SONAR Committees and Investigators, Correa-Rotter R. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019 05 11; 393(10184):1937-1947. PMID: 30995972.
      Citations: 200     Fields:    Translation:Humans
    215. Bakris G. Similarities and Differences Between the ACC/AHA and ESH/ESC Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Circ Res. 2019 03 29; 124(7):969-971. PMID: 30920926.
      Citations: 3     Fields:    Translation:Humans
    216. Sarafidis PA, Loutradis C, Karpetas A, Tzanis G, Bikos A, Raptis V, Syrgkanis C, Liakopoulos V, Papagianni A, Bakris G, Parati G. The association of interdialytic blood pressure variability with cardiovascular events and all-cause mortality in haemodialysis patients. Nephrol Dial Transplant. 2019 03 01; 34(3):515-523. PMID: 30184172.
      Citations: 12     Fields:    Translation:Humans
    217. Vijayakumar S, Butler J, Bakris GL. Barriers to guideline mandated renin-angiotensin inhibitor use: focus on hyperkalaemia. Eur Heart J Suppl. 2019 Feb; 21(Suppl A):A20-A27. PMID: 30837801; PMCID: PMC6392419.
      Citations: 4     
    218. Sternlicht H, Bakris GL. Blood Pressure Lowering and Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2is): More Than Osmotic Diuresis. Curr Hypertens Rep. 2019 02 12; 21(2):12. PMID: 30747296.
      Citations: 18     Fields:    Translation:Humans
    219. Ihm SH, Bakris G, Sakuma I, Sohn IS, Koh KK. Controversies in the 2017 ACC/AHA Hypertension Guidelines: Who Can Be Eligible for Treatments Under the New Guidelines? - An Asian Perspective. Circ J. 2019 02 25; 83(3):504-510. PMID: 30606943.
      Citations: 11     Fields:    Translation:Humans
    220. Parati G, Agabiti-Rosei E, Bakris GL, Bilo G, Branzi G, Chrostowska M, De la Sierra A, Dorobantu M, Faria T, Huo Y, Jelakovic B, Kahan T, Konradi A, Li N, Madan K, Mancia G, McManus RJ, Modesti PA, Ochoa JE, Omboni S, Palatini P, Park JB, Pellegrini D, Perl S, Podoleanu C, Pucci G, Redon J, Rhee MY, Rodilla Sala E, Sanchez R, Schmieder R, Soranna D, Stergiou G, Stojanovic M, Tsioufis K, Valsecchi MG, Waisman GD, Wang JG, Wijnmaalen P, Zambon A, Zanchetti A, Zhang Y, Cecchi F, Domenech M, Laurent S, Octavio JA, Renna N, Veglio F. MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol. BMJ Open. 2018 12 19; 8(12):e021038. PMID: 30573476; PMCID: PMC6303603.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    221. Bakris GL, Agarwal R. Creatinine Bump Following Antihypertensive Therapy. Hypertension. 2018 12; 72(6):1274-1276. PMID: 30571245.
      Citations: 2     Fields:    Translation:Humans
    222. Hammes M, Bakris GL. Intradialytic Hypotension: Is Midodrine the Answer? Am J Nephrol. 2018; 48(5):378-380. PMID: 30423560.
      Citations: 2     Fields:    Translation:Humans
    223. Vaduganathan M, White WB, Charytan DM, Morrow DA, Liu Y, Cannon CP, Bakris GL, EXAMINE Investigators, Zannad F. Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial). Am J Cardiol. 2019 02 01; 123(3):382-391. PMID: 30477800.
      Citations: 5     Fields:    Translation:Humans
    224. Polonsky TS, Bakris GL. Ambulatory Blood Pressure Monitoring. JAMA. 2018 Nov 06; 320(17):1807-1808. PMID: 30398582.
      Citations: 2     Fields:    Translation:Humans
    225. de Zeeuw D, Renfurm RW, Bakris G, Rossing P, Perkovic V, Hou FF, Nangaku M, Sharma K, Heerspink HJL, Garcia-Hernandez A, Larsson TE. Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2018 12; 6(12):925-933. PMID: 30413396.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    226. Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, Egan BM, Flack JM, Gidding SS, Judd E, Lackland DT, Laffer CL, Newton-Cheh C, Smith SM, Taler SJ, Textor SC, Turan TN, White WB, American Heart Association Professional/Public Education and Publications Committee of the Council o. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018 11; 72(5):e53-e90. PMID: 30354828; PMCID: PMC6530990.
      Citations: 276     Fields:    Translation:Humans
    227. Ali WE, Bakris GL. Initial single-pill combinations for antihypertensive treatment: greater cardiovascular mortality reduction yet still not used. Eur Heart J. 2018 10 21; 39(40):3662-3663. PMID: 30137271.
      Citations:    Fields:    Translation:Humans
    228. White WB, Jalil F, Cushman WC, Bakris GL, Bergenstal R, Heller SR, Liu Y, Mehta C, Cannon CP, Zannad F. Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial. J Am Heart Assoc. 2018 10 16; 7(20):e009114. PMID: 30371278; PMCID: PMC6474950.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    229. Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, Fulcher G, Desai M, Li Q, Deng H, Rosenthal N, Jardine MJ, Bakris G, Perkovic V. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. Circulation. 2018 10 09; 138(15):1537-1550. PMID: 29941478; PMCID: PMC6181277.
      Citations: 92     Fields:    Translation:Humans
    230. Laffin LJ, Bakris GL. Has the Sun Set on Nighttime Dosing in Uncomplicated Hypertension? Hypertension. 2018 10; 72(4):836-838. PMID: 30354732; PMCID: PMC6289950.
      Citations: 1     Fields:    Translation:Humans
    231. Schlaich MP, Bakris GL. Renal denervation: one step backwards, three steps forward. Nat Rev Nephrol. 2018 10; 14(10):602-604. PMID: 29980772.
      Citations: 1     Fields:    Translation:Humans
    232. Bakris GL, Polonsky TS. Presence of Diabetes Does Not Mandate Lower Blood Pressure to Reduce Cardiovascular Events. J Am Coll Cardiol. 2018 09 11; 72(11):1224-1226. PMID: 30189999.
      Citations:    Fields:    Translation:Humans
    233. Bakris G, Sorrentino M. Perspective on the New Blood-Pressure Guidelines. Eur Heart J. 2018 Sep 01; 39(33):3008-3009. PMID: 30990868.
      Citations:    Fields:    
    234. Ferdinand KC, Bakris GL, Cushman WC, Weber MA, Lloyd E, Wu J, White WB. Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension. Am J Cardiol. 2018 11 01; 122(9):1496-1505. PMID: 30217371.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    235. K Dojki F, Bakris GL. Hyperkalaemia in diabetes: a silent risk predicting poor outcomes. Diabet Med. 2018 08; 35(8):1049-1050. PMID: 29790205.
      Citations:    Fields:    Translation:Humans
    236. Riddle MC, Bakris G, Boulton AJM, Blonde L, D'Alessio D, Greene EL, de Groot M, Hood K, Hu FB, Kahn SE, Kaul S, LeRoith D, Moses RG, Rich SS, Rosenstock J, Tamborlane WV, Wylie-Rosett J, Reynolds L. Big Topics for Diabetes Care in 2018: Clinical Guidelines, Costs of Diabetes, and Information Technology. Diabetes Care. 2018 07; 41(7):1327-1329. PMID: 29934474.
      Citations:    Fields:    
    237. Pitt B, Bakris GL, Weir MR, Freeman MW, Lainscak M, Mayo MR, Garza D, Zawadzki R, Berman L, Bushinsky DA. Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN. ESC Heart Fail. 2018 08; 5(4):592-602. PMID: 29767459; PMCID: PMC6073017.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    238. Cannon CP, White WB, Liu Y, Bakris GL, Cushman WC, Sharma A, Zannad F. Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial. J Am Heart Assoc. 2018 05 16; 7(11). PMID: 29769203; PMCID: PMC6015373.
      Citations: 3     Fields:    Translation:Humans
    239. Heerspink HJL, Andress DL, Bakris G, Brennan JJ, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray J, Perkovic V, Tobe S, Wigderson M, Yi T, Parving HH, de Zeeuw D, Correa-Rotter R. Baseline characteristics and enrichment results from the SONAR trial. Diabetes Obes Metab. 2018 08; 20(8):1829-1835. PMID: 29604160; PMCID: PMC6055730.
      Citations: 16     Fields:    Translation:Humans
    240. de Boer IH, Bakris G, Cannon CP. Individualizing Blood Pressure Targets for People With Diabetes and Hypertension: Comparing the ADA and the ACC/AHA Recommendations. JAMA. 2018 Apr 03; 319(13):1319-1320. PMID: 29543954.
      Citations: 13     Fields:    Translation:Humans
    241. Cushman WC, Bakris GL, White WB, Weber MA, Sica D, Roberts A, Lloyd E, Kupfer S. A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension. J Hypertens. 2018 04; 36(4):947-956. PMID: 29334491; PMCID: PMC5862000.
      Citations: 3     Fields:    Translation:Humans
    242. de Boer IH, Bakris GL. Diabetic Kidney Disease: A Determinant of Cardiovascular Risk in Type 1 Diabetes. Diabetes Care. 2018 04; 41(4):662-663. PMID: 29559452; PMCID: PMC6463621.
      Citations: 8     Fields:    Translation:Humans
    243. Omboni S, Kario K, Bakris G, Parati G. Effect of antihypertensive treatment on 24-h blood pressure variability: pooled individual data analysis of ambulatory blood pressure monitoring studies based on olmesartan mono or combination treatment. J Hypertens. 2018 04; 36(4):720-733. PMID: 29045341; PMCID: PMC5862001.
      Citations: 9     Fields:    Translation:Humans
    244. Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Dominiczak AF, Grassi G, Jordan J, Poulter NR, Rodgers A, Whelton PK, Cífková R. Hypertension. Nat Rev Dis Primers. 2018 03 22; 4:18014. PMID: 29565029; PMCID: PMC6477925.
      Citations: 330     Fields:    Translation:Humans
    245. Al Dhaybi O, Bakris GL. Blood pressure reduced to new guideline goals in patients with high-normal glucose further reduces cardiovascular events. J Clin Hypertens (Greenwich). 2018 04; 20(4):625-626. PMID: 29532984; PMCID: PMC8031035.
      Citations: 1     Fields:    Translation:Humans
    246. Greene SJ, Vaduganathan M, Khan MS, Bakris GL, Weir MR, Seltzer JH, Sattar N, McGuire DK, Januzzi JL, Stockbridge N, Butler J. Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. J Am Coll Cardiol. 2018 03 27; 71(12):1379-1390. PMID: 29534825; PMCID: PMC5832063.
      Citations: 17     Fields:    Translation:Humans
    247. Heerspink HJL, Andress DL, Bakris G, Brennan JJ, Dey J, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray J, Perkovic V, Tobe S, Wigderson M, Parving HH, de Zeeuw D, Correa-Rotter R. Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes Obes Metab. 2018 06; 20(6):1369-1376. PMID: 29405626; PMCID: PMC5969254.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    248. Bakris GL, Zhao L, Kupfer S, Juhasz A, Hisada M, Lloyd E, Oparil S. Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease. J Clin Hypertens (Greenwich). 2018 04; 20(4):694-702. PMID: 29504252; PMCID: PMC8031057.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    249. Bakris GL, Molitch M. Are All Patients With Type 1 Diabetes Destined for Dialysis if They Live Long Enough? Probably Not. Diabetes Care. 2018 03; 41(3):389-390. PMID: 29463664.
      Citations: 10     Fields:    Translation:Humans
    250. Dojki FK, Bakris GL. Blood Pressure Control and Cardiovascular/Renal Outcomes. Endocrinol Metab Clin North Am. 2018 03; 47(1):175-184. PMID: 29407050.
      Citations: 4     Fields:    Translation:Humans
    251. Laffin LJ, Bakris GL. Results of ACCORDIAN in ACCORD with lower blood pressure begetting lower mortality in patients with diabetes. Diabetes Obes Metab. 2018 06; 20(6):1335-1336. PMID: 29424470; PMCID: PMC5948152.
      Citations: 1     Fields:    Translation:Humans
    252. Johnson RJ, Bakris GL, Borghi C, Chonchol MB, Feldman D, Lanaspa MA, Merriman TR, Moe OW, Mount DB, Stahl E, Weiner DE, Chertow GM, Sanchez Lozada LG. Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation. Am J Kidney Dis. 2018 06; 71(6):851-865. PMID: 29496260; PMCID: PMC7286363.
      Citations: 176     Fields:    Translation:Humans
    253. Briasoulis A, Al Dhaybi O, Bakris GL. SGLT2 Inhibitors and Mechanisms of Hypertension. Curr Cardiol Rep. 2018 01 19; 20(1):1. PMID: 29349558.
      Citations: 26     Fields:    Translation:Humans
    254. Chin MP, Bakris GL, Block GA, Chertow GM, Goldsberry A, Inker LA, Heerspink HJL, O'Grady M, Pergola PE, Wanner C, Warnock DG, Meyer CJ. Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study. Am J Nephrol. 2018; 47(1):40-47. PMID: 29402767; PMCID: PMC5841134.
      Citations: 67     Fields:    Translation:HumansCTClinical Trials
    255. Bakris G, Sorrentino M. Redefining Hypertension - Assessing the New Blood-Pressure Guidelines. N Engl J Med. 2018 02 08; 378(6):497-499. PMID: 29341841.
      Citations: 36     Fields:    Translation:Humans
    256. White WB, Bakris GL, Zannad F, Wilson CA, Kupfer S, Vaduganathan M, Morrow DA, Cannon CP, Charytan DM, Garlo KG. Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes. Clin J Am Soc Nephrol. 2018 03 07; 13(3):398-405. PMID: 29339356; PMCID: PMC5967667.
      Citations: 15     Fields:    Translation:Humans
    257. Plutzky J, Bakris G. Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease: Turning the Page. Circulation. 2018 01 09; 137(2):130-133. PMID: 29311346.
      Citations: 2     Fields:    Translation:Humans
    258. Brook RD, Kaciroti N, Bakris G, Pitt B, Velazquez E, Weber M, Zappe DH, Hau T, Jamerson KA, Dahlöf B. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients. J Am Heart Assoc. 2018 01 04; 7(1). PMID: 29301757; PMCID: PMC5778960.
      Citations: 4     Fields:    Translation:Humans
    259. Bakris GL. Update on reducing the development of diabetic kidney disease and cardiovascular death in diabetes. Kidney Int Suppl (2011). 2018 Jan; 8(1):1. PMID: 30675432; PMCID: PMC6336218.
      Citations: 2     
    260. Cherney DZI, Bakris GL. Novel therapies for diabetic kidney disease. Kidney Int Suppl (2011). 2018 Jan; 8(1):18-25. PMID: 30675435; PMCID: PMC6336219.
      Citations: 18     
    261. Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Pollock C, Wheeler DC, Xie J, Zhang H, Zinman B, Desai M, Perkovic V, CREDENCE study investigators. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. Am J Nephrol. 2017 Dec 13; 46(6):462-472. PMID: 29253846; PMCID: PMC5804835.
      Citations: 82     Fields:    
    262. Weir MR, Bushinsky DA, Benton WW, Woods SD, Mayo MR, Arthur SP, Pitt B, Bakris GL. Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors. Am J Med. 2018 05; 131(5):555-564.e3. PMID: 29180023.
      Citations: 24     Fields:    Translation:Humans
    263. Hwang YC, Morrow DA, Cannon CP, Liu Y, Bergenstal R, Heller S, Mehta C, Cushman W, Bakris GL, Zannad F, White WB. High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial. Diabetes Obes Metab. 2018 03; 20(3):654-659. PMID: 29064626; PMCID: PMC5836896.
      Citations: 15     Fields:    Translation:Humans
    264. Al Dhabyi O, Bakris GL. Initial Single-Pill Blood Pressure-Lowering Therapy: Should It Be for Most People? J Am Heart Assoc. 2017 11 18; 6(11). PMID: 29151038; PMCID: PMC5721807.
      Citations: 1     Fields:    Translation:Humans
    265. Yamout H, Bakris GL. Consequences of Overinterpreting Serum Creatinine Increases when Achieving BP Reduction: Balancing Risks and Benefits of BP Reduction in Hypertension. Clin J Am Soc Nephrol. 2018 01 06; 13(1):9-10. PMID: 29101187; PMCID: PMC5753324.
      Citations: 4     Fields:    Translation:Humans
    266. Deedwania P, Weber M, Reimitz PE, Bakris G. Olmesartan-based monotherapy vs combination therapy in hypertension: A meta-analysis based on age and chronic kidney disease status. J Clin Hypertens (Greenwich). 2017 Dec; 19(12):1309-1318. PMID: 29067756; PMCID: PMC5765479.
      Citations: 3     Fields:    Translation:Humans
    267. Bakris GL. MY APPROACH to the elderly patient with resistant hypertension. Trends Cardiovasc Med. 2018 01; 28(1):79-80. PMID: 29032932.
      Citations:    Fields:    Translation:Humans
    268. de Boer IH, Bangalore S, Davis AM, Michos ED, Muntner P, Rossing P, Zoungas S, Bakris G, Benetos A. Diabetes and Hypertension: A Position Statement by the American Diabetes Association. Diabetes Care. 2017 09; 40(9):1273-1284. PMID: 28830958.
      Citations: 204     Fields:    
    269. Dojki FK, Bakris G. Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease. Curr Opin Nephrol Hypertens. 2017 09; 26(5):368-374. PMID: 28771453.
      Citations: 11     Fields:    Translation:Humans
    270. Laffin LJ, Bakris GL. Catheter-Based Renal Denervation for Resistant Hypertension: Will It Ever Be Ready for "Prime Time"? Am J Hypertens. 2017 Sep 01; 30(9):841-846. PMID: 27838622; PMCID: PMC6279104.
      Citations: 2     Fields:    Translation:Humans
    271. Ai Dhaybi O, Bakris GL. Renal Targeted Therapies of Antihypertensive and Cardiovascular Drugs for Patients With Stages 3 Through 5d Kidney Disease. Clin Pharmacol Ther. 2017 Sep; 102(3):450-458. PMID: 28589612.
      Citations: 4     Fields:    Translation:HumansAnimals
    272. Waksman R, Bakris GL, Steinvil A, Garcia-Garcia H, Brown AL, DiFilippo W, Scott T, Singh J, DeBruin V, Jones D, Jolivette D, Bhatt DL. High screen failure rate in patients with resistant hypertension: Findings from SYMPLICITY HTN-3. Am Heart J. 2017 Oct; 192:76-84. PMID: 28938966.
      Citations: 3     Fields:    Translation:HumansPHPublic Health
    273. Laffin LJ, Jafar MS, Bakris GL. Severe menses-associated hypertension successfully treated with gonadotropin-releasing hormone agonist. J Clin Hypertens (Greenwich). 2017 Nov; 19(11):1202-1203. PMID: 28646567; PMCID: PMC5745160.
      Citations: 1     Fields:    Translation:Humans
    274. Johnson W, White WB, Sica D, Bakris GL, Weber MA, Handley A, Perez A, Cao C, Kupfer S, Saunders EB. Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertension. J Clin Hypertens (Greenwich). 2017 Jul; 19(7):695-701. PMID: 28493376; PMCID: PMC8031359.
      Citations: 4     Fields:    Translation:Humans
    275. Ku E, Bakris G, Johansen KL, Lin F, Sarnak MJ, Campese VM, Jamerson K, Gassman JJ, Smogorzewski M, Hsu CY. Acute Declines in Renal Function during Intensive BP Lowering: Implications for Future ESRD Risk. J Am Soc Nephrol. 2017 Sep; 28(9):2794-2801. PMID: 28473636; PMCID: PMC5576942.
      Citations: 16     Fields:    Translation:Humans
    276. Kario K, Bhatt DL, Brar S, Bakris GL. Differences in Dynamic Diurnal Blood Pressure Variability Between Japanese and American Treatment-Resistant Hypertensive Populations. Circ J. 2017 Aug 25; 81(9):1337-1345. PMID: 28458378.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    277. Sternlicht H, Bakris GL. Resistant Hypertension: A Refractory Disease or Refractory Patient. Hypertension. 2017 04; 69(4):582-583. PMID: 28264919.
      Citations: 2     Fields:    Translation:Humans
    278. de Leeuw PW, Bisognano JD, Bakris GL, Nadim MK, Haller H, Kroon AA, DEBuT-HT and Rheos Trial Investigators. Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy: Results of the 6-Year Open Follow-Up. Hypertension. 2017 May; 69(5):836-843. PMID: 28320856.
      Citations: 36     Fields:    Translation:HumansCells
    279. Cavender MA, White WB, Jarolim P, Bakris GL, Cushman WC, Kupfer S, Gao Q, Mehta CR, Zannad F, Cannon CP, Morrow DA. Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care). Circulation. 2017 May 16; 135(20):1911-1921. PMID: 28246236.
      Citations: 25     Fields:    Translation:Humans
    280. Heller SR, Bergenstal RM, White WB, Kupfer S, Bakris GL, Cushman WC, Mehta CR, Nissen SE, Wilson CA, Liu Y, Gourlie NM, Cannon CP, EXAMINE Investigators, Zannad F. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial. Diabetes Obes Metab. 2017 05; 19(5):664-671. PMID: 28058763; PMCID: PMC5836868.
      Citations: 24     Fields:    Translation:HumansPHPublic Health
    281. Bakris G. Response by Bakris to Letter Regarding Article, "The Implications of Blood Pressure Measurement Methods on Treatment Targets for Blood Pressure". Circulation. 2017 02 14; 135(7):e47. PMID: 28193804.
      Citations: 2     Fields:    
    282. Bakris G, Briasoulis A. Searching for the Optimal Blood Pressure Range in the Elderly: Are We There Yet? J Am Coll Cardiol. 2017 02 07; 69(5):494-496. PMID: 28153105.
      Citations:    Fields:    Translation:Humans
    283. Bakris G, Blacher J, Levy BI, Mourad JJ, Safar ME. Hypertension control and cardiovascular disease - Authors' reply. Lancet. 2017 01 14; 389(10065):154-155. PMID: 28102139.
      Citations: 1     Fields:    Translation:Humans
    284. Bakris G, Bhatt DL, Esler M, Fahy M, Kandzari D, Kario K, Mancia G, Weber M, Mahfoud F, Ewen S, Böhm M. Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry. Eur Heart J. 2017 01 07; 38(2):93-100. PMID: 28158510; PMCID: PMC5381589.
      Citations: 57     Fields:    Translation:Humans
    285. Yano Y, Rakugi H, Bakris GL, Lloyd-Jones DM, Oparil S, Saruta T, Shimada K, Matsuoka H, Imai Y, Ogihara T. On-Treatment Blood Pressure and Cardiovascular Outcomes in Older Adults With Isolated Systolic Hypertension. Hypertension. 2017 02; 69(2):220-227. PMID: 28049699.
      Citations: 8     Fields:    Translation:Humans
    286. Cefalu WT, Boulton AJ, Tamborlane WV, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Kahn SE, Weinger K, Blonde L, de Groot M, Rich S, D'Alessio D, Reynolds L, Riddle MC. Diabetes Care: "Taking It to the Limit One More Time". Diabetes Care. 2017 01; 40(1):3-6. PMID: 27999000; PMCID: PMC5180460.
      Citations: 2     Fields:    
    287. Sternlicht H, Bakris GL. The Kidney in Hypertension. Med Clin North Am. 2017 Jan; 101(1):207-217. PMID: 27884230.
      Citations: 10     Fields:    Translation:Humans
    288. Dhaybi OA, Bakris G. Mineralocorticoid antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens. 2017 01; 26(1):50-55. PMID: 27753685.
      Citations: 8     Fields:    Translation:Humans
    289. Halbach M, Bakris GL, Bisognano JD, Haller H, Beige J, Kroon AA, Nadim MK, Lovett EG, Schafer JE, de Leeuw PW, Wachter R. An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systems. J Am Soc Hypertens. 2017 02; 11(2):81-91. PMID: 28065708.
      Citations: 8     Fields:    Translation:Humans
    290. Skyler JS, Bakris GL, Darsow T, Eckel RH, Groop PH, Handelsman Y, Insel RA, Mathieu C, McElvaine AT, Palmer JP, Pugliese A, Schatz DA, Sosenko JM, Wilding JP, Ratner RE, Bonifacio E, Groop L. Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes. 2017 02; 66(2):241-255. PMID: 27980006; PMCID: PMC5384660.
      Citations: 209     Fields:    Translation:Humans
    291. Bakris G, Vardeny O, Claggett B, McMurray JJV, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Spanyers S, Vincent J, Solomon SD, Pitt B, Rossignol P, Girerd N, Fay R, Lamiral Z, Zannad F. Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. Eur J Heart Fail. 2017 06; 19(6):792-799. PMID: 27868385.
      Citations: 13     Fields:    Translation:Humans
    292. Eskander MF, Bliss LA, McCarthy EP, de Geus SW, Chau Ng S, Nagle D, Rodrigue JR, Tseng JF. Massachusetts Healthcare Reform and Trends in Emergent Colon Resection. Dis Colon Rectum. 2016 Nov; 59(11):1063-1072. PMID: 27753946.
      Citations:    
    293. Eskander MF, Bliss LA, McCarthy EP, de Geus SW, Chau Ng S, Nagle D, Rodrigue JR, Tseng JF. Massachusetts Healthcare Reform and Trends in Emergent Colon Resection. Dis Colon Rectum. 2016 Nov; 59(11):1063-1072. PMID: 27754003.
      Citations:    
    294. Eskander MF, Bliss LA, McCarthy EP, de Geus SW, Chau Ng S, Nagle D, Rodrigue JR, Tseng JF. Massachusetts Healthcare Reform and Trends in Emergent Colon Resection. Dis Colon Rectum. 2016 Nov; 59(11):1063-1072. PMID: 27754080.
      Citations:    
    295. Eskander MF, Bliss LA, McCarthy EP, de Geus SW, Chau Ng S, Nagle D, Rodrigue JR, Tseng JF. Massachusetts Healthcare Reform and Trends in Emergent Colon Resection. Dis Colon Rectum. 2016 Nov; 59(11):1063-1072. PMID: 27754182.
      Citations:    
    296. Bakris GL, Burkart JM, Weinhandl ED, McCullough PA, Kraus MA. Intensive Hemodialysis, Blood Pressure, and Antihypertensive Medication Use. Am J Kidney Dis. 2016 Nov; 68(5S1):S15-S23. PMID: 27772639.
      Citations: 5     Fields:    Translation:Humans
    297. McCullough PA, Chan CT, Weinhandl ED, Burkart JM, Bakris GL. Intensive Hemodialysis, Left Ventricular Hypertrophy, and Cardiovascular Disease. Am J Kidney Dis. 2016 Nov; 68(5S1):S5-S14. PMID: 27772643.
      Citations: 31     Fields:    Translation:Humans
    298. Kraus MA, Kansal S, Copland M, Komenda P, Weinhandl ED, Bakris GL, Chan CT, Fluck RJ, Burkart JM. Intensive Hemodialysis and Potential Risks With Increasing Treatment. Am J Kidney Dis. 2016 Nov; 68(5S1):S51-S58. PMID: 27772644.
      Citations: 6     Fields:    Translation:Humans
    299. Pocock SJ, Bakris G, Bhatt DL, Brar S, Fahy M, Gersh BJ. Regression to the Mean in SYMPLICITY HTN-3: Implications for Design and Reporting of Future Trials. J Am Coll Cardiol. 2016 11 01; 68(18):2016-2025. PMID: 27788856.
      Citations: 16     Fields:    Translation:Humans
    300. Briasoulis A, Bakris GL. Current Status of Renal Denervation in Hypertension. Curr Cardiol Rep. 2016 11; 18(11):107. PMID: 27614466.
      Citations: 1     Fields:    Translation:Humans
    301. Cornel JH, Bakris GL, Stevens SR, Alvarsson M, Bax WA, Chuang LM, Engel SS, Lopes RD, McGuire DK, Riefflin A, Rodbard HW, Sinay I, Tankova T, Wainstein J, Peterson ED, Holman RR, TECOS Study Group. Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. Diabetes Care. 2016 Dec; 39(12):2304-2310. PMID: 27742728.
      Citations: 68     Fields:    Translation:Humans
    302. Dojki FK, Bakris G. Diabetes: Blood pressure goals in T2DM - time for a rethink? Nat Rev Endocrinol. 2016 11; 12(11):629-630. PMID: 27688044.
      Citations:    Fields:    Translation:Humans
    303. Al Dhaybi O, Bakris G. New Onset Hypertension Linked to Generic Cyclosporine Substitution in Post-Renal Transplant Patient. Am J Nephrol. 2016; 44(3):219-23. PMID: 27576478.
      Citations:    Fields:    Translation:Humans
    304. Bakris GL. The Implications of Blood Pressure Measurement Methods on Treatment Targets for Blood Pressure. Circulation. 2016 09 27; 134(13):904-5. PMID: 27576778.
      Citations: 18     Fields:    Translation:Humans
    305. Ku E, Gassman J, Appel LJ, Smogorzewski M, Sarnak MJ, Glidden DV, Bakris G, Hebert LA, Ix JH, Lea J, Lipkowitz MS, Norris K, Ploth D, Pogue VA, Rostand SG, Siew ED, Sika M, Tisher CC, Toto R, Wright JT, Wyatt C, Hsu CY, Gutiérrez OM. BP Control and Long-Term Risk of ESRD and Mortality. J Am Soc Nephrol. 2017 02; 28(2):671-677. PMID: 27516235; PMCID: PMC5280023.
      Citations: 36     Fields:    Translation:Humans
    306. EXAMINE Investigators, White WB, Wilson CA, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Heller SK, Mehta CR, Nissen SE, Zannad F, Kupfer S. Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. Hypertension. 2016 09; 68(3):606-13. PMID: 27480840.
      Citations: 8     Fields:    Translation:Humans
    307. Yamout H, Bakris GL. Diabetic nephropathy: SGLT2 inhibitors might halt progression of diabetic nephropathy. Nat Rev Nephrol. 2016 10; 12(10):583-4. PMID: 27425155.
      Citations:    Fields:    Translation:Humans
    308. Bakris GL, Molitch ME. Should Restrictions Be Relaxed for Metformin Use in Chronic Kidney Disease? Yes, They Should Be Relaxed! What's the Fuss? Diabetes Care. 2016 Jul; 39(7):1287-91. PMID: 27330130.
      Citations: 15     Fields:    Translation:Humans
    309. Laffin LJ, Bakris GL. Renal Denervation: a Field in Flux. Curr Hypertens Rep. 2016 Jul; 18(7):56. PMID: 27245681.
      Citations: 1     Fields:    Translation:Humans
    310. Ruilope LM, Nowack C, Bakris GL. Masked and Nocturnal Hypertension in the ARTS-DN ABPM Sub-Study with Finerenone. J Am Soc Hypertens. 2016 07; 10 Suppl 1:e7. PMID: 27677144.
      Citations: 3     Fields:    
    311. Weber MA, Bakris GL, White WB, Xie L, Bharucha D, Patel M. The Effects of Nebivolol-Valsartan Single-Pill Combinations in Reducing Blood Pressure in Patients with Stage I or II Hypertension. J Am Soc Hypertens. 2016 07; 10 Suppl 1:e8. PMID: 27677146.
      Citations:    Fields:    
    312. Weir MR, Bakris GL, Gross C, Mayo MR, Garza D, Stasiv Y, Yuan J, Berman L, Williams GH. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Kidney Int. 2016 09; 90(3):696-704. PMID: 27350174.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    313. White WB, Kupfer S, Zannad F, Mehta CR, Wilson CA, Lei L, Bakris GL, Nissen SE, Cushman WC, Heller SR, Bergenstal RM, Fleck PR, Cannon CP, EXAMINE Investigators. Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial. Diabetes Care. 2016 Jul; 39(7):1267-73. PMID: 27289121.
      Citations: 23     Fields:    Translation:Humans
    314. Cefalu WT, Boulton AJ, Tamborlane WV, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Weinger K, Blonde L, de Groot M, Rich SS, D'Alessio D, Riddle MC, Reynolds L. Diabetes Care: "Lagniappe" and "Seeing Is Believing"! Diabetes Care. 2016 07; 39(7):1069-71. PMID: 27631957; PMCID: PMC5013720.
      Citations: 1     Fields:    
    315. Laffin LJ, Majewski C, Liao C, Bakris GL. Relationship Between Obesity, Hypertension, and Aldosterone Production in Postmenopausal African American Women: A Pilot Study. J Clin Hypertens (Greenwich). 2016 12; 18(12):1216-1221. PMID: 27259699; PMCID: PMC8031884.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    316. Kario K, Bhatt DL, Kandzari DE, Brar S, Flack JM, Gilbert C, Oparil S, Robbins M, Townsend RR, Bakris G. Impact of Renal Denervation on Patients With Obstructive Sleep Apnea and Resistant Hypertension - Insights From the SYMPLICITY HTN-3 Trial. Circ J. 2016 May 25; 80(6):1404-12. PMID: 27118620.
      Citations: 23     Fields:    Translation:Humans
    317. Stough WG, Epstein M, Alonso Garcia Mde L, Bakris GL, Butler J, Kosiborod M, Berman L, Rasmussen HS, Ruilope LM, Stockbridge N, Thompson A, Wittes J, Pitt B, Zannad F, Rossignol P, Mebazaa A. New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval. Int J Cardiol. 2016 Aug 01; 216:46-51. PMID: 27140336.
      Citations: 7     Fields:    Translation:Humans
    318. Stough WG, Lipicky RJ, Tamargo J, Bakris GL, Borer JS, Kupfer S, McCullough PA, Mosenzon O, Pocock S, Sourij H, Van der Schueren B, Stahre C, White WB, Calvo G, Zannad F, Alonso García Mde L, Hadjadj S, Koenig W, Scheen AJ. Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. Eur Heart J Cardiovasc Pharmacother. 2016 07; 2(3):200-5. PMID: 27418973; PMCID: PMC4907355.
      Citations: 10     Fields:    Translation:HumansAnimals
    319. Bakris GL. Current and future potassium binders. Nephrol News Issues. 2016 Apr; 30(4):suppl 27-31. PMID: 27254903.
      Citations: 3     Fields:    Translation:Humans
    320. White WB, Lloyd E, Bakris GL, Kupfer S, Cuadra RH. Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes. J Hypertens. 2016 Apr; 34(4):788-97. PMID: 26766564; PMCID: PMC4947533.
      Citations: 11     Fields:    Translation:Humans
    321. Majewski C, Bakris GL. Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy? Curr Diab Rep. 2016 Apr; 16(4):24. PMID: 26879307.
      Citations: 7     Fields:    Translation:Humans
    322. Weber MA, Bloch M, Bakris GL, Weir MR, Zappe DH, Dahlof B, Velazquez EJ, Pitt B, Basile JN, Jamerson K, Hua TA. Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy. J Clin Hypertens (Greenwich). 2016 Apr; 18(4):299-307. PMID: 27060568; PMCID: PMC8032014.
      Citations: 11     Fields:    Translation:Humans
    323. Nissen SE, Wolski KE, Prcela L, Wadden T, Buse JB, Bakris G, Perez A, Smith SR. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. JAMA. 2016 Mar 08; 315(10):990-1004. PMID: 26954408.
      Citations: 68     Fields:    Translation:HumansCTClinical Trials
    324. Bakris G, Blacher J, Levy BI, Mourad JJ, Safar ME. From epidemiological transition to modern cardiovascular epidemiology: hypertension in the 21st century. Lancet. 2016 Jul 30; 388(10043):530-2. PMID: 26856636.
      Citations: 25     Fields:    Translation:Humans
    325. Sternlicht H, Bakris GL. Hydrochlorothiazide as the Diuretic of Choice for Hypertension: Time to Kick the Habit. J Am Coll Cardiol. 2016 Feb 02; 67(4):390-391. PMID: 26821626.
      Citations: 2     Fields:    Translation:Humans
    326. Shimada YJ, Cannon CP, Liu Y, Wilson C, Kupfer S, Menon V, Cushman WC, Mehta CR, Bakris GL, White WB, EXAMINE Investigators, Zannad F. Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial. Am Heart J. 2016 May; 175:18-27. PMID: 27179720.
      Citations: 3     Fields:    Translation:Humans
    327. Bakris GL, Nowack C. Finerenone for Albuminuria in Patients With Diabetic Nephropathy--Reply. JAMA. 2016 Jan 19; 315(3):306. PMID: 26784785.
      Citations: 1     Fields:    Translation:Humans
    328. Sternlicht H, Bakris GL. Management of Hypertension in Diabetic Nephropathy: How Low Should We Go? Blood Purif. 2016; 41(1-3):139-43. PMID: 26766168.
      Citations: 6     Fields:    Translation:Humans
    329. Cefalu WT, Boulton AJ, Tamborlane WV, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Weinger K, Blonde L, de Groot M, Riddle MC, Hill Golden S, Rich SS, D'Alessio D, Reynolds L. Building Momentum: Taking on the Real “Issues” of Diabetes Care! Diabetes Care. 2016 Jan; 39(1):10-12. PMID: 27606379; PMCID: PMC4822403.
      Citations: 1     Fields:    Translation:Humans
    330. Sternlicht H, Bakris GL. Hypertension: SGLT2 inhibitors: not just another glucose-lowering agent. Nat Rev Nephrol. 2016 Mar; 12(3):128-9. PMID: 26714579.
      Citations:    Fields:    Translation:Humans
    331. Yeh JS, Bakris GL, Taler SJ. CLINICAL DECISIONS. Blood-Pressure Control. N Engl J Med. 2015 Nov 26; 373(22):2180-2. PMID: 26551540.
      Citations: 1     Fields:    Translation:Humans
    332. Puri R, Nissen SE, Menon V, Shao M, Hsu A, Bakris GL, Kastelein JJ, Williams B, Armbrecht J, Brunel P, Kataoka Y, Nicholls SJ. Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS. Atherosclerosis. 2015 Dec; 243(2):553-9. PMID: 26523993.
      Citations: 2     Fields:    Translation:Humans
    333. Bakris G, Ritz E, Covic A, Goldsmith D, Heine GH, Jager KJ, Kanbay M, Mallamaci F, Vanholder R, Wiecek A, Zoccali C, ERA-EDTA EURECA-m working group, Cardiovascular and Renal Clinical Trialists (F-CRIN INI-CRCT) network, Rossignol P, Massy ZA, Azizi M, Ortiz A, London GM, Stengel B, Fouque D, Red de Investigación Renal (REDINREN) network. The double challenge of resistant hypertension and chronic kidney disease. Lancet. 2015 Oct 17; 386(10003):1588-98. PMID: 26530623.
      Citations: 55     Fields:    Translation:Humans
    334. Pitt B, Bakris GL, Bushinsky DA, Garza D, Mayo MR, Stasiv Y, Christ-Schmidt H, Berman L, Weir MR. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail. 2015 Oct; 17(10):1057-65. PMID: 26459796; PMCID: PMC5057342.
      Citations: 57     Fields:    Translation:Humans
    335. Kario K, Bhatt DL, Brar S, Cohen SA, Fahy M, Bakris GL. Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure: Insights From SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension. 2015 Dec; 66(6):1130-7. PMID: 26558819.
      Citations: 14     Fields:    Translation:Humans
    336. Sternlicht H, Bakris GL. Spironolactone for resistant hypertension--hard to resist? Lancet. 2015 Nov 21; 386(10008):2032-2034. PMID: 26414969.
      Citations: 5     Fields:    Translation:Humans
    337. Bushinsky DA, Williams GH, Pitt B, Weir MR, Freeman MW, Garza D, Stasiv Y, Li E, Berman L, Bakris GL. Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. Kidney Int. 2015 Dec; 88(6):1427-1433. PMID: 26376130; PMCID: PMC4678168.
      Citations: 41     Fields:    
    338. Sarafidis PA, Georgianos PI, Bakris GL. Advances in treatment of hyperkalemia in chronic kidney disease. Expert Opin Pharmacother. 2015; 16(14):2205-15. PMID: 26330193.
      Citations: 14     Fields:    Translation:Humans
    339. Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Kimmeskamp-Kirschbaum N, Ruilope LM, Remuzzi G, Pieper A, Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015 Sep 01; 314(9):884-94. PMID: 26325557.
      Citations: 208     Fields:    Translation:HumansCTClinical Trials
    340. Pitt B, Bakris GL. New potassium binders for the treatment of hyperkalemia: current data and opportunities for the future. Hypertension. 2015 Oct; 66(4):731-8. PMID: 26303290.
      Citations: 22     Fields:    Translation:Humans
    341. Giles TD, Bakris G, Oparil S, Weber MA, Li H, Mallick M, Bharucha DB, Chen C, Ferguson WG, NAC-MD-01 Substudy Investigators. Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension. J Am Soc Hypertens. 2015 Nov; 9(11):845-54. PMID: 26362831.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    342. Flack JM, Bhatt DL, Kandzari DE, Brown D, Brar S, Choi JW, D'Agostino R, East C, Katzen BT, Lee L, Leon MB, Mauri L, O'Neill WW, Oparil S, Rocha-Singh K, Townsend RR, Bakris G, SYMPLICITY HTN-3 Investigators. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. J Am Soc Hypertens. 2015 Oct; 9(10):769-779. PMID: 26362830.
      Citations: 16     Fields:    Translation:Humans
    343. Patney V, Whaley-Connell A, Bakris G. Hypertension Management in Diabetic Kidney Disease. Diabetes Spectr. 2015 Aug; 28(3):175-80. PMID: 26300610; PMCID: PMC4536650.
      Citations: 17     
    344. Iliescu R, Lohmeier TE, Tudorancea I, Laffin L, Bakris GL. Renal denervation for the treatment of resistant hypertension: review and clinical perspective. Am J Physiol Renal Physiol. 2015 Oct 01; 309(7):F583-94. PMID: 26224718; PMCID: PMC4593817.
      Citations: 24     Fields:    Translation:Humans
    345. Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA, AMETHYST-DN Investigators. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial. JAMA. 2015 Jul 14; 314(2):151-61. PMID: 26172895.
      Citations: 145     Fields:    Translation:HumansCTClinical Trials
    346. Bakris G. Summary and Conclusions. High Blood Press Cardiovasc Prev. 2015 Jul; 22 Suppl 1:S23. PMID: 26149526.
      Citations:    Fields:    Translation:Humans
    347. Cefalu WT, Boulton AJ, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Weinger K, Blonde L, de Groot M, Riddle MC, Henry R, Golden SH, Rich S, Reynolds L. Status of Diabetes Care: New Challenges, New Concepts, New Measures--Focusing on the Future! Diabetes Care. 2015 Jul; 38(7):1177-80. PMID: 26312261; PMCID: PMC5131862.
      Citations: 4     Fields:    
    348. de Leeuw PW, Bakris GL, Nadim MK, Haller H, Lovett EG, Bisognano JD. 8B.06: BAROREFLEX ACTIVATION THERAPY CONSISTENTLY MAINTAINS BLOOD PRESSURE REDUCTION IN A LARGE RESISTANT HYPERTENSION COHORT FOR AT LEAST 6 YEARS. J Hypertens. 2015 Jun; 33 Suppl 1:e108. PMID: 26102672.
      Citations:    
    349. Kario K, Bakris GL, Bhatt D. 4A.10: PREFERENTIAL REDUCTION IN MORNING/NOCTURNAL HYPERTENSION BY RENAL DENERVATION FOR DRUG- RESISTANT HYPERTENSION: A NEW ABPM ANALYSIS OF SYMPLICITY HTN-3 AND HTN-JAPAN. J Hypertens. 2015 Jun; 33 Suppl 1:e52. PMID: 26102846.
      Citations:    
    350. Laffin LJ, Bakris GL. Update on blood pressure goals in diabetes mellitus. Curr Cardiol Rep. 2015 Jun; 17(6):37. PMID: 25899655.
      Citations: 1     Fields:    Translation:Humans
    351. Weir MR, Bakris GL, Pitt B. New agents for hyperkalemia. N Engl J Med. 2015 04 16; 372(16):1570-1. PMID: 25875263.
      Citations:    Fields:    Translation:Humans
    352. Bakris GL, Townsend RR, Flack JM, Brar S, Cohen SA, D'Agostino R, Kandzari DE, Katzen BT, Leon MB, Mauri L, Negoita M, O'Neill WW, Oparil S, Rocha-Singh K, Bhatt DL, SYMPLICITY HTN-3 Investigators. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. J Am Coll Cardiol. 2015 Apr 07; 65(13):1314-1321. PMID: 25835443.
      Citations: 51     Fields:    Translation:Humans
    353. Glassock RJ, Bakris GL. Hypertension: Impact of blood pressure lowering in type 2 diabetes. Nat Rev Nephrol. 2015 Jun; 11(6):320-1. PMID: 25848880.
      Citations:    Fields:    Translation:Humans
    354. Briasoulis A, Bakris GL. A clinician's perspective of the role of renal sympathetic nerves in hypertension. Front Physiol. 2015; 6:75. PMID: 25859218; PMCID: PMC4373248.
      Citations: 3     
    355. Bakris GL, Bhatt DL. Reply: A mechanistic explanation for the minimal impact of renal denervation on 24-h ambulatory blood pressure in SIMPLICITY HTN-3. J Am Coll Cardiol. 2015 Mar 10; 65(9):959-60. PMID: 25744018.
      Citations: 1     Fields:    Translation:Humans
    356. Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Lam H, White WB, EXAMINE Investigators, Zannad F. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015 May 23; 385(9982):2067-76. PMID: 25765696.
      Citations: 245     Fields:    Translation:Humans
    357. Laffin LJ, Bakris GL. Endothelin antagonism and hypertension: an evolving target. Semin Nephrol. 2015 Mar; 35(2):168-75. PMID: 25966348.
      Citations: 8     Fields:    Translation:Humans
    358. Laffin LJ, Bakris GL. Renal denervation for resistant hypertension and beyond. Adv Chronic Kidney Dis. 2015 Mar; 22(2):133-9. PMID: 25704350.
      Citations: 2     Fields:    Translation:Humans
    359. Majewski C, Bakris GL. Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes. Diabetes Care. 2015 Mar; 38(3):429-30. PMID: 25715414; PMCID: PMC4876696.
      Citations: 41     Fields:    Translation:Humans
    360. McMullan CJ, Yano Y, Bakris GL, Kario K, Phillips RA, Forman JP. Racial impact of diurnal variations in blood pressure on cardiovascular events in chronic kidney disease. J Am Soc Hypertens. 2015 Apr; 9(4):299-306. PMID: 25891362.
      Citations: 6     Fields:    Translation:Humans
    361. Elliott WJ, Whitmore J, Feldstein JD, Bakris GL. Efficacy and safety of perindopril arginine + amlodipine in hypertension. J Am Soc Hypertens. 2015 Apr; 9(4):266-74. PMID: 25804495.
      Citations: 2     Fields:    Translation:Humans
    362. Ruilope LM, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Ferreira AC, Pieper A, Kimmeskamp-Kirschbaum N, Bakris GL. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. Am J Nephrol. 2014; 40(6):572-81. PMID: 25591469.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    363. Laffin LJ, Bakris GL. Hypertension and new treatment approaches targeting the sympathetic nervous system. Curr Opin Pharmacol. 2015 Apr; 21:20-4. PMID: 25541034.
      Citations: 4     Fields:    Translation:HumansAnimals
    364. Schumacher H, Schmieder RE, Mann JF, Teo K, Lonn E, Sleight P, Mancia G, Sliwa K, Bakris G, Yusuf S, Böhm M, Linz D, Mahfoud F, Ukena C. Resting heart rate is associated with renal disease outcomes in patients with vascular disease: results of the ONTARGET and TRANSCEND studies. J Intern Med. 2015 Jul; 278(1):38-49. PMID: 25431275.
      Citations: 18     Fields:    Translation:Humans
    365. Sarafidis PA, Bakris GL. Cardiovascular disease in CKD in 2014: new insights into cardiovascular risk factors and outcomes. Nat Rev Nephrol. 2015 Feb; 11(2):70-2. PMID: 25511758.
      Citations: 5     Fields:    Translation:Humans
    366. Briasoulis A, Bakris G. Renal Denervation After SYMPLICITY HTN-3: Where Do We Go? Can J Cardiol. 2015 May; 31(5):642-8. PMID: 25828371.
      Citations: 8     Fields:    Translation:Humans
    367. Nathan S, Bakris GL. The future of renal denervation in resistant hypertension. Curr Hypertens Rep. 2014 Dec; 16(12):494. PMID: 25304105.
      Citations: 3     Fields:    Translation:HumansAnimals
    368. Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B, OPAL-HK Investigators. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015 Jan 15; 372(3):211-21. PMID: 25415805.
      Citations: 227     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    369. Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, Flack JM, Katzen BT, Lea J, Lee DP, Leon MB, Ma A, Massaro J, Mauri L, Oparil S, O'Neill WW, Patel MR, Rocha-Singh K, Sobotka PA, Svetkey L, Townsend RR, Bakris GL. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015 Jan 21; 36(4):219-27. PMID: 25400162; PMCID: PMC4301597.
      Citations: 174     Fields:    Translation:Humans
    370. Zannad F, Stough WG, Mahfoud F, Bakris GL, Kjeldsen SE, Kieval RS, Haller H, Yared N, De Ferrari GM, Piña IL, Stein K, Azizi M. Design considerations for clinical trials of autonomic modulation therapies targeting hypertension and heart failure. Hypertension. 2015 Jan; 65(1):5-15. PMID: 25350982.
      Citations: 4     Fields:    Translation:HumansCells
    371. Chin MP, Wrolstad D, Bakris GL, Chertow GM, de Zeeuw D, Goldsberry A, Linde PG, McCullough PA, McMurray JJ, Wittes J, Meyer CJ. Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. J Card Fail. 2014 Dec; 20(12):953-8. PMID: 25307295.
      Citations: 71     Fields:    Translation:HumansCTClinical Trials
    372. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, Neumiller JJ, Patel UD, Ratner RE, Whaley-Connell AT, Molitch ME. Diabetic kidney disease: a report from an ADA Consensus Conference. Am J Kidney Dis. 2014 Oct; 64(4):510-33. PMID: 25257325.
      Citations: 237     Fields:    Translation:Humans
    373. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, Neumiller JJ, Patel UD, Ratner RE, Whaley-Connell AT, Molitch ME. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014 Oct; 37(10):2864-83. PMID: 25249672; PMCID: PMC4170131.
      Citations: 390     Fields:    Translation:Humans
    374. Yamout H, Bakris GL. In search for the 'sweet spot' for blood pressure level in diabetes. Heart. 2014 Sep 15; 100(18):1404-5. PMID: 25073888.
      Citations:    Fields:    Translation:Humans
    375. Yale JF, Bakris G, Cariou B, Nieto J, David-Neto E, Yue D, Wajs E, Figueroa K, Jiang J, Law G, Usiskin K, Meininger G, DIA3004 Study Group. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014 Oct; 16(10):1016-27. PMID: 24965700.
      Citations: 99     Fields:    Translation:Humans
    376. Yamout H, Perkovic V, Davies M, Woo V, de Zeeuw D, Mayer C, Vijapurkar U, Kline I, Usiskin K, Meininger G, Bakris G. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol. 2014; 40(1):64-74. PMID: 25059406.
      Citations: 40     Fields:    Translation:Humans
    377. White WB, Turner JR, Sica DA, Bisognano JD, Calhoun DA, Townsend RR, Aronow HD, Bhatt DL, Bakris GL. Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., October 10th 2013. J Am Soc Hypertens. 2014 Oct; 8(10):743-57. PMID: 25418497.
      Citations: 21     Fields:    Translation:Humans
    378. Bhatt DL, Bakris GL. Renal denervation for resistant hypertension. N Engl J Med. 2014 07 10; 371(2):184. PMID: 25006731.
      Citations: 14     Fields:    Translation:Humans
    379. Cefalu WT, Boulton AJ, Tamborlane WV, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Weinger K, Blonde L, de Groot M, Riddle MC, Henry RR, Hill Golden S, Rich S, Reynolds L. Status of Diabetes Care: "It just doesn't get any better . . . or does it?". Diabetes Care. 2014 Jul; 37(7):1782-5. PMID: 25093231; PMCID: PMC5131856.
      Citations: 4     Fields:    Translation:Humans
    380. Chin MP, Reisman SA, Bakris GL, O'Grady M, Linde PG, McCullough PA, Packham D, Vaziri ND, Ward KW, Warnock DG, Meyer CJ. Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. Am J Nephrol. 2014; 39(6):499-508. PMID: 24903467.
      Citations: 75     Fields:    Translation:HumansAnimalsCTClinical Trials
    381. Bakris GL, Townsend RR, Liu M, Cohen SA, D'Agostino R, Flack JM, Kandzari DE, Katzen BT, Leon MB, Mauri L, Negoita M, O'Neill WW, Oparil S, Rocha-Singh K, Bhatt DL, SYMPLICITY HTN-3 Investigators. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. J Am Coll Cardiol. 2014 Sep 16; 64(11):1071-8. PMID: 24858423.
      Citations: 60     Fields:    Translation:Humans
    382. Yamout H, Lazich I, Bakris GL. Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease. Adv Chronic Kidney Dis. 2014 May; 21(3):281-6. PMID: 24780456.
      Citations: 25     Fields:    Translation:Humans
    383. Lazich I, Bakris GL. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin Nephrol. 2014 May; 34(3):333-9. PMID: 25016403.
      Citations: 36     Fields:    Translation:Humans
    384. Bakris GL. The role of aldosterone in the spectrum of cardiovascular and kidney disease risk: introduction. Semin Nephrol. 2014 May; 34(3):245-6. PMID: 25016396.
      Citations:    Fields:    Translation:Humans
    385. Weber MA, White WB, Sica D, Bakris GL, Cao C, Roberts A, Kupfer S. Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension. Blood Press Monit. 2014 Apr; 19(2):90-7. PMID: 24445723; PMCID: PMC3966914.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    386. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL, SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014 Apr 10; 370(15):1393-401. PMID: 24678939.
      Citations: 644     Fields:    Translation:Humans
    387. Karovic S, Wen Y, Karrison TG, Bakris GL, Levine MR, House LK, Wu K, Thomeas V, Rudek MA, Wright JJ, Cohen EE, Fleming GF, Ratain MJ, Maitland ML. Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. Clin Pharmacol Ther. 2014 Jul; 96(1):27-35. PMID: 24637941; PMCID: PMC4165641.
      Citations: 6     Fields:    Translation:Humans
    388. Byrd JB, Bakris G, Jamerson K. The contribution of the ACCOMPLISH trial to the treatment of stage 2 hypertension. Curr Hypertens Rep. 2014 Mar; 16(3):419. PMID: 24474031.
      Citations: 1     Fields:    Translation:Humans
    389. Sarafidis PA, Bakris GL. Renin inhibition in patients with chronic kidney disease: is it conclusively non-indicated? J Renin Angiotensin Aldosterone Syst. 2014 Mar; 15(1):97-8. PMID: 24526392.
      Citations:    Fields:    Translation:Humans
    390. Smith SM, Gong Y, Handberg E, Messerli FH, Bakris GL, Ahmed A, Bavry AA, Pepine CJ, Cooper-Dehoff RM. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens. 2014 Mar; 32(3):635-43. PMID: 24299915; PMCID: PMC4118668.
      Citations: 49     Fields:    Translation:Humans
    391. Vemulapalli S, Ard J, Bakris GL, Bhatt DL, Brown AS, Cushman WC, Ferdinand KC, Flack JM, Fleg JL, Katzen BT, Kostis JB, Oparil S, Patel CB, Pepine CJ, Rocha-Singh KJ, Townsend RR, Peterson ED, Califf RM, Patel MR, Piña IL. Proceedings from Duke resistant hypertension think tank. Am Heart J. 2014 Jun; 167(6):775-88.e1. PMID: 24890525.
      Citations: 9     Fields:    Translation:HumansCells
    392. Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014 May; 8(5):330-9. PMID: 24631482.
      Citations: 80     Fields:    Translation:Humans
    393. Sarafidis PA, Bakris GL. Early patterns of blood pressure change and future coronary atherosclerosis. JAMA. 2014 Feb 05; 311(5):471-2. PMID: 24496535.
      Citations: 4     Fields:    Translation:Humans
    394. Briasoulis A, Silver A, Yano Y, Bakris GL. Orthostatic hypotension associated with baroreceptor dysfunction: treatment approaches. J Clin Hypertens (Greenwich). 2014 Feb; 16(2):141-8. PMID: 24588814; PMCID: PMC8031868.
      Citations: 9     Fields:    Translation:HumansCells
    395. Yano Y, Bakris GL, Inokuchi T, Ohba Y, Tamaki N, Nagata M, Kuwabara M, Yokota N, Eto T, Kuroki M, Shimada K, Kario K. Association of cognitive dysfunction with cardiovascular disease events in elderly hypertensive patients. J Hypertens. 2014 Feb; 32(2):423-31. PMID: 24351802.
      Citations: 13     Fields:    Translation:Humans
    396. Tsioufis C, Kasiakogias A, Kordalis A, Dimitriadis K, Thomopoulos C, Tsiachris D, Vasileiou P, Doumas M, Makris T, Papademetriou V, Kallikazaros I, Bakris G, Stefanadis C. Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity: a 4-year prospective study. J Hypertens. 2014 Feb; 32(2):415-22. PMID: 24241057.
      Citations: 33     Fields:    Translation:Humans
    397. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, Flack JM, Carter BL, Materson BJ, Ram CV, Cohen DL, Cadet JC, Jean-Charles RR, Taler S, Kountz D, Townsend R, Chalmers J, Ramirez AJ, Bakris GL, Wang J, Schutte AE, Bisognano JD, Touyz RM, Sica D, Harrap SB. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014 Jan; 32(1):3-15. PMID: 24270181.
      Citations: 223     Fields:    Translation:Humans
    398. Briasoulis A, Bakris G. The future of interventional management of hypertension: threats and opportunities. Curr Vasc Pharmacol. 2014 Jan; 12(1):69-76. PMID: 23905592.
      Citations: 2     Fields:    Translation:HumansCells
    399. Oliva RV, Bakris GL. Sympathetic activation in resistant hypertension: theory and therapy. Semin Nephrol. 2014; 34(5):550-9. PMID: 25416664.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    400. Bakris GL, Molitch M. Microalbuminuria as a risk predictor in diabetes: the continuing saga. Diabetes Care. 2014; 37(3):867-75. PMID: 24558077.
      Citations: 57     Fields:    Translation:Humans
    401. Thomas CC, Bakris G. Metformin nephrotoxicity insights: will they change clinical management? J Diabetes. 2014 Mar; 6(2):111-2. PMID: 24274706.
      Citations: 3     Fields:    Translation:HumansAnimals
    402. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, Flack JM, Carter BL, Materson BJ, Ram CV, Cohen DL, Cadet JC, Jean-Charles RR, Taler S, Kountz D, Townsend RR, Chalmers J, Ramirez AJ, Bakris GL, Wang J, Schutte AE, Bisognano JD, Touyz RM, Sica D, Harrap SB. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014 Jan; 16(1):14-26. PMID: 24341872; PMCID: PMC8031779.
      Citations: 356     Fields:    Translation:Humans
    403. Yamout H, Bakris GL. Evidence-based triple antihypertensive therapy yields lower mortality in older patients with diabetes mellitus. Hypertension. 2014 Feb; 63(2):220-1. PMID: 24324049.
      Citations:    Fields:    Translation:Humans
    404. Bakris G, Nathan S. Renal denervation and left ventricular mass regression: a benefit beyond blood pressure reduction? J Am Coll Cardiol. 2014 May 13; 63(18):1924-5. PMID: 24315916.
      Citations: 6     Fields:    Translation:Humans
    405. Bakris G, Sarafidis P, Agarwal R, Ruilope L. Review of blood pressure control rates and outcomes. J Am Soc Hypertens. 2014 Feb; 8(2):127-41. PMID: 24309125.
      Citations: 29     Fields:    Translation:Humans
    406. Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Messig M, Vincent J, Girerd N, Bakris G, Pitt B, Zannad F. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail. 2014 Jan; 7(1):51-8. PMID: 24297687.
      Citations: 84     Fields:    Translation:Humans
    407. Bakris GL, Doghramji PP, Keenan RT, Silber SH. CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts. Am J Med. 2014 Jan; 127(1):S1. PMID: 24268074.
      Citations: 1     Fields:    Translation:Humans
    408. Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, Chertow GM, BEACON Trial Investigators, de Zeeuw D. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013 12 26; 369(26):2492-503. PMID: 24206459; PMCID: PMC4496027.
      Citations: 435     Fields:    Translation:HumansCTClinical Trials
    409. Lambers Heerspink HJ, Chertow GM, Akizawa T, Audhya P, Bakris GL, Goldsberry A, Krauth M, Linde P, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Christ-Schmidt H, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, de Zeeuw D. Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. Nephrol Dial Transplant. 2013 Nov; 28(11):2841-50. PMID: 24169612.
      Citations: 11     Fields:    Translation:Humans
    410. Yano Y, Briasoulis A, Bakris GL, Hoshide S, Wang JG, Shimada K, Kario K. Effects of antihypertensive treatment in Asian populations: a meta-analysis of prospective randomized controlled studies (CARdiovascular protectioN group in Asia: CARNA). J Am Soc Hypertens. 2014 Feb; 8(2):103-16. PMID: 24157055.
      Citations: 11     Fields:    Translation:Humans
    411. Bakris G. Chronic kidney disease: optimal blood pressure for kidney disease-lower is not better. Nat Rev Nephrol. 2013 Nov; 9(11):634-5. PMID: 24080799.
      Citations: 2     Fields:    Translation:Humans
    412. Schlaich MP, Schmieder RE, Bakris G, Blankestijn PJ, Campese VM, Francis DP, Grassi G, Hering D, Katholi R, Kjeldsen S, Krum H, Mahfoud F, Mancia G, Messerli FH, Narkiewicz K, Parati G, Rocha-Singh KJ, Ruilope LM, Rump LC, Sica DA, Sobotka PA, Tsioufis C, Vonend O, Weber MA, Williams B, Zeller T, Esler MD, Böhm M. International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol. 2013 Dec 03; 62(22):2031-45. PMID: 24021387.
      Citations: 34     Fields:    Translation:Humans
    413. Nicholls SJ, Bakris GL, Kastelein JJ, Menon V, Williams B, Armbrecht J, Brunel P, Nicolaides M, Hsu A, Hu B, Fang H, Puri R, Uno K, Kataoka Y, Bash D, Nissen SE. Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. JAMA. 2013 Sep 18; 310(11):1135-44. PMID: 23999933.
      Citations: 29     Fields:    Translation:Humans
    414. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F, EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013 Oct 03; 369(14):1327-35. PMID: 23992602.
      Citations: 849     Fields:    Translation:Humans
    415. Yano Y, Bakris GL, Matsushita K, Hoshide S, Shimada K, Kario K. Both chronic kidney disease and nocturnal blood pressure associate with strokes in the elderly. Am J Nephrol. 2013; 38(3):195-203. PMID: 23970169.
      Citations: 3     Fields:    Translation:Humans
    416. Bakris G, Fafin C, Favre G, Pradier C, Esnault VL, Moranne O. Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy. Clin J Am Soc Nephrol. 2013 Oct; 8(10):1694-701. PMID: 23929924; PMCID: PMC3789346.
      Citations: 15     Fields:    Translation:Humans
    417. Briasoulis A, Bakris G. Initial single-pill combination therapy for cardiovascular risk factor management: it is not just convenience. J Hypertens. 2013 Aug; 31(8):1537-8. PMID: 23822927.
      Citations: 3     Fields:    Translation:Humans
    418. Bhatta SS, Wroblewski KE, Agarwal KL, Sit L, Cohen EE, Seiwert TY, Karrison T, Bakris GL, Ratain MJ, Vokes EE, Maitland ML. Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis. Oncologist. 2013; 18(8):965-70. PMID: 23900000; PMCID: PMC3755935.
      Citations: 5     Fields:    Translation:HumansCells
    419. Rajagopalan S, Bakris GL, Abraham WT, Pitt B, Brook RD. Complete renin-angiotensin-aldosterone system (RAAS) blockade in high-risk patients: recent insights from renin blockade studies. Hypertension. 2013 Sep; 62(3):444-9. PMID: 23876474.
      Citations: 4     Fields:    Translation:HumansAnimals
    420. Bakris GL. The author replies. Kidney Int. 2013 Jul; 84(1):215. PMID: 23812368.
      Citations:    Fields:    Translation:Humans
    421. Weber MA, Bakris GL, Weir MR, Jamerson K. Obesity, blood pressure, and cardiovascular outcomes - Authors' reply. Lancet. 2013 Jun 08; 381(9882):1982-3. PMID: 23746892.
      Citations:    Fields:    Translation:Humans
    422. Bakris GL. Interventional cardiology: Indications for renal denervation: a balanced approach? Nat Rev Cardiol. 2013 Aug; 10(8):434-6. PMID: 23736520.
      Citations: 2     Fields:    Translation:Humans
    423. Flynn C, Bakris GL. Role of ambulatory blood pressure monitoring in hypertension and diabetes. Curr Hypertens Rep. 2013 Jun; 15(3):137-42. PMID: 23595358.
      Citations: 3     Fields:    Translation:Humans
    424. Taler SJ, Agarwal R, Bakris GL, Flynn JT, Nilsson PM, Rahman M, Sanders PW, Textor SC, Weir MR, Townsend RR. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis. 2013 Aug; 62(2):201-13. PMID: 23684145; PMCID: PMC3929429.
      Citations: 79     Fields:    Translation:Humans
    425. Bakris GL. Lowering blood pressure limits in patients with type 2 diabetes: is it still warranted? J Diabetes Complications. 2013 Sep-Oct; 27(5):415-6. PMID: 23659775.
      Citations:    Fields:    Translation:Humans
    426. Briasoulis A, Bakris G. Efficacy of baroreflex activation therapy for the treatment of resistant hypertension. EuroIntervention. 2013 May; 9 Suppl R:R136-9. PMID: 23732146.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    427. Briasoulis A, Oliva R, Kalaitzidis R, Flynn C, Lazich I, Schlaffer C, Bakris G. Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study. J Clin Hypertens (Greenwich). 2013 Jul; 15(7):473-9. PMID: 23815535; PMCID: PMC8033810.
      Citations: 8     Fields:    Translation:Humans
    428. Elliott WJ, Egan B, Giles TD, Bakris GL, White WB, Sansone TM. Rationale for establishing a mechanism to increase reimbursement to hypertension specialists. J Clin Hypertens (Greenwich). 2013 Jun; 15(6):397-403. PMID: 23730988; PMCID: PMC8033840.
      Citations: 5     Fields:    Translation:Humans
    429. Bakris G, Briasoulis A, Dahlof B, Jamerson K, Weber MA, Kelly RY, Hester A, Hua T, Zappe D, Pitt B, ACCOMPLISH Investigators. Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. Am J Cardiol. 2013 Jul 15; 112(2):255-9. PMID: 23582626.
      Citations: 8     Fields:    Translation:Humans
    430. Weber MA, Bakris GL, Hester A, Weir MR, Hua TA, Zappe D, Dahlof B, Velazquez EJ, Pitt B, Jamerson K. Systolic blood pressure and cardiovascular outcomes during treatment of hypertension. Am J Med. 2013 Jun; 126(6):501-8. PMID: 23541376.
      Citations: 27     Fields:    Translation:Humans
    431. Yale JF, Bakris G, Cariou B, Yue D, David-Neto E, Xi L, Figueroa K, Wajs E, Usiskin K, Meininger G. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013 May; 15(5):463-73. PMID: 23464594; PMCID: PMC3654568.
      Citations: 184     Fields:    Translation:HumansCTClinical Trials
    432. Bakris GL, Sica D, Weber MA, White WB, Perez A, Cao C, Handley A, Kupfer S, Bönner G. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens. 2013 Aug; 27(8):479-86. PMID: 23514842; PMCID: PMC3715765.
      Citations: 14     Fields:    Translation:Humans
    433. Yano Y, Bakris GL. Recognition and management of masked hypertension: a review and novel approach. J Am Soc Hypertens. 2013 May-Jun; 7(3):244-52. PMID: 23523411.
      Citations: 12     Fields:    Translation:Humans
    434. McMullan CJ, Bakris GL, Phillips RA, Forman JP. Association of BP variability with mortality among African Americans with CKD. Clin J Am Soc Nephrol. 2013 May; 8(5):731-8. PMID: 23493382; PMCID: PMC3641624.
      Citations: 27     Fields:    Translation:Humans
    435. Briasoulis A, Bakris GL. Chronic kidney disease as a coronary artery disease risk equivalent. Curr Cardiol Rep. 2013 Mar; 15(3):340. PMID: 23338722.
      Citations: 60     Fields:    Translation:Humans
    436. de Zeeuw D, Akizawa T, Agarwal R, Audhya P, Bakris GL, Chin M, Krauth M, Lambers Heerspink HJ, Meyer CJ, McMurray JJ, Parving HH, Pergola PE, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Warnock DG, Wittes J, Chertow GM. Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON). Am J Nephrol. 2013; 37(3):212-22. PMID: 23467003.
      Citations: 42     Fields:    Translation:HumansCTClinical Trials
    437. Bakris G. Clinical guidelines: blood pressure goals in T2DM: a Latin American perspective. Nat Rev Endocrinol. 2013 Mar; 9(3):138-9. PMID: 23381031.
      Citations:    Fields:    Translation:Humans
    438. Flynn C, Bakris GL. Noninsulin glucose-lowering agents for the treatment of patients on dialysis. Nat Rev Nephrol. 2013 Mar; 9(3):147-53. PMID: 23358424.
      Citations: 10     Fields:    Translation:Humans
    439. Briasoulis A, Bakris GL. The OSCAR for cardiovascular disease prevention in chronic kidney disease goes to blood pressure control. Kidney Int. 2013 Jan; 83(1):20-2. PMID: 23271487.
      Citations:    Fields:    Translation:Humans
    440. Socolovsky C, Masi C, Hamlish T, Aduana G, Arora S, Bakris G, Johnson D. Evaluating the role of key learning theories in ECHO: a telehealth educational program for primary care providers. Prog Community Health Partnersh. 2013; 7(4):361-8. PMID: 24375176.
      Citations: 25     Fields:    Translation:Humans
    441. Babayev R, Whaley-Connell A, Kshirsagar A, Klemmer P, Navaneethan S, Chen SC, Li S, McCullough PA, Bakris G, Bomback A, KEEP Investigators. Association of race and body mass index with ESRD and mortality in CKD stages 3-4: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2013 Mar; 61(3):404-12. PMID: 23260275.
      Citations: 21     Fields:    Translation:Humans
    442. Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, Dahlof B, Velazquez EJ, Pitt B. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet. 2013 Feb 16; 381(9866):537-45. PMID: 23219284.
      Citations: 37     Fields:    Translation:Humans
    443. Cunnane RT, Bakris GL. Hypertensive goals in patients with coronary artery disease. Curr Cardiol Rep. 2012 Dec; 14(6):667-72. PMID: 22890754.
      Citations:    Fields:    Translation:Humans
    444. Sarafidis PA, Georgianos P, Bakris GL. Resistant hypertension--its identification and epidemiology. Nat Rev Nephrol. 2013 Jan; 9(1):51-8. PMID: 23165303.
      Citations: 68     Fields:    Translation:Humans
    445. Rahman M, Greene T, Phillips RA, Agodoa LY, Bakris GL, Charleston J, Contreras G, Gabbai F, Hiremath L, Jamerson K, Kendrick C, Kusek JW, Lash JP, Lea J, Miller ER, Rostand S, Toto R, Wang X, Wright JT, Appel LJ. A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease. Hypertension. 2013 Jan; 61(1):82-8. PMID: 23172931; PMCID: PMC3523681.
      Citations: 34     Fields:    Translation:Humans
    446. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC, Crowley K, Goto S, Ohman EM, Bakris GL, Perlstein TS, Kinlay S, Bhatt DL, REACH Registry Investigators. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J. 2013 Apr; 34(16):1204-14. PMID: 23144048.
      Citations: 79     Fields:    Translation:Humans
    447. Mentz RJ, Bakris GL, Waeber B, McMurray JJ, Gheorghiade M, Ruilope LM, Maggioni AP, Swedberg K, Fiuzat M, O'Connor CM, Zannad F, Pitt B, Piña IL. The past, present and future of renin-angiotensin aldosterone system inhibition. Int J Cardiol. 2013 Sep 01; 167(5):1677-87. PMID: 23121914; PMCID: PMC4145865.
      Citations: 44     Fields:    Translation:HumansAnimals
    448. Bakris GL, Oparil S, Purkayastha D, Yadao AM, Alessi T, Sowers JR. Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2013 Feb; 15(2):92-100. PMID: 23339726; PMCID: PMC8108251.
      Citations: 12     Fields:    Translation:Humans
    449. Briasoulis A, Bakris GL. Timing and efficacy of alternative methods of sympathetic blockade. Curr Hypertens Rep. 2012 Oct; 14(5):455-61. PMID: 22833367.
      Citations: 1     Fields:    Translation:HumansCells
    450. Sarafidis PA, Bakris GL. Use of a single target blood pressure level in type 2 diabetes mellitus for all cardiovascular risk reduction: comment on "intensive and standard blood pressure targets in patients with type 2 diabetes mellitus". Arch Intern Med. 2012 Sep 24; 172(17):1304-5. PMID: 22868907.
      Citations: 2     Fields:    
    451. Guralnick A, Bakris GL. Approaches for targeting blood pressure control in sleep disorders. Curr Opin Nephrol Hypertens. 2012 Sep; 21(5):469-74. PMID: 22820373.
      Citations: 2     Fields:    Translation:Humans
    452. Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJ, Swedberg K, Struthers AD, Voors AA, Ruilope LM, Bakris GL, O'Connor CM, Gheorghiade M, Mentz RJ, Cohen-Solal A, Maggioni AP, Beygui F, Filippatos GS, Massy ZA, Pathak A, Sabbah HN, Sica DA, Tavazzi L, Pitt B, Zannad F, Piña IL. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J. 2012 Nov; 33(22):2782-95. PMID: 22942339.
      Citations: 49     Fields:    Translation:HumansAnimals
    453. Bakris GL, Sica D, White WB, Cushman WC, Weber MA, Handley A, Song E, Kupfer S. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med. 2012 Dec; 125(12):1229.e1-1229.e10. PMID: 22939358.
      Citations: 31     Fields:    Translation:Humans
    454. Oliva RV, Bakris GL. Management of hypertension in the elderly population. J Gerontol A Biol Sci Med Sci. 2012 Dec; 67(12):1343-51. PMID: 22913963.
      Citations: 11     Fields:    Translation:Humans
    455. Bhatt DL, Bakris GL. The promise of renal denervation. Cleve Clin J Med. 2012 Jul; 79(7):498-500. PMID: 22751634.
      Citations: 3     Fields:    Translation:Humans
    456. Polonsky TS, Bakris GL. Chronic kidney disease: a coronary heart disease equivalent? Lancet. 2012 Sep 01; 380(9844):783-5. PMID: 22717316.
      Citations: 4     Fields:    Translation:Humans
    457. Cushman WC, Bakris GL, White WB, Weber MA, Sica D, Roberts A, Lloyd E, Kupfer S. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension. 2012 Aug; 60(2):310-8. PMID: 22710649.
      Citations: 23     Fields:    Translation:Humans
    458. Bakris GL. Lipid disorders in uremia and dialysis. Contrib Nephrol. 2012; 178:100-105. PMID: 22652724.
      Citations: 9     Fields:    Translation:Humans
    459. Whaley-Connell A, Shlipak MG, Inker LA, Kurella Tamura M, Bomback AS, Saab G, Szpunar SM, McFarlane SI, Li S, Chen SC, Norris K, Bakris GL, McCullough PA, Kidney Early Evaluation Program Investigators. Awareness of kidney disease and relationship to end-stage renal disease and mortality. Am J Med. 2012 Jul; 125(7):661-9. PMID: 22626510; PMCID: PMC3383388.
      Citations: 31     Fields:    Translation:HumansPHPublic Health
    460. Kandzari DE, Bhatt DL, Sobotka PA, O'Neill WW, Esler M, Flack JM, Katzen BT, Leon MB, Massaro JM, Negoita M, Oparil S, Rocha-Singh K, Straley C, Townsend RR, Bakris G. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol. 2012 Sep; 35(9):528-35. PMID: 22573363; PMCID: PMC6652693.
      Citations: 89     Fields:    Translation:Humans
    461. Doumas M, Anyfanti P, Bakris G. Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: a perspective. J Hypertens. 2012 May; 30(5):874-6. PMID: 22495128.
      Citations: 18     Fields:    Translation:Humans
    462. Gulati M, Black HR, Arnsdorf MF, Shaw LJ, Bakris GL. Kidney dysfunction, cardiorespiratory fitness, and the risk of death in women. J Womens Health (Larchmt). 2012 Sep; 21(9):917-24. PMID: 22480201.
      Citations: 4     Fields:    Translation:Humans
    463. Sica D, Bakris GL, White WB, Weber MA, Cushman WC, Huang P, Roberts A, Kupfer S. Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. J Clin Hypertens (Greenwich). 2012 May; 14(5):284-92. PMID: 22533654; PMCID: PMC8108928.
      Citations: 23     Fields:    Translation:Humans
    464. Sharma AM, Bakris G, Neutel JM, Littlejohn TW, Kobe M, Ting N, Ley L. Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial. Clin Ther. 2012 Mar; 34(3):537-51. PMID: 22386829.
      Citations: 9     Fields:    Translation:Humans
    465. Kalaitzidis RG, Bakris GL. Pros and cons of aggressive blood pressure lowering in patients with type 2 diabetes. Curr Vasc Pharmacol. 2012 Mar; 10(2):156-61. PMID: 22239626.
      Citations: 7     Fields:    Translation:Humans
    466. Oliva RV, Bakris GL. Can ambulatory blood pressure serve as a biomarker for presence of chronic kidney disease? J Hypertens. 2012 Mar; 30(3):466-7. PMID: 22317991.
      Citations:    Fields:    Translation:Humans
    467. Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens. 2012 Mar-Apr; 6(2):152-8. PMID: 22341199.
      Citations: 78     Fields:    Translation:Humans
    468. Ahmed A, Fonarow GC, Zhang Y, Sanders PW, Allman RM, Arnett DK, Feller MA, Love TE, Aban IB, Levesque R, Ekundayo OJ, Dell'Italia LJ, Bakris GL, Rich MW. Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease. Am J Med. 2012 Apr; 125(4):399-410. PMID: 22321760; PMCID: PMC3324926.
      Citations: 33     Fields:    Translation:Humans
    469. Steingart RM, Bakris GL, Chen HX, Chen MH, Force T, Ivy SP, Leier CV, Liu G, Lenihan D, Lindenfeld J, Maitland ML, Remick SC, Tang WH. Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. Am Heart J. 2012 Feb; 163(2):156-63. PMID: 22305831.
      Citations: 35     Fields:    Translation:HumansCells
    470. Peralta CA, Norris KC, Li S, Chang TI, Tamura MK, Jolly SE, Bakris G, McCullough PA, Shlipak M, KEEP Investigators. Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2012 Jan 09; 172(1):41-7. PMID: 22232147; PMCID: PMC3417125.
      Citations: 49     Fields:    Translation:Humans
    471. Sarafidis PA, Bakris G. A reappraisal of renin-angiotensin system blockade on microalbuminuria development: do they offer anything unique? J Hypertens. 2012 Jan; 30(1):48-50. PMID: 22157588.
      Citations:    Fields:    Translation:Humans
    472. Weir MR, Bakris GL, Weber MA, Dahlof B, Devereux RB, Kjeldsen SE, Pitt B, Wright JT, Kelly RY, Hua TA, Hester RA, Velazquez E, Jamerson KA. Renal outcomes in hypertensive Black patients at high cardiovascular risk. Kidney Int. 2012 Mar; 81(6):568-76. PMID: 22189843.
      Citations: 13     Fields:    Translation:HumansCells
    473. Bakris GL. Hypertension in 2011: New insights--from risk factors to treatment implications. Nat Rev Cardiol. 2011 Dec 13; 9(2):75-7. PMID: 22158080.
      Citations: 4     Fields:    Translation:Humans
    474. Masi C, Hamlish T, Davis A, Bordenave K, Brown S, Perea B, Aduana G, Wolfe M, Bakris G, Johnson D. Using an established telehealth model to train urban primary care providers on hypertension management. J Clin Hypertens (Greenwich). 2012 Jan; 14(1):45-50. PMID: 22235823; PMCID: PMC8108817.
      Citations: 11     Fields:    Translation:Humans
    475. Flynn C, Bakris GL. Blood pressure targets for patients with diabetes or kidney disease. Curr Hypertens Rep. 2011 Dec; 13(6):452-5. PMID: 21904985.
      Citations: 3     Fields:    Translation:Humans
    476. Lazich I, Sarafidis P, de Guzman E, Patel A, Oliva R, Bakris G. Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study. Diabetes Obes Metab. 2012 Feb; 14(2):181-6. PMID: 21955403.
      Citations: 6     Fields:    Translation:Humans
    477. Guichard JL, Desai RV, Ahmed MI, Mujib M, Fonarow GC, Feller MA, Ekundayo OJ, Bittner V, Aban IB, White M, Aronow WS, Love TE, Bakris GL, Zieman SJ, Ahmed A. Isolated diastolic hypotension and incident heart failure in older adults. Hypertension. 2011 Nov; 58(5):895-901. PMID: 21947466; PMCID: PMC3390027.
      Citations: 21     Fields:    Translation:Humans
    478. Bhavsar NA, Appel LJ, Kusek JW, Contreras G, Bakris G, Coresh J, Astor BC, AASK Study Group. Comparison of measured GFR, serum creatinine, cystatin C, and beta-trace protein to predict ESRD in African Americans with hypertensive CKD. Am J Kidney Dis. 2011 Dec; 58(6):886-93. PMID: 21944667; PMCID: PMC3221777.
      Citations: 40     Fields:    Translation:Humans
    479. Mensah GA, Bakris G. The United Nations high level meeting addresses noncommunicable diseases, but where is hypertension? J Clin Hypertens (Greenwich). 2011 Nov; 13(11):787-90. PMID: 22051421; PMCID: PMC8108954.
      Citations: 2     Fields:    Translation:Humans
    480. White WB, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Fleck P, Heller S, Mehta C, Nissen SE, Perez A, Wilson C, Zannad F. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J. 2011 Oct; 162(4):620-626.e1. PMID: 21982652.
      Citations: 49     Fields:    Translation:HumansCTClinical Trials
    481. Lazich I, Bakris GL. Newer renin-angiotensin-aldosterone system blocker combinations: is there an advantage? Curr Opin Nephrol Hypertens. 2011 Sep; 20(5):471-5. PMID: 21709549.
      Citations:    Fields:    Translation:Humans
    482. Lazich I, Bakris GL. Endothelin antagonism in patients with resistant hypertension and hypertension nephropathy. Contrib Nephrol. 2011; 172:223-234. PMID: 21894002.
      Citations: 4     Fields:    Translation:Humans
    483. Kjeldsen SE, Jamerson KA, Bakris GL, Pitt B, Velazquez EJ, Hua TA, Kelly RY, Zappe D, Hester A, Tuomilehto J, Ostergren J, Ibsen H, Weber M, Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hyperten, Dahlöf B. Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study. Blood Press. 2012 Apr; 21(2):82-7. PMID: 21830844.
      Citations: 2     Fields:    Translation:Humans
    484. Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, de Leeuw PW, Sica DA. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011 Aug 09; 58(7):765-73. PMID: 21816315.
      Citations: 173     Fields:    Translation:HumansCTClinical Trials
    485. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Ann Forciea M, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ, Harrington RA, Bates ER, Bhatt DL, Bridges CR, Eisenberg MJ, Ferrari VA, Fisher JD, Gardner TJ, Gentile F, Gilson MF, Hlatky MA, Jacobs AK, Kaul S, Moliterno DJ, Mukherjee D, Rosenson RS, Stein JH, Weitz HH. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Soc Hypertens. 2011 Jul-Aug; 5(4):259-352. PMID: 21771565.
      Citations: 51     Fields:    Translation:Humans
    486. Sica D, White WB, Weber MA, Bakris GL, Perez A, Cao C, Handley A, Kupfer S. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2011 Jul; 13(7):467-72. PMID: 21762358; PMCID: PMC8108745.
      Citations: 43     Fields:    Translation:Humans
    487. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, Lernmark A, Metzger BE, Nathan DM, National Academy of Clinical Biochemistry, Evidence-Based Laboratory Medicine Committee of the American Association for Clinical Chemistry. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care. 2011 Jun; 34(6):e61-99. PMID: 21617108; PMCID: PMC3114322.
      Citations: 143     Fields:    Translation:Humans
    488. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, Lernmark A, Metzger BE, Nathan DM, National Academy of Clinical Biochemistry. Position statement executive summary: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care. 2011 Jun; 34(6):1419-23. PMID: 21617111; PMCID: PMC3114347.
      Citations: 50     Fields:    Translation:Humans
    489. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, Lernmark A, Metzger BE, Nathan DM. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2011 Jun; 57(6):e1-e47. PMID: 21617152.
      Citations: 127     Fields:    Translation:Humans
    490. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, Lernmark A, Metzger BE, Nathan DM. Executive summary: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2011 Jun; 57(6):793-8. PMID: 21617153.
      Citations: 30     Fields:    Translation:Humans
    491. Bakris GL. American Society of Hypertension, Inc: Leadership message. J Clin Hypertens (Greenwich). 2011 Jul; 13(7):533. PMID: 21762368; PMCID: PMC8816463.
      Citations:    Fields:    Translation:Humans
    492. Brown WV, Bakris G, Lerma E, Chertow G. Assessment and management of vascular disease risk in patients with chronic kidney disease. J Clin Lipidol. 2011 Jul-Aug; 5(4):251-60. PMID: 21784369.
      Citations:    Fields:    Translation:Humans
    493. Bakris GL. Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. Mayo Clin Proc. 2011 May; 86(5):444-56. PMID: 21531886; PMCID: PMC3084647.
      Citations: 59     Fields:    Translation:Humans
    494. Bakris G, Weir MR, Schmieder RE. Telmisartan in incipient and overt diabetic renal disease. J Nephrol. 2011 May-Jun; 24(3):263-73. PMID: 21374585.
      Citations: 4     Fields:    Translation:Humans
    495. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Ann Forciea M, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol. 2011 May 17; 57(20):2037-114. PMID: 21524875.
      Citations: 159     Fields:    Translation:Humans
    496. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Forciea MA, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ, Harrington RA, ACCF Task Force. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2011 May 31; 123(21):2434-506. PMID: 21518977.
      Citations: 118     Fields:    Translation:Humans
    497. Saab G, Whaley-Connell A, Bombeck A, Kurella Tamura M, Li S, Chen SC, McFarlane SI, Sowers JR, Norris K, Bakris GL, McCullough PA, Kidney Early Evaluation Program Investigators. The Association between Parathyroid Hormone Levels and the Cardiorenal Metabolic Syndrome in Non-Diabetic Chronic Kidney Disease. Cardiorenal Med. 2011; 1(2):123-130. PMID: 22258399; PMCID: PMC3101512.
      Citations: 7     Fields:    
    498. Flynn C, Bakris GL. Interaction between Adiponectin and Aldosterone. Cardiorenal Med. 2011; 1(2):96-101. PMID: 22258396; PMCID: PMC3101509.
      Citations: 12     Fields:    
    499. Bakris GL. CON: blood pressure treatment goal for patients with diabetes should be <130/80 mm Hg. J Clin Hypertens (Greenwich). 2011 Apr; 13(4):263-5. PMID: 21466622; PMCID: PMC8672985.
      Citations: 4     Fields:    Translation:Humans
    500. Bakris GL. Blood pressure targets in diabetes: is this the time for change?--CON (Rebuttal). J Clin Hypertens (Greenwich). 2011 Apr; 13(4):268-9. PMID: 21466624; PMCID: PMC8673118.
      Citations: 1     Fields:    Translation:Humans
    501. Ruilope LM, Bakris GL. Renal function and target organ damage in hypertension. Eur Heart J. 2011 Jul; 32(13):1599-604. PMID: 21444366.
      Citations: 30     Fields:    Translation:Humans
    502. White WB, Schnitzer TJ, Bakris GL, Frayssinet H, Duquesroix B, Weber M. Effects of naproxcinod on blood pressure in patients with osteoarthritis. Am J Cardiol. 2011 May 01; 107(9):1338-45. PMID: 21371681.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    503. McFarlane SI, McCullough PA, Sowers JR, Soe K, Chen SC, Li S, Vassalotti JA, Stevens LA, Salifu MO, Kurella Tamura M, Bomback AS, Norris KC, Collins AJ, Bakris GL, Whaley-Connell AT, KEEP Steering Committee. Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: prevalence of and risk factors for diabetes mellitus in CKD in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2011 Mar; 57(3 Suppl 2):S24-31. PMID: 21338847; PMCID: PMC3237700.
      Citations: 9     Fields:    Translation:Humans
    504. McCullough PA, Brown WW, Gannon MR, Vassalotti JA, Collins AJ, Chen SC, Bakris GL, Whaley-Connell AT. Sustainable community-based CKD screening methods employed by the National Kidney Foundation's Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2011 Mar; 57(3 Suppl 2):S4-8. PMID: 21338848.
      Citations: 9     Fields:    Translation:HumansPHPublic Health
    505. Stevens LA, Li S, Kurella Tamura M, Chen SC, Vassalotti JA, Norris KC, Whaley-Connell AT, Bakris GL, McCullough PA. Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2011 Mar; 57(3 Suppl 2):S9-16. PMID: 21338849; PMCID: PMC3298760.
      Citations: 54     Fields:    Translation:HumansPHPublic Health
    506. McCullough PA, Vassalotti JA, Collins AJ, Chen SC, Bakris GL, Whaley-Connell AT. National Kidney Foundation's Kidney Early Evaluation Program (KEEP) annual data report 2010: executive summary. Am J Kidney Dis. 2011 Mar; 57(3 Suppl 2):S1-3. PMID: 21338845.
      Citations: 4     Fields:    Translation:HumansPHPublic Health
    507. Udani SM, Bakris GL. Do fibrates truly preserve kidney function? Nat Rev Endocrinol. 2011 Mar; 7(3):130-1. PMID: 21301489.
      Citations: 2     Fields:    Translation:Humans
    508. Bakris GL, Sica D, Weber M, White WB, Roberts A, Perez A, Cao C, Kupfer S. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich). 2011 Feb; 13(2):81-8. PMID: 21272195; PMCID: PMC8673073.
      Citations: 57     Fields:    Translation:Humans
    509. White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, Kupfer S. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011 Mar; 57(3):413-20. PMID: 21282560.
      Citations: 80     Fields:    Translation:Humans
    510. Whaley-Connell A, Bomback AS, McFarlane SI, Li S, Roberts T, Chen SC, Collins AJ, Norris K, Bakris GL, Sowers JR, McCullough PA, Kidney Early Evaluation Program Investigators. Diabetic Cardiovascular Disease Predicts Chronic Kidney Disease Awareness in the Kidney Early Evaluation Program. Cardiorenal Med. 2011; 1(1):45-52. PMID: 22258465; PMCID: PMC3101520.
      Citations: 11     Fields:    
    511. Lazich I, Bakris G. Initial combination antihypertensives: let's ACCELERATE. Lancet. 2011 Jan 22; 377(9762):278-9. PMID: 21236482.
      Citations:    Fields:    Translation:Humans
    512. Jamerson KA, Devereux R, Bakris GL, Pitt B, Velazquez EJ, Weir M, Kelly RY, Hua TA, Hester A, Weber MA, Dahlöf B. Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control. Hypertension. 2011 Feb; 57(2):174-9. PMID: 21189401.
      Citations: 14     Fields:    Translation:Humans
    513. Gradman AH, Basile JN, Carter BL, Bakris GL, American Society of Hypertension Writing Group. Combination therapy in hypertension. J Clin Hypertens (Greenwich). 2011 Mar; 13(3):146-54. PMID: 21366845; PMCID: PMC8673364.
      Citations: 37     Fields:    
    514. McCullough PA, Whaley-Connell A, Brown WW, Collins AJ, Chen SC, Li S, Norris KC, Jurkovitz C, McFarlane S, Obialo C, Sowers J, Stevens L, Vassalotti JA, Bakris GL, Kidney Early Evaluation Program (KEEP) Investigators. Cardiovascular risk modification in participants with coronary disease screened by the Kidney Early Evaluation Program. Intern Med J. 2010 Dec; 40(12):833-41. PMID: 21199222.
      Citations: 3     Fields:    Translation:HumansPHPublic Health
    515. Vasisht KP, Chen SC, Peng Y, Bakris GL. Limitations of metformin use in patients with kidney disease: are they warranted? Diabetes Obes Metab. 2010 Dec; 12(12):1079-83. PMID: 20977579.
      Citations: 20     Fields:    Translation:Humans
    516. Udani S, Lazich I, Bakris GL. Epidemiology of hypertensive kidney disease. Nat Rev Nephrol. 2011 Jan; 7(1):11-21. PMID: 21079654.
      Citations: 54     Fields:    Translation:Humans
    517. Singh M, Mensah GA, Bakris G. Pathogenesis and clinical physiology of hypertension. Cardiol Clin. 2010 Nov; 28(4):545-59. PMID: 20937440.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    518. Mensah GA, Bakris G. Treatment and control of high blood pressure in adults. Cardiol Clin. 2010 Nov; 28(4):609-22. PMID: 20937445.
      Citations: 11     Fields:    Translation:Humans
    519. Miller AB, Reichek N, St John Sutton M, Iyengar M, Henderson LS, Tarka EA, Bakris GL. Importance of blood pressure control in left ventricular mass regression. J Am Soc Hypertens. 2010 Nov-Dec; 4(6):302-10. PMID: 20980215.
      Citations: 7     Fields:    Translation:Humans
    520. Bakris GL, Lindholm LH, Black HR, Krum H, Linas S, Linseman JV, Arterburn S, Sager P, Weber M. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension. 2010 Nov; 56(5):824-30. PMID: 20921430.
      Citations: 54     Fields:    Translation:Humans
    521. Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm RH, Hall WD, Jones WE, Kountz DS, Lea JP, Nasser S, Nesbitt SD, Saunders E, Scisney-Matlock M, Jamerson KA, International Society on Hypertension in Blacks. Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension. 2010 Nov; 56(5):780-800. PMID: 20921433.
      Citations: 177     Fields:    Translation:Humans
    522. Weir MR, Bakris GL. Optimal blood pressure for a patient with type 2 diabetes mellitus: insight from the ACCORD study. Curr Hypertens Rep. 2010 Oct; 12(5):313-5. PMID: 20725808.
      Citations: 2     Fields:    
    523. Contreras G, Hu B, Astor BC, Greene T, Erlinger T, Kusek JW, Lipkowitz M, Lewis JA, Randall OS, Hebert L, Wright JT, Kendrick CA, Gassman J, Bakris G, Kopple JD, Appel LJ, African-American Study of Kidney Disease, and Hypertension Study Group. Malnutrition-inflammation modifies the relationship of cholesterol with cardiovascular disease. J Am Soc Nephrol. 2010 Dec; 21(12):2131-42. PMID: 20864686; PMCID: PMC3014026.
      Citations: 17     Fields:    Translation:Humans
    524. Appel LJ, Wright JT, Greene T, Agodoa LY, Astor BC, Bakris GL, Cleveland WH, Charleston J, Contreras G, Faulkner ML, Gabbai FB, Gassman JJ, Hebert LA, Jamerson KA, Kopple JD, Kusek JW, Lash JP, Lea JP, Lewis JB, Lipkowitz MS, Massry SG, Miller ER, Norris K, Phillips RA, Pogue VA, Randall OS, Rostand SG, Smogorzewski MJ, Toto RD, Wang X, AASK Collaborative Research Group. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010 Sep 02; 363(10):918-29. PMID: 20818902; PMCID: PMC3662974.
      Citations: 268     Fields:    Translation:Humans
    525. Burney B, Oliva R, Zorn KC, Bakris G. Hypertension following kidney injury. J Clin Hypertens (Greenwich). 2010 Sep; 12(9):727-30. PMID: 20883234; PMCID: PMC8673324.
      Citations: 1     Fields:    Translation:Humans
    526. Kalaitzidis RG, Bakris GL. Serum creatinine vs. albuminuria as biomarkers for the estimation of cardiovascular risk. Curr Vasc Pharmacol. 2010 Sep; 8(5):604-11. PMID: 20507275.
      Citations: 5     Fields:    Translation:Humans
    527. Hopkins KA, Bakris GL. Fixed-dose combination and chronic kidney disease progression: which is the best? Curr Opin Nephrol Hypertens. 2010 Sep; 19(5):450-5. PMID: 20539227.
      Citations: 2     Fields:    Translation:Humans
    528. Bomback AS, Rekhtman Y, Whaley-Connell AT, Kshirsagar AV, Sowers JR, Chen SC, Li S, Chinnaiyan KM, Bakris GL, McCullough PA. Gestational diabetes mellitus alone in the absence of subsequent diabetes is associated with microalbuminuria: results from the Kidney Early Evaluation Program (KEEP). Diabetes Care. 2010 Dec; 33(12):2586-91. PMID: 20807871; PMCID: PMC2992195.
      Citations: 14     Fields:    Translation:Humans
    529. Hart PD, Bakris GL. Hypertensive nephropathy: prevention and treatment recommendations. Expert Opin Pharmacother. 2010 Nov; 11(16):2675-86. PMID: 20718588.
      Citations: 27     Fields:    Translation:HumansAnimals
    530. Bakris G, Vassalotti J, Ritz E, Wanner C, Stergiou G, Molitch M, Nesto R, Kaysen GA, Sowers JR, CKD Consensus Working Group. National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney Int. 2010 Oct; 78(8):726-36. PMID: 20720529.
      Citations: 23     Fields:    Translation:Humans
    531. DeVore AD, Sorrentino M, Arnsdorf MF, Ward RP, Bakris GL, Blankstein R. Predictors of hypertension control in a diverse general cardiology practice. J Clin Hypertens (Greenwich). 2010 Aug; 12(8):570-7. PMID: 20695933; PMCID: PMC8816457.
      Citations: 9     Fields:    Translation:Humans
    532. Bakris GL. Leadership message. Forging ahead into the new healthcare frontier. J Clin Hypertens (Greenwich). 2010 Aug; 12(8):631-2. PMID: 20695942; PMCID: PMC8816440.
      Citations: 1     Fields:    Translation:Humans
    533. Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DE, Eagle KA, Hermann LK, Isselbacher EM, Kazerooni EA, Kouchoukos NT, Lytle BW, Milewicz DM, Reich DL, Sen S, Shinn JA, Svensson LG, Williams DM, American College of Cardiology Foundation, American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, Society for Vascular Medicine. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Catheter Cardiovasc Interv. 2010 Aug 01; 76(2):E43-86. PMID: 20687249.
      Citations: 107     Fields:    Translation:Humans
    534. Bakris GL. Diabetes, the kidney, and cardiovascular risk. Preface. Cardiol Clin. 2010 Aug; 28(3):xi. PMID: 20621246.
      Citations:    Fields:    Translation:Humans
    535. Hopkins KA, Bakris GL. Lower blood pressure goals in high-risk cardiovascular patients: are they defensible? Cardiol Clin. 2010 Aug; 28(3):447-52. PMID: 20621249.
      Citations: 1     Fields:    Translation:Humans
    536. Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DE, Eagle KA, Hermann LK, Isselbacher EM, Kazerooni EA, Kouchoukos NT, Lytle BW, Milewicz DM, Reich DL, Sen S, Shinn JA, Svensson LG, Williams DM, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelin, American Association for Thoracic surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, Society for Vascular Medicine. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Anesth Analg. 2010 Aug; 111(2):279-315. PMID: 20664093.
      Citations: 30     Fields:    Translation:Humans
    537. Chugh A, Bakris G. Intensive lowering of systolic blood pressure to a target of less than 120 mm Hg has no effect on the rate of fatal and non-fatal major cardiovascular events in high-risk patients with type 2 diabetes. Evid Based Med. 2010 Oct; 15(5):142-3. PMID: 20667901.
      Citations: 1     Fields:    
    538. Bakris GL. Dual RAAS blockade is desirable in kidney disease: con. Kidney Int. 2010 Sep; 78(6):546-9. PMID: 20664560.
      Citations: 3     Fields:    Translation:Humans
    539. Bakris GL, Iyengar M, Lukas MA, Ordronneau P, Weber MA. Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study. J Clin Hypertens (Greenwich). 2010 Sep; 12(9):678-86. PMID: 20883227; PMCID: PMC8673069.
      Citations: 7     Fields:    Translation:Humans
    540. Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, Pepine CJ. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010 Jul 07; 304(1):61-8. PMID: 20606150; PMCID: PMC3008411.
      Citations: 211     Fields:    Translation:Humans
    541. Taylor AA, Bakris GL. The role of vasodilating beta-blockers in patients with hypertension and the cardiometabolic syndrome. Am J Med. 2010 Jul; 123(7 Suppl 1):S21-6. PMID: 20609696.
      Citations: 6     Fields:    Translation:Humans
    542. Bakris GL, Bidani A. More complete renin-angiotensin system blockade: better outcomes or smoke and mirrors. J Hypertens. 2010 Jul; 28(7):1382-3. PMID: 20574248.
      Citations:    Fields:    Translation:HumansAnimals
    543. Jamerson KA, Bakris GL, Weber MA. 24-hour ambulatory blood pressure in the ACCOMPLISH trial. N Engl J Med. 2010 Jul 01; 363(1):98. PMID: 20592305.
      Citations: 10     Fields:    Translation:Humans
    544. Bakris GL, Basile JN, Giles TD, Taylor AA. The role of nitric oxide in improving endothelial function and cardiovascular health: focus on nebivolol. Am J Med. 2010 Jul; 123(7 Suppl 1):S2-8. PMID: 20609695.
      Citations: 2     Fields:    Translation:Humans
    545. Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, Velazquez EJ, Kelly RY, Hua TA, Hester A, Pitt B, ACCOMPLISH Investigators, Dahlöf B. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol. 2010 Jun 29; 56(1):77-85. PMID: 20620720.
      Citations: 47     Fields:    Translation:Humans
    546. Ruilope L, Izzo J, Haller H, Waeber B, Oparil S, Weber M, Bakris G, Sowers J. Prevention of microalbuminuria in patients with type 2 diabetes: what do we know? J Clin Hypertens (Greenwich). 2010 Jun; 12(6):422-30. PMID: 20591087; PMCID: PMC8673278.
      Citations: 8     Fields:    Translation:Humans
    547. Weir MR, Bakris GL. Editorial perspective. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol. 2010; 31(5):469-70. PMID: 20413964.
      Citations: 10     Fields:    Translation:Humans
    548. Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DE, Eagle KA, Hermann LK, Isselbacher EM, Kazerooni EA, Kouchoukos NT, Lytle BW, Milewicz DM, Reich DL, Sen S, Shinn JA, Svensson LG, Williams DM, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelin, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, Society for Vascular Medicine. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology,American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons,and Society for Vascular Medicine. J Am Coll Cardiol. 2010 Apr 06; 55(14):e27-e129. PMID: 20359588.
      Citations: 434     Fields:    Translation:Humans
    549. Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, Ivy SP, Leier CV, Lindenfeld J, Liu G, Remick SC, Steingart R, Tang WH, Cardiovascular Toxicities Panel, Convened by the Angiogenesis Task Force of the National Cancer Inst. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010 May 05; 102(9):596-604. PMID: 20351338; PMCID: PMC2864290.
      Citations: 156     Fields:    Translation:HumansCellsPHPublic Health
    550. Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DE, Eagle KA, Hermann LK, Isselbacher EM, Kazerooni EA, Kouchoukos NT, Lytle BW, Milewicz DM, Reich DL, Sen S, Shinn JA, Svensson LG, Williams DM, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelin, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, Society for Vascular Medicine. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation. 2010 Apr 06; 121(13):e266-369. PMID: 20233780.
      Citations: 759     Fields:    Translation:Humans
    551. McCullough PA, Vassalotti JA, Collins AJ, Chen SC, Bakris GL. National Kidney Foundation's Kidney Early Evaluation Program (KEEP) annual data report 2009: executive summary. Am J Kidney Dis. 2010 Mar; 55(3 Suppl 2):S1-3. PMID: 20172443.
      Citations: 12     Fields:    Translation:Humans
    552. Stevens LA, Li S, Wang C, Huang C, Becker BN, Bomback AS, Brown WW, Jurkovitz CT, McFarlane SI, Norris KC, Shlipak M, Whaley-Connell AT, Chen SC, Bakris GL, McCullough PA, Burrows NR. Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2010 Mar; 55(3 Suppl 2):S23-33. PMID: 20172445; PMCID: PMC4574484.
      Citations: 118     Fields:    Translation:HumansPHPublic Health
    553. Bomback AS, Kshirsagar AV, Whaley-Connell AT, Chen SC, Li S, Klemmer PJ, McCullough PA, Bakris GL. Racial differences in kidney function among individuals with obesity and metabolic syndrome: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2010 Mar; 55(3 Suppl 2):S4-S14. PMID: 20172446.
      Citations: 6     Fields:    Translation:Humans
    554. Mak RH, Bakris G. Pediatrics: Masked hypertension: a risk factor in children with CKD. Nat Rev Nephrol. 2010 Mar; 6(3):132-4. PMID: 20186228.
      Citations: 2     Fields:    Translation:Humans
    555. Bakris GL, Sowers JR, Glies TD, Black HR, Izzo JL, Materson BJ, Oparil S, Weber MA. Treatment of hypertension in patients with diabetes--an update. J Am Soc Hypertens. 2010 Mar-Apr; 4(2):62-7. PMID: 20400050.
      Citations: 5     Fields:    
    556. Gradman AH, Basile JN, Carter BL, Bakris GL, Materson BJ, Black HR, Izzo JL, Oparil S, Weber MA. Combination therapy in hypertension. J Am Soc Hypertens. 2010 Mar-Apr; 4(2):90-8. PMID: 20400053.
      Citations: 56     Fields:    
    557. Bakris GL. Overview of the KEEP international articles. Kidney Int Suppl. 2010 Mar; (116):S1. PMID: 20186174.
      Citations:    Fields:    Translation:HumansPHPublic Health
    558. Bakris GL, Sarafidis PA, Weir MR, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA, ACCOMPLISH Trial investigators, Dahlöf B. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010 Apr 03; 375(9721):1173-81. PMID: 20170948.
      Citations: 133     Fields:    Translation:Humans
    559. Mak RH, Flynn J, Bakris G. Pediatrics: blood pressure target for renoprotection in children. Nat Rev Nephrol. 2010 Feb; 6(2):67-8. PMID: 20111045.
      Citations:    Fields:    Translation:Humans
    560. Bowling CB, Pitt B, Ahmed MI, Aban IB, Sanders PW, Mujib M, Campbell RC, Love TE, Aronow WS, Allman RM, Bakris GL, Ahmed A. Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. Circ Heart Fail. 2010 Mar; 3(2):253-60. PMID: 20103777; PMCID: PMC2909749.
      Citations: 50     Fields:    Translation:Humans
    561. Oliva R, Angelos P, Kaplan E, Bakris G. Pheochromocytoma in pregnancy: a case series and review. Hypertension. 2010 Mar; 55(3):600-6. PMID: 20083723.
      Citations: 31     Fields:    Translation:Humans
    562. Bakris G. Are there effects of renin-angiotensin system antagonists beyond blood pressure control? Am J Cardiol. 2010 Jan 04; 105(1 Suppl):21A-9A. PMID: 20102970.
      Citations: 16     Fields:    Translation:Humans
    563. Whaley-Connell A, Pavey BS, McCullough PA, Saab G, Li S, McFarlane SI, Chen SC, Vassalotti JA, Collins AJ, Bakris G, Sowers JR, KEEP Investigators. Dysglycemia predicts cardiovascular and kidney disease in the Kidney Early Evaluation Program. J Clin Hypertens (Greenwich). 2010 Jan; 12(1):51-8. PMID: 20047632; PMCID: PMC8673269.
      Citations: 21     Fields:    Translation:Humans
    564. Vassalotti JA, Li S, McCullough PA, Bakris GL. Kidney early evaluation program: a community-based screening approach to address disparities in chronic kidney disease. Semin Nephrol. 2010 Jan; 30(1):66-73. PMID: 20116650.
      Citations: 19     Fields:    Translation:Humans
    565. Iyer AS, Ahmed MI, Filippatos GS, Ekundayo OJ, Aban IB, Love TE, Nanda NC, Bakris GL, Fonarow GC, Aronow WS, Ahmed A. Uncontrolled hypertension and increased risk for incident heart failure in older adults with hypertension: findings from a propensity-matched prospective population study. J Am Soc Hypertens. 2010 Jan-Feb; 4(1):22-31. PMID: 20374948; PMCID: PMC2914566.
      Citations: 30     Fields:    Translation:Humans
    566. Gradman AH, Basile JN, Carter BL, Bakris GL, American Society of Hypertension Writing Group. Combination therapy in hypertension. J Am Soc Hypertens. 2010 Jan-Feb; 4(1):42-50. PMID: 20374950.
      Citations: 60     Fields:    Translation:Humans
    567. Hopkins K, Bakris GL. Hypertension goals in advanced-stage kidney disease. Clin J Am Soc Nephrol. 2009 Dec; 4 Suppl 1:S92-4. PMID: 19996011.
      Citations: 2     Fields:    Translation:Humans
    568. Kalaitzidis RG, Bakris GL. Prehypertension: is it relevant for nephrologists? Kidney Int. 2010 Feb; 77(3):194-200. PMID: 19924105.
      Citations: 14     Fields:    Translation:Humans
    569. Bhatnagar V, Garcia EP, O'Connor DT, Brophy VH, Alcaraz J, Richard E, Bakris GL, Middleton JP, Norris KC, Wright J, Hiremath L, Contreras G, Appel LJ, Lipkowitz MS, AASK Study Investigators. CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease. Am J Nephrol. 2010; 31(2):95-103. PMID: 19907160; PMCID: PMC2853591.
      Citations: 28     Fields:    Translation:Humans
    570. Bakris GL. Retraction statement. Am J Nephrol. 2009; 30(6):563. PMID: 19893299.
      Citations:    Fields:    
    571. Duka I, Bakris G. Inhibiting the renin-angiotensin system in patients with type 1 diabetes: is it worth it? Pol Arch Med Wewn. 2009 Nov; 119(11):692-3. PMID: 19920790.
      Citations:    Fields:    Translation:Humans
    572. Kalaitzidis RG, Bakris GL. The current state of RAAS blockade in the treatment of hypertension and proteinuria. Curr Cardiol Rep. 2009 Nov; 11(6):436-42. PMID: 19863868.
      Citations: 6     Fields:    Translation:Humans
    573. Kalaitzidis R, Bakris G. Pathogenesis and treatment of microalbuminuria in patients with diabetes: the road ahead. J Clin Hypertens (Greenwich). 2009 Nov; 11(11):636-43. PMID: 19878372; PMCID: PMC8673001.
      Citations: 12     Fields:    Translation:Humans
    574. Burney BO, Bakris GL. Hypertension and its management in the elderly. Semin Nephrol. 2009 Nov; 29(6):604-9. PMID: 20006792.
      Citations:    Fields:    Translation:Humans
    575. Roberts WC, Bakris GL, Black HR, Sica DA, Sulkes DJ. The editor's roundtable: prehypertension. Am J Cardiol. 2009 Oct 15; 104(8):1105-15. PMID: 19801033.
      Citations:    Fields:    Translation:Humans
    576. Saab G, Whaley-Connell A, McFarlane SI, Li S, Chen SC, Sowers JR, McCullough PA, Bakris GL, Kidney Early Evaluation Program Investigators. Obesity is associated with increased parathyroid hormone levels independent of glomerular filtration rate in chronic kidney disease. Metabolism. 2010 Mar; 59(3):385-9. PMID: 19800639.
      Citations: 14     Fields:    Translation:Humans
    577. Bakris G. Home blood pressure monitoring to manage hypertension in patients with nephropathy: the time has arrived. Curr Hypertens Rep. 2009 Oct; 11(5):299-300. PMID: 19737444.
      Citations:    Fields:    
    578. Bakris G. Hypertension guidelines and chronic kidney disease: physicians, please follow directions. Curr Hypertens Rep. 2009 Oct; 11(5):301-2. PMID: 19737445.
      Citations:    Fields:    
    579. Weinberg JM, Appel LJ, Bakris G, Gassman JJ, Greene T, Kendrick CA, Wang X, Lash J, Lewis JA, Pogue V, Thornley-Brown D, Phillips RA, African American Study of Hypertension and Kidney Disease Collaborative Research Group. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med. 2009 Sep 28; 169(17):1587-94. PMID: 19786678.
      Citations: 36     Fields:    Translation:Humans
    580. Weber MA, Black H, Bakris G, Krum H, Linas S, Weiss R, Linseman JV, Wiens BL, Warren MS, Lindholm LH. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Oct 24; 374(9699):1423-31. PMID: 19748665.
      Citations: 87     Fields:    Translation:Humans
    581. Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol. 2009; 30(5):418-24. PMID: 19738369.
      Citations: 63     Fields:    Translation:HumansCTClinical Trials
    582. Kalaitzidis RG, Bakris GL. Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease? Curr Opin Nephrol Hypertens. 2009 Sep; 18(5):386-91. PMID: 19561494.
      Citations: 6     Fields:    Translation:Humans
    583. Bakris GL. The future of blood pressure control in a population with a growing girth. Curr Opin Nephrol Hypertens. 2009 Sep; 18(5):379-80. PMID: 19623066.
      Citations:    Fields:    Translation:Humans
    584. Bakris GL. Is blockade of the renin-angiotensin system appropriate for all patients with diabetes? J Am Soc Hypertens. 2009 Sep-Oct; 3(5):288-90. PMID: 20409971.
      Citations: 1     Fields:    
    585. Bakris GL, Kuritzky L. Monitoring and managing urinary albumin excretion: practical advice for primary care clinicians. Postgrad Med. 2009 Jul; 121(4):51-60. PMID: 19641270.
      Citations: 6     Fields:    Translation:Humans
    586. Kalaitzidis R, Bakris GL. Effects of angiotensin II receptor blockers on diabetic nephropathy. J Hypertens Suppl. 2009 Jul; 27(5):S15-21. PMID: 19587550.
      Citations: 14     Fields:    Translation:Humans
    587. Kalaitzidis R, Bakris GL. Lower blood pressure goals for cardiovascular and renal risk reduction: are they defensible? J Clin Hypertens (Greenwich). 2009 Jul; 11(7):345-7. PMID: 19583629; PMCID: PMC8673160.
      Citations: 7     Fields:    Translation:Humans
    588. Kalaitzidis R, Bakris G. Management of hypertension in patients with diabetes: the place of angiotensin-II receptor blockers. Diabetes Obes Metab. 2009 Aug; 11(8):757-69. PMID: 19519867.
      Citations: 2     Fields:    Translation:Humans
    589. Ahmed MI, Ekundayo OJ, Mujib M, Campbell RC, Sanders PW, Pitt B, Perry GJ, Bakris G, Aban I, Love TE, Aronow WS, Ahmed A. Mild hyperkalemia and outcomes in chronic heart failure: a propensity matched study. Int J Cardiol. 2010 Oct 29; 144(3):383-8. PMID: 19500863; PMCID: PMC2888731.
      Citations: 24     Fields:    Translation:Humans
    590. Dronovalli S, Burney BO, Bakris GL. Glycemic control and cardiovascular disease in chronic kidney disease. Curr Diab Rep. 2009 Jun; 9(3):243-8. PMID: 19490827.
      Citations: 1     Fields:    Translation:Humans
    591. Sarafidis PA, Bakris GL. Does evidence support renin-angiotensin system blockade for slowing nephropathy progression in elderly persons? Ann Intern Med. 2009 May 19; 150(10):731-3. PMID: 19451583.
      Citations: 8     Fields:    Translation:Humans
    592. Bakris G. An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade. J Cardiovasc Pharmacol. 2009 May; 53(5):379-87. PMID: 19454898.
      Citations: 12     Fields:    Translation:Humans
    593. Khosla N, Kalaitzidis R, Bakris GL. The kidney, hypertension, and remaining challenges. Med Clin North Am. 2009 May; 93(3):697-715, Table of Contents. PMID: 19427500.
      Citations: 14     Fields:    Translation:Humans
    594. Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009 Jun; 75(12):1272-1277. PMID: 19357717.
      Citations: 119     Fields:    Translation:HumansAnimals
    595. Bakris GL, McCullough PA, Collins AJ. Executive summary: Kidney Early Evaluation Program (KEEP) 2008 annual data report. Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S1-2. PMID: 19285606.
      Citations: 6     Fields:    Translation:HumansPHPublic Health
    596. Whaley-Connell A, Sowers JR, McCullough PA, Roberts T, McFarlane SI, Chen SC, Li S, Wang C, Collins AJ, Bakris GL, KEEP Investigators. Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S11-21. PMID: 19285607.
      Citations: 44     Fields:    Translation:HumansPHPublic Health
    597. Kalaitzidis R, Li S, Wang C, Chen SC, McCullough PA, Bakris GL. Hypertension in early-stage kidney disease: an update from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S22-31. PMID: 19285608.
      Citations: 13     Fields:    Translation:HumansPHPublic Health
    598. Bhuriya R, Li S, Chen SC, McCullough PA, Bakris GL. Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S3-10. PMID: 19285609.
      Citations: 25     Fields:    Translation:HumansPHPublic Health
    599. Zanchetti A, Mancia G, Black HR, Oparil S, Waeber B, Schmieder RE, Bakris GL, Messerli FH, Kjeldsen SE, Ruilope LM. Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. J Hypertens. 2009 Apr; 27(4):673-9. PMID: 19516168.
      Citations: 18     Fields:    Translation:Humans
    600. Bakris GL, Ritz E, World Kidney Day Steering Committee. Hypertension: the message of World Kidney Day 2009. Nat Rev Nephrol. 2009 Apr; 5(4):188-90. PMID: 19322182.
      Citations: 1     Fields:    Translation:Humans
    601. Ritz E, Bakris G, World Kidney Day Organising Committee. World Kidney Day: hypertension and chronic kidney disease. Lancet. 2009 Apr 04; 373(9670):1157-8. PMID: 19282027.
      Citations: 8     Fields:    Translation:Humans
    602. Burney BO, Kalaitzidis RG, Bakris GL. Novel therapies of diabetic nephropathy. Curr Opin Nephrol Hypertens. 2009 Mar; 18(2):107-11. PMID: 19434047.
      Citations: 6     Fields:    Translation:HumansAnimals
    603. Kalaitzidis R, Bakris G. Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy? Postgrad Med. 2009 Mar; 121(2):77-88. PMID: 19332965.
      Citations: 2     Fields:    Translation:Humans
    604. Bakris GL, Ritz E, World Kidney Day Steering Committee. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. J Am Soc Hypertens. 2009 Mar-Apr; 3(2):80-3. PMID: 20409949.
      Citations: 5     Fields:    
    605. Bakris GL, Sowers JR, American Society of Hypertension Writing Group. Treatment of hypertension in patients with diabetes-an update. J Am Soc Hypertens. 2009 Mar-Apr; 3(2):150-5. PMID: 20409955.
      Citations: 2     Fields:    
    606. Bakris GL, Ritz E, World Kidney Day Steering Committee. The message for World Kidney Day 2009: hypertension and kidney disease--a marriage that should be prevented. J Hypertens. 2009 Mar; 27(3):666-9. PMID: 19262237.
      Citations: 11     Fields:    Translation:Humans
    607. Bakris GL, Ritz E, World Kidney Day Steering Committee. The message for World Kidney Day 2009: hypertension and kidney disease--a marriage that should be prevented. Clin Nephrol. 2009 Mar; 71(3):239-43. PMID: 19281733.
      Citations:    Fields:    Translation:HumansPHPublic Health
    608. Bakris GL, Ritz E, World Kidney Day Steering Committee. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. J Clin Hypertens (Greenwich). 2009 Mar; 11(3):144-7. PMID: 19302426; PMCID: PMC8673147.
      Citations: 13     Fields:    Translation:Humans
    609. Bakris GL, Ritz E. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. Kidney Int. 2009 Mar; 75(5):449-52. PMID: 19218998.
      Citations: 14     Fields:    Translation:Humans
    610. Bakris GL, Ritz E, World Kidney Day Steering Committee. The message for World Kidney Day 2009: Hypertension and kidney disease: a marriage that should be prevented. Nephrol Dial Transplant. 2009 Mar; 24(3):695-7. PMID: 19225021.
      Citations: 1     Fields:    Translation:Humans
    611. Bakris GL, Ritz E. World Kidney Day 2009: hypertension and kidney disease is a marriage that should be prevented. Am J Kidney Dis. 2009 Mar; 53(3):373-6. PMID: 19231738.
      Citations:    Fields:    Translation:Humans
    612. Bakris GL, Ritz E, World Kidney Day Steering Committee. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. Blood Purif. 2009; 27(2):231-4. PMID: 19246897.
      Citations:    Fields:    Translation:Humans
    613. Bakris GL, Ritz E. The message for World Kidney Day 2009: Hypertension and kidney disease: a marriage that should be prevented. Kidney Blood Press Res. 2009; 32(1):67-70. PMID: 19246931.
      Citations: 1     Fields:    Translation:Humans
    614. Bakris GL, Ritz E, World Kidney Day Steering Committee. The message for World Kidney Day 2009. Hypertension and kidney disease: a marriage that should be prevented. Nephron Clin Pract. 2009; 111(2):c155-8. PMID: 19246932.
      Citations:    Fields:    Translation:Humans
    615. Bakris GL, Ritz E, World Kidney Day Steering Committee. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. Am J Nephrol. 2009; 30(1):95-8. PMID: 19252399.
      Citations: 3     Fields:    Translation:Humans
    616. Bakris GL, Ritz E, World Kidney Day Steering Committee. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. Clin J Am Soc Nephrol. 2009 Mar; 4(3):517-9. PMID: 19211670; PMCID: PMC4571533.
      Citations: 2     Fields:    Translation:HumansPHPublic Health
    617. Ekundayo OJ, Dell'Italia LJ, Sanders PW, Arnett D, Aban I, Love TE, Filippatos G, Anker SD, Lloyd-Jones DM, Bakris G, Mujib M, Ahmed A. Association between hyperuricemia and incident heart failure among older adults: a propensity-matched study. Int J Cardiol. 2010 Jul 23; 142(3):279-87. PMID: 19201041; PMCID: PMC2906633.
      Citations: 55     Fields:    Translation:Humans
    618. Bakris GL, Ritz E. The message for World Kidney Day 2009: Hypertension and kidney disease: a marriage that should be prevented. Nephrology (Carlton). 2009 Feb; 14(1):49-51. PMID: 19335844.
      Citations:    Fields:    Translation:Humans
    619. Bakris GL, Ritz E, World Kidney Day Steering Committee. Hypertension and kidney disease: a combination that should be prevented. Nephrol News Issues. 2009 Feb; 23(2):42, 44, 46. PMID: 19278152.
      Citations:    Fields:    Translation:Humans
    620. Bakris GL, Ritz E, World Kidney Day Steering Committee. The message for World Kidney Day 2009: hypertension and kidney disease-a marriage that should be prevented. Clin Exp Nephrol. 2009 Feb; 13(1):96-9. PMID: 19184272.
      Citations:    Fields:    Translation:HumansPHPublic Health
    621. Bakris GL, Ritz E, World Kidney Day Steering Committee. The message for World Kidney Day 2009: hypertension and kidney disease--a marriage that should be prevented. J Hum Hypertens. 2009 Mar; 23(3):222-5. PMID: 19158823.
      Citations: 5     Fields:    Translation:Humans
    622. Hopkins K, Bakris GL. Assessing blood pressure control in dialysis patients: finally a step forward. Hypertension. 2009 Mar; 53(3):448-9. PMID: 19153262.
      Citations: 2     Fields:    Translation:Humans
    623. Bakris GL, Ritz E. The message for World Kidney Day 2009: hypertension and kidney disease-a marriage that should be prevented. Pediatr Nephrol. 2009 Mar; 24(3):427-30. PMID: 19152007.
      Citations:    Fields:    Translation:Humans
    624. Ekundayo OJ, Adamopoulos C, Ahmed MI, Pitt B, Young JB, Fleg JL, Love TE, Sui X, Perry GJ, Siscovick DS, Bakris G, Ahmed A. Oral potassium supplement use and outcomes in chronic heart failure: a propensity-matched study. Int J Cardiol. 2010 May 28; 141(2):167-74. PMID: 19135741; PMCID: PMC2900187.
      Citations: 13     Fields:    Translation:Humans
    625. Bakris GL, Ritz E, World Kidney Day Steering Committee. The message for World Kidney Day 2009: hypertension and kidney disease, a marriage that should be prevented. Iran J Kidney Dis. 2009 Jan; 3(1):7-10. PMID: 19377251.
      Citations: 1     Fields:    Translation:Humans
    626. Kalaitzidis RG, Sarafidis PA, Bakris GL. Effects of thiazolidinediones beyond glycaemic control. Curr Pharm Des. 2009; 15(5):529-36. PMID: 19199979.
      Citations: 16     Fields:    Translation:HumansAnimals
    627. Bakris GL, Ritz E, World Kidney Day Steering Committee. The message for World Kidney Day 2009: Hypertension and kidney disease: a marriage that should be prevented. Arch Iran Med. 2009 Jan; 12(1):102-5. PMID: 19111042.
      Citations:    Fields:    Translation:Humans
    628. Bhatnagar V, O'Connor DT, Brophy VH, Schork NJ, Richard E, Salem RM, Nievergelt CM, Bakris GL, Middleton JP, Norris KC, Wright J, Hiremath L, Contreras G, Appel LJ, Lipkowitz MS, AASK Study Investigators. G-protein-coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among African Americans: sex-specificity and interactions. Am J Hypertens. 2009 Mar; 22(3):332-8. PMID: 19119263; PMCID: PMC2715837.
      Citations: 29     Fields:    Translation:HumansCells
    629. Kalaitzidis R, Bakris G. Should nephrologists use beta-blockers? A perspective. Nephrol Dial Transplant. 2009 Mar; 24(3):701-2. PMID: 19073654.
      Citations: 6     Fields:    Translation:Humans
    630. Jamerson K, Weber MA, Bakris GL, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ, ACCOMPLISH Trial Investigators, Dahlöf B. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008 Dec 04; 359(23):2417-28. PMID: 19052124.
      Citations: 539     Fields:    Translation:Humans
    631. Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol. 2008 Nov 25; 52(22):1749-57. PMID: 19022154.
      Citations: 100     Fields:    Translation:Humans
    632. Dronavalli S, Bakris GL. Mechanistic insights into diuretic-induced insulin resistance. Hypertension. 2008 Dec; 52(6):1009-11. PMID: 18981323.
      Citations: 13     Fields:    Translation:Humans
    633. Bakris GL. ASH: renaissance of a society -- a movement of vigorous renewal. J Clin Hypertens (Greenwich). 2008 Oct; 10(10):808. PMID: 19090885; PMCID: PMC8673328.
      Citations:    Fields:    Translation:Humans
    634. Blankstein R, Bakris GL. Renal hemodynamic changes in heart failure. Heart Fail Clin. 2008 Oct; 4(4):411-23. PMID: 18760753.
      Citations: 8     Fields:    Translation:HumansCells
    635. Blankstein R, Bakris GL. Changes in kidney function following heart failure treatment: focus on renin-angiotensin system blockade. Heart Fail Clin. 2008 Oct; 4(4):425-38. PMID: 18760754.
      Citations: 1     Fields:    Translation:Humans
    636. Bakris GL. Should a lower blood pressure goal and albuminuria reduction be mandated to slow hypertensive nephropathy? Curr Hypertens Rep. 2008 Oct; 10(5):387-8. PMID: 18775116.
      Citations:    Fields:    
    637. Bakris GL. Albuminuria reduction and nephropathy progression. Curr Hypertens Rep. 2008 Oct; 10(5):388-9. PMID: 18775117.
      Citations:    Fields:    
    638. Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R, EPHESUS Investigators. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation. 2008 Oct 14; 118(16):1643-50. PMID: 18824643.
      Citations: 74     Fields:    Translation:Humans
    639. Norris KC, Shlipak MG, Bakris G. KEEP launches follow-up initiative aimed at predicting the future. Nephrol News Issues. 2008 Sep; 22(10):44-6. PMID: 18814556.
      Citations:    Fields:    Translation:HumansPHPublic Health
    640. Bakris GL, Sowers JR, American Society of Hypertension Writing Group. ASH position paper: treatment of hypertension in patients with diabetes-an update. J Clin Hypertens (Greenwich). 2008 Sep; 10(9):707-13; discussion 714-5. PMID: 18844766; PMCID: PMC8673265.
      Citations: 14     Fields:    Translation:Humans
    641. Duka I, Bakris G. Influence of microalbuminuria in achieving blood pressure goals. Curr Opin Nephrol Hypertens. 2008 Sep; 17(5):457-63. PMID: 18695385.
      Citations: 3     Fields:    Translation:Humans
    642. Bakris G, Dagenais G, Diener HC, Fujita T, Gorelick P, Kjeldsen SE, Laakso M, Mancia G, Pitt B, Sharma A, Sleight P, Teo K, Unger T, Weber M, Williams B, Zannad F, Böhm M. Cardiovascular protection for all individuals at high risk: evidence-based best practice. Clin Res Cardiol. 2008 Oct; 97(10):713-25. PMID: 18726243.
      Citations: 5     Fields:    Translation:Humans
    643. Sarafidis PA, Bakris GL. Renin-angiotensin blockade and kidney disease. Lancet. 2008 Aug 16; 372(9638):511-2. PMID: 18707969.
      Citations: 12     Fields:    Translation:Humans
    644. Alper AB, Campbell RC, Anker SD, Bakris G, Wahle C, Love TE, Hamm LL, Mujib M, Ahmed A. A propensity-matched study of low serum potassium and mortality in older adults with chronic heart failure. Int J Cardiol. 2009 Sep 11; 137(1):1-8. PMID: 18691778; PMCID: PMC2771189.
      Citations: 15     Fields:    Translation:Humans
    645. Saab G, Whaley-Connell AT, McCullough PA, Bakris GL. CKD awareness in the United States: the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2008 Aug; 52(2):382-3. PMID: 18640489.
      Citations: 20     Fields:    Translation:HumansPHPublic Health
    646. Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab. 2008 Aug; 4(8):444-52. PMID: 18607402.
      Citations: 223     Fields:    Translation:HumansAnimals
    647. Bell DS, Bakris GL, McGill JB. Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients. Diabetes Obes Metab. 2009 Mar; 11(3):234-8. PMID: 18564334.
      Citations: 13     Fields:    Translation:Humans
    648. Bakris G, Stockert J, Molitch M, Zhou Q, Champion A, Bacher P, Sowers J, STAR Investigators. Risk factor assessment for new onset diabetes: literature review. Diabetes Obes Metab. 2009 Mar; 11(3):177-87. PMID: 18564174.
      Citations: 13     Fields:    Translation:Humans
    649. McCullough PA, Li S, Jurkovitz CT, Stevens L, Collins AJ, Chen SC, Norris KC, McFarlane S, Johnson B, Shlipak MG, Obialo CI, Brown WW, Vassalotti J, Vassaloti J, Whaley-Connell AT, Brenner RM, Bakris GL, KEEP Investigators. Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. Am Heart J. 2008 Aug; 156(2):277-83. PMID: 18657657.
      Citations: 61     Fields:    Translation:Humans
    650. Carter BL, Einhorn PT, Brands M, He J, Cutler JA, Whelton PK, Bakris GL, Brancati FL, Cushman WC, Oparil S, Wright JT, Working Group from the National Heart, Lung, and Blood Institute. Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute. Hypertension. 2008 Jul; 52(1):30-6. PMID: 18504319.
      Citations: 44     Fields:    Translation:Humans
    651. Vasisht KP, Bakris G. New onset diabetes: can it be delayed? J Hum Hypertens. 2008 Aug; 22(8):517-9. PMID: 18496556.
      Citations: 1     Fields:    Translation:Humans
    652. Bakris G, Burgess E, Weir M, Davidai G, Koval S, AMADEO Study Investigators. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int. 2008 Aug; 74(3):364-9. PMID: 18496508.
      Citations: 40     Fields:    Translation:HumansCTClinical Trials
    653. Gradman AH, Weir MR, Bakris GL. Newer combination therapies in the management of hypertension: an update. J Clin Hypertens (Greenwich). 2008 May; 10(5):398-405. PMID: 18453800; PMCID: PMC8110169.
      Citations: 1     Fields:    Translation:Humans
    654. Appel LJ, Wright JT, Greene T, Kusek JW, Lewis JB, Wang X, Lipkowitz MS, Norris KC, Bakris GL, Rahman M, Contreras G, Rostand SG, Kopple JD, Gabbai FB, Schulman GI, Gassman JJ, Charleston J, Agodoa LY, African American Study of Kidney Disease and Hypertension Collaborative Research Group. Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med. 2008 Apr 28; 168(8):832-9. PMID: 18443258; PMCID: PMC3870204.
      Citations: 67     Fields:    Translation:Humans
    655. Filippatos GS, Adamopoulos C, Sui X, Love TE, Pullicino PM, Lubsen J, Bakris G, Anker SD, Howard G, Kremastinos DT, Ahmed A. A propensity-matched study of hypertension and increased stroke-related hospitalization in chronic heart failure. Am J Cardiol. 2008 Jun 15; 101(12):1772-6. PMID: 18549857; PMCID: PMC2474775.
      Citations: 12     Fields:    Translation:Humans
    656. Bakris GL, Weir MR. Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression. Postgrad Med. 2008 Apr; 120(1):33-42. PMID: 18467807.
      Citations: 2     Fields:    Translation:Humans
    657. Sarafidis PA, Li S, Chen SC, Collins AJ, Brown WW, Klag MJ, Bakris GL. Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med. 2008 Apr; 121(4):332-40. PMID: 18374693.
      Citations: 90     Fields:    Translation:Humans
    658. Hart P, Bakris GL. Calcium antagonists: Do they equally protect against kidney injury? Kidney Int. 2008 Apr; 73(7):795-6. PMID: 18340349.
      Citations: 5     Fields:    Translation:HumansAnimals
    659. Bakris G, Collins AJ. Executive summary: Kidney Early Evaluation Program (KEEP) 2007 Annual Data Report. Am J Kidney Dis. 2008 Apr; 51(4 Suppl 2):S1-2. PMID: 18359402.
      Citations: 4     Fields:    Translation:Humans
    660. McFarlane SI, Chen SC, Whaley-Connell AT, Sowers JR, Vassalotti JA, Salifu MO, Li S, Wang C, Bakris G, McCullough PA, Collins AJ, Norris KC, Kidney Early Evaluation Program Investigators. Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis. 2008 Apr; 51(4 Suppl 2):S46-55. PMID: 18359408.
      Citations: 41     Fields:    Translation:HumansPHPublic Health
    661. Rao MV, Qiu Y, Wang C, Bakris G. Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004. Am J Kidney Dis. 2008 Apr; 51(4 Suppl 2):S30-7. PMID: 18359406.
      Citations: 57     Fields:    Translation:HumansPHPublic Health
    662. Astor BC, Yi S, Hiremath L, Corbin T, Pogue V, Wilkening B, Peterson G, Lewis J, Lash JP, Van Lente F, Gassman J, Wang X, Bakris G, Appel LJ, Contreras G. N-terminal prohormone brain natriuretic peptide as a predictor of cardiovascular disease and mortality in blacks with hypertensive kidney disease: the African American Study of Kidney Disease and Hypertension (AASK). Circulation. 2008 Apr 01; 117(13):1685-92. PMID: 18362234.
      Citations: 25     Fields:    Translation:Humans
    663. Bakris GL, Toto RD, McCullough PA, Rocha R, Purkayastha D, Davis P, GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension) Study Inves. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008 Jun; 73(11):1303-9. PMID: 18354383.
      Citations: 49     Fields:    Translation:Humans
    664. Bakris GL, Berkwits M. Trials that matter: the effect of a fixed-dose combination of an Angiotensin-converting enzyme inhibitor and a diuretic on the complications of type 2 diabetes. Ann Intern Med. 2008 Mar 04; 148(5):400-1. PMID: 18316758.
      Citations: 2     Fields:    Translation:Humans
    665. Weber MA, Bakris GL, Giles TD, Messerli FH. Beta-blockers in the treatment of hypertension: new data, new directions. J Clin Hypertens (Greenwich). 2008 Mar; 10(3):234-8. PMID: 18326967; PMCID: PMC8110173.
      Citations: 3     Fields:    Translation:Humans
    666. Sarafidis PA, Bakris GL. State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension. J Clin Hypertens (Greenwich). 2008 Feb; 10(2):130-9. PMID: 18256578; PMCID: PMC8110159.
      Citations: 36     Fields:    Translation:Humans
    667. Weir MR, Bakris GL. Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come? J Clin Hypertens (Greenwich). 2008 Feb; 10(2):146-52. PMID: 18256579; PMCID: PMC8109960.
      Citations: 13     Fields:    Translation:Humans
    668. Sarafidis P, Bogojevic Z, Basta E, Kirstner E, Bakris GL. Comparative efficacy of two different beta-blockers on 24-hour blood pressure control. J Clin Hypertens (Greenwich). 2008 Feb; 10(2):112-8. PMID: 18259123; PMCID: PMC8109968.
      Citations: 6     Fields:    Translation:Humans
    669. Duru OK, Li S, Jurkovitz C, Bakris G, Brown W, Chen SC, Collins A, Klag M, McCullough PA, McGill J, Narva A, Pergola P, Singh A, Norris K. Race and sex differences in hypertension control in CKD: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2008 Feb; 51(2):192-8. PMID: 18215697; PMCID: PMC2866650.
      Citations: 29     Fields:    Translation:Humans
    670. Giles TD, Bakris GL, Weber MA. Beta-blocker therapy in hypertension: a need to pause and reflect. J Am Coll Cardiol. 2008 Jan 29; 51(4):516-7; author reply 517-8. PMID: 18222366.
      Citations:    Fields:    Translation:Humans
    671. Bakris G, Molitch M, Zhou Q, Sarafidis P, Champion A, Bacher P, Sowers JR. Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study. J Cardiometab Syndr. 2008; 3(1):18-25. PMID: 18326972.
      Citations: 3     Fields:    Translation:Humans
    672. Bakris G, Fonseca V, Foody J. Challenges to the diagnosis, evaluation, treatment, and management of clustered cardiometabolic risk factors. J Cardiometab Syndr. 2008; 3(2):119-25. PMID: 18453814.
      Citations:    Fields:    Translation:Humans
    673. Phillips RA, Fonseca V, Katholi RE, McGill JB, Messerli FH, Bell DS, Raskin P, Wright JT, Iyengar M, Anderson KM, Lukas MA, Bakris GL, GEMINI Investigators. Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) study. J Cardiometab Syndr. 2008; 3(4):211-7. PMID: 19040589.
      Citations: 8     Fields:    Translation:Humans
    674. Bakris G, Hester A, Weber M, Dahlof B, Pitt B, Velasquez E, Staikos-Byrne L, Shi V, Jamerson K, ACCOMPLISH Investigators. The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial. J Cardiometab Syndr. 2008; 3(4):229-33. PMID: 19040592.
      Citations:    Fields:    Translation:Humans
    675. Cushman WC, Neutel JM, Saunders E, Bakris GL, Ferdinand KC, Ofili EO, Sowers JR, Madder R, Weber MA. Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy. Am J Geriatr Cardiol. 2008 Jan-Feb; 17(1):27-36. PMID: 18174757.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    676. Bakris GL. Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker. J Clin Hypertens (Greenwich). 2008 Jan; 10(1 Suppl 1):27-32. PMID: 18174781; PMCID: PMC8110040.
      Citations: 11     Fields:    Translation:Humans
    677. Bakris GL, Sowers JR, Ferdinand KC. Blood pressure control in the patient with difficult-to-control hypertension: which agent for which patient? Prev Cardiol. 2008; 11(1):42-9. PMID: 18174791.
      Citations:    Fields:    Translation:Humans
    678. Bakris GL. Slowing nephropathy progression: focus on proteinuria reduction. Clin J Am Soc Nephrol. 2008 Jan; 3 Suppl 1:S3-10. PMID: 18178794; PMCID: PMC3152266.
      Citations: 50     Fields:    Translation:Humans
    679. Kjeldsen SE, Jamerson KA, Bakris GL, Pitt B, Velazquez EJ, Gupte J, Staikos L, Hua TA, Shi V, Hester A, Tuomilehto J, Ostergren J, Ibsen H, Weber M, Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hyperten, Dahlöf B. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study. Blood Press. 2008; 17(1):7-17. PMID: 18568687.
      Citations: 11     Fields:    Translation:Humans
    680. Bakris GL, Weber MA. Appropriate dose transition to a controlled-release formulation of carvedilol in patients with hypertension. Rev Cardiovasc Med. 2008; 9(2):96-105. PMID: 18660730.
      Citations:    Fields:    Translation:Humans
    681. Li S, Chen SC, Shlipak M, Bakris G, McCullough PA, Sowers J, Stevens L, Jurkovitz C, McFarlane S, Norris K, Vassalotti J, Klag MJ, Brown WW, Narva A, Calhoun D, Johnson B, Obialo C, Whaley-Connell A, Becker B, Collins AJ, Kidney Early Evaluation Program Investigators. Low birth weight is associated with chronic kidney disease only in men. Kidney Int. 2008 Mar; 73(5):637-42. PMID: 18094674.
      Citations: 46     Fields:    Translation:Humans
    682. Sarafidis PA, Riehle J, Bogojevic Z, Basta E, Chugh A, Bakris GL. A comparative evaluation of various methods for microalbuminuria screening. Am J Nephrol. 2008; 28(2):324-9. PMID: 18046079.
      Citations: 14     Fields:    Translation:HumansPHPublic Health
    683. Stafylas PC, Sarafidis PA, Lasaridis AN, Tsakni E, Niakas DA, Dombros NV, Grekas DM, Bakris GL. Cost-effectiveness of losartan in diabetic nephropathy: a Greek perspective. J Nephrol. 2007 Nov-Dec; 20(6):703-15. PMID: 18046673.
      Citations: 3     Fields:    Translation:Humans
    684. Wright JT, Bakris GL, Bell DS, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Holdbrook FK, Lukas MA, Iyengar M. Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial. J Clin Hypertens (Greenwich). 2007 Nov; 9(11):842-9. PMID: 17978591; PMCID: PMC8110139.
      Citations: 8     Fields:    Translation:Humans
    685. Bakris GL. Lifestyle changes and unanswered questions about hypertension and cardiovascular risk. Curr Hypertens Rep. 2007 Nov; 9(5):392. PMID: 18177586.
      Citations:    Fields:    
    686. Karthikeyan VJ, Bakris G, MacFadyen RJ. The ADVANCE trial: further PROGRESS with HOPE. J Hum Hypertens. 2007 Dec; 21(12):911-3. PMID: 17960167.
      Citations: 2     Fields:    Translation:Humans
    687. Bhatnagar V, O'Connor DT, Schork NJ, Salem RM, Nievergelt CM, Rana BK, Smith DW, Bakris GL, Middleton JP, Norris KC, Wright JT, Cheek D, Hiremath L, Contreras G, Appel LJ, Lipkowitz MS. Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial. J Hypertens. 2007 Oct; 25(10):2082-92. PMID: 17885551; PMCID: PMC2792638.
      Citations: 15     Fields:    Translation:Humans
    688. Black HR, Bakris GL, Weber MA, Weiss R, Shahawy ME, Marple R, Tannoury G, Linas S, Wiens BL, Linseman JV, Roden R, Gerber MJ. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich). 2007 Oct; 9(10):760-9. PMID: 17917503; PMCID: PMC8110158.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    689. Duka I, Bakris GL. Should all patients with type 2 diabetes receive initial combination therapy: an assessment of the ADVANCE trial. Pol Arch Med Wewn. 2007 Sep; 117(9):389-90. PMID: 18062558.
      Citations:    Fields:    Translation:Humans
    690. Chugh A, Bakris GL. Pulse pressure and arterial stiffness: an emerging renal risk predictor? J Hypertens. 2007 Sep; 25(9):1796-7. PMID: 17762642.
      Citations: 3     Fields:    Translation:Humans
    691. Hart PD, Bakris GL. Should beta-blockers be used to control hypertension in people with chronic kidney disease? Semin Nephrol. 2007 Sep; 27(5):555-64. PMID: 17868793.
      Citations: 14     Fields:    Translation:Humans
    692. Bakris G, Hill M, Mancia G, Steyn K, Black HR, Pickering T, De Geest S, Ruilope L, Giles TD, Morgan T, Kjeldsen S, Schiffrin EL, Coenen A, Mulrow P, Loh A, Mensah G. Achieving blood pressure goals globally: five core actions for health-care professionals. A worldwide call to action. J Hum Hypertens. 2008 Jan; 22(1):63-70. PMID: 17728797.
      Citations: 14     Fields:    Translation:Humans
    693. Bakris GL, Ruilope L, Locatelli F, Ptaszynska A, Pieske B, de Champlain J, Weber MA, Raz I. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int. 2007 Oct; 72(7):879-85. PMID: 17667984.
      Citations: 38     Fields:    Translation:Humans
    694. Messerli F, Bakris G, Zhou Q, Champion A, Pepine CJ, Mancia G. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension. 2007 Aug; 50(2):299-305. PMID: 17606861.
      Citations: 45     Fields:    Translation:Humans
    695. Messerli FH, Bell DS, Fonseca V, Katholi RE, McGill JB, Phillips RA, Raskin P, Wright JT, Bangalore S, Holdbrook FK, Lukas MA, Anderson KM, Bakris GL, GEMINI Investigators. Body weight changes with beta-blocker use: results from GEMINI. Am J Med. 2007 Jul; 120(7):610-5. PMID: 17602935.
      Citations: 32     Fields:    Translation:Humans
    696. McCullough PA, Jurkovitz CT, Pergola PE, McGill JB, Brown WW, Collins AJ, Chen SC, Li S, Singh A, Norris KC, Klag MJ, Bakris GL, KEEP Investigators. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2007 Jun 11; 167(11):1122-9. PMID: 17563019.
      Citations: 65     Fields:    Translation:HumansPHPublic Health
    697. Roberts WC, Black HR, Bakris GL, Mason RP, Giles TD, Sulkes DJ. The editor's roundtable: revisiting the role of beta blockers in hypertension. Am J Cardiol. 2007 Jul 15; 100(2):253-67. PMID: 17631080.
      Citations:    Fields:    Translation:Humans
    698. Bakris GL. ACE inhibitors and ARBs: are they better than other agents to slow nephropathy progression? J Clin Hypertens (Greenwich). 2007 Jun; 9(6):413-5. PMID: 17541325; PMCID: PMC8110074.
      Citations: 2     Fields:    Translation:Humans
    699. Sarafidis PA, McFarlane SI, Bakris GL. Antihypertensive agents, insulin sensitivity, and new-onset diabetes. Curr Diab Rep. 2007 Jun; 7(3):191-9. PMID: 17547836.
      Citations: 8     Fields:    Translation:Humans
    700. Bakris GL. Pharmacological augmentation of endothelium-derived nitric oxide synthesis. J Manag Care Pharm. 2007 Jun; 13(5 Suppl):S9-12. PMID: 17605505; PMCID: PMC10438270.
      Citations: 5     Fields:    Translation:Humans
    701. Bakris GL, Gonzalez ER. Case study: the link between hypertension and diabetes. J Manag Care Pharm. 2007 Jun; 13(5 Suppl):S17-9. PMID: 17605507; PMCID: PMC10437442.
      Citations: 1     Fields:    Translation:Humans
    702. Bakris GL. Current perspectives on hypertension and metabolic syndrome. J Manag Care Pharm. 2007 Jun; 13(5 Suppl):S3-5. PMID: 17605509; PMCID: PMC10438322.
      Citations: 2     Fields:    Translation:Humans
    703. Bakris GL. Protein kinase C-beta inhibition: a promise not yet fulfilled. Clin J Am Soc Nephrol. 2007 Jul; 2(4):619-20. PMID: 17699472.
      Citations: 3     Fields:    Translation:Humans
    704. Smith TR, Philipp T, Vaisse B, Bakris GL, Wernsing M, Yen J, Glazer R. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens (Greenwich). 2007 May; 9(5):355-64. PMID: 17485971; PMCID: PMC8109965.
      Citations: 29     Fields:    Translation:Humans
    705. McGill JB, Bakris GL, Fonseca V, Raskin P, Messerli FH, Phillips RA, Katholi RE, Wright JT, Iyengar M, Anderson KM, Lukas MA, Dalal MR, Bell DS. beta-blocker use and diabetes symptom score: results from the GEMINI study. Diabetes Obes Metab. 2007 May; 9(3):408-17. PMID: 17391169.
      Citations: 8     Fields:    Translation:Humans
    706. Sarafidis PA, Lasaridis AN, Nilsson PM, Pikilidou MI, Stafilas PC, Kanaki A, Kazakos K, Yovos J, Bakris GL. Validity and reproducibility of HOMA-IR, 1/HOMA-IR, QUICKI and McAuley's indices in patients with hypertension and type II diabetes. J Hum Hypertens. 2007 Sep; 21(9):709-16. PMID: 17443211.
      Citations: 72     Fields:    Translation:Humans
    707. Fonseca V, Bakris GL, Bell DS, McGill JB, Raskin P, Messerli FH, Phillips RA, Katholi RE, Wright JT, Waterhouse B, Lukas MA, Anderson KM, GEMINI Investigators. Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI. Diabet Med. 2007 Jul; 24(7):759-63. PMID: 17451422.
      Citations: 6     Fields:    Translation:Humans
    708. Bakris G, Dickholtz M, Meyer PM, Kravitz G, Avery E, Miller M, Brown J, Woodfield C, Bell B. Atlas vertebra realignment and achievement of arterial pressure goal in hypertensive patients: a pilot study. J Hum Hypertens. 2007 May; 21(5):347-52. PMID: 17252032.
      Citations: 26     Fields:    Translation:Humans
    709. Chugh A, Bakris GL. Microalbuminuria: what is it? Why is it important? What should be done about it? An update. J Clin Hypertens (Greenwich). 2007 Mar; 9(3):196-200. PMID: 17341995; PMCID: PMC8110171.
      Citations: 14     Fields:    Translation:Humans
    710. Bakris GL, Weir MR, Black HR. Improving blood pressure control rates: is there more we can do? J Clin Hypertens (Greenwich). 2007 Feb; 9(2):134-42. PMID: 17268218; PMCID: PMC8110133.
      Citations: 4     Fields:    Translation:Humans
    711. Sarafidis PA, Bakris GL. The antinatriuretic effect of insulin: an unappreciated mechanism for hypertension associated with insulin resistance? Am J Nephrol. 2007; 27(1):44-54. PMID: 17245074.
      Citations: 21     Fields:    Translation:HumansAnimals
    712. Gilbert RE, Kim SA, Tuttle KR, Bakris GL, Toto RD, McGill JB, Haney DJ, Kelly DJ, Anderson PW. Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes. Diabetes Care. 2007 Apr; 30(4):995-6. PMID: 17229944.
      Citations: 22     Fields:    Translation:Humans
    713. Sarafidis PA, Bakris GL. Metabolic effects of beta-blockers: importance of dissociating newer from conventional agents. J Hypertens. 2007 Jan; 25(1):249-52; author reply 252-3. PMID: 17143201.
      Citations: 2     Fields:    Translation:HumansCells
    714. Weber MA, Bakris GL, Pitt B, Velazquez E, Gupte J, Lefkowitz M, Hester A, Shi V, Weir M, Kjeldsen S, Massie B, Nesbitt S, Ofili E, Jamerson K, Dahlöf B. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press. 2007; 16(1):13-9. PMID: 17453747.
      Citations: 15     Fields:    Translation:Humans
    715. Sarafidis PA, Bakris GL. Are antihypertensive drugs associated with an increased risk of incident type 2 diabetes? Nat Clin Pract Endocrinol Metab. 2007 Jan; 3(1):8-9. PMID: 17179923.
      Citations:    Fields:    
    716. Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis. 2007 Jan; 49(1):12-26. PMID: 17185142.
      Citations: 55     Fields:    Translation:Humans
    717. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ, American Heart Association, American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007 Jan; 30(1):162-72. PMID: 17192355.
      Citations: 163     Fields:    Translation:HumansPHPublic Health
    718. Ruilope L, Kjeldsen SE, de la Sierra A, Mancia G, Ruggenenti P, Stergiou GS, Bakris GL, Giles TD. The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of Hypertension. Blood Press. 2007; 16(2):72-9. PMID: 17612904.
      Citations: 7     Fields:    Translation:Humans
    719. Sowers JR, Bakris GL, Black HR, Giles TD. The cardiometabolic syndrome and calcium channel blocker combination drugs. J Cardiometab Syndr. 2007; 2(3):207-12. PMID: 17786085.
      Citations: 3     Fields:    Translation:Humans
    720. Jamerson K, Bakris GL, Pitt B, Velazquez E, Gupte J, Lefkowitz M, Hester A, Shi V, Kjeldsen SE, Cushman W, Papademetriou V, Weber M, ACCOMPLISH Investigators, Dahlöf B. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press. 2007; 16(2):80-6. PMID: 17612905.
      Citations: 33     Fields:    Translation:Humans
    721. Bakris GL, Cooper-Dehoff RM, Zhou Q, Kupfer S, Champion A, Pepine CJ, INVEST Investigators. Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers. Am J Cardiovasc Drugs. 2007; 7 Suppl 1:25-9. PMID: 19845074.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    722. Robinson JG, Bakris G, Torner J, Stone NJ, Wallace R. Is it time for a cardiovascular primary prevention trial in the elderly? Stroke. 2007 Feb; 38(2):441-50. PMID: 17194877.
      Citations: 18     Fields:    Translation:HumansPHPublic Health
    723. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ, American Heart Association, American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007 Jan 02; 115(1):114-26. PMID: 17192512.
      Citations: 234     Fields:    Translation:Humans
    724. Ahmed A, Rich MW, Sanders PW, Perry GJ, Bakris GL, Zile MR, Love TE, Aban IB, Shlipak MG. Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol. 2007 Feb 01; 99(3):393-8. PMID: 17261405; PMCID: PMC2708087.
      Citations: 113     Fields:    Translation:HumansCTClinical Trials
    725. Weber MA, Bakris GL, Tarka EA, Iyengar M, Fleck R, Sica DA. Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension. J Clin Hypertens (Greenwich). 2006 Dec; 8(12):840-9. PMID: 17170609; PMCID: PMC8109495.
      Citations: 8     Fields:    Translation:Humans
    726. Bakris G, Molitch M, Hewkin A, Kipnes M, Sarafidis P, Fakouhi K, Bacher P, Sowers J, STAR Investigators. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006 Dec; 29(12):2592-7. PMID: 17130190.
      Citations: 48     Fields:    Translation:Humans
    727. Sarafidis PA, Bakris GL. Review: Insulin and endothelin: an interplay contributing to hypertension development? J Clin Endocrinol Metab. 2007 Feb; 92(2):379-85. PMID: 17118997.
      Citations: 32     Fields:    Translation:HumansAnimals
    728. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007 Jan; 71(1):31-8. PMID: 17091124.
      Citations: 537     Fields:    Translation:Humans
    729. Sarafidis PA, Bakris GL. Non-esterified fatty acids and blood pressure elevation: a mechanism for hypertension in subjects with obesity/insulin resistance? J Hum Hypertens. 2007 Jan; 21(1):12-9. PMID: 17051236.
      Citations: 28     Fields:    Translation:Humans
    730. Bakris GL, Hart P, Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int. 2006 Dec; 70(11):1905-13. PMID: 17021610.
      Citations: 56     Fields:    Translation:HumansAnimals
    731. Bakris GL, Ruilope LM, McMorn SO, Weston WM, Heise MA, Freed MI, Porter LE. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens. 2006 Oct; 24(10):2047-55. PMID: 16957566.
      Citations: 30     Fields:    Translation:Humans
    732. Bakris G. The continuum of blood pressure risk: when is the best time to intervene? Curr Hypertens Rep. 2006 Oct; 8(5):395-7. PMID: 16965725.
      Citations:    Fields:    Translation:Humans
    733. Khosla N, Sarafidis PA, Bakris GL. Microalbuminuria. Clin Lab Med. 2006 Sep; 26(3):635-53, vi-vii. PMID: 16938588.
      Citations: 13     Fields:    Translation:Humans
    734. Bakris GL, Tarka EA, Waterhouse B, Goulding MR, Madan A, Anderson KM, St John Sutton M, Miller AB, Reichek N. Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile. Am J Cardiol. 2006 Oct 02; 98(7A):46L-52L. PMID: 17023232.
      Citations: 1     Fields:    Translation:Humans
    735. Weber MA, Sica DA, Tarka EA, Iyengar M, Fleck R, Bakris GL. Controlled-release carvedilol in the treatment of essential hypertension. Am J Cardiol. 2006 Oct 02; 98(7A):32L-38L. PMID: 17023230.
      Citations: 6     Fields:    Translation:Humans
    736. Cooper-Dehoff R, Cohen JD, Bakris GL, Messerli FH, Erdine S, Hewkin AC, Kupfer S, Pepine CJ, INVEST Investigators. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol. 2006 Oct 01; 98(7):890-4. PMID: 16996868.
      Citations: 28     Fields:    Translation:Humans
    737. Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int. 2006 Oct; 70(7):1223-33. PMID: 16883325.
      Citations: 75     Fields:    Translation:HumansAnimals
    738. Messerli FH, Bakris GL, Ferrera D, Houston MC, Petrella RJ, Flack JM, Sun W, Lee E, Neutel JM, AVALON Investigators. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. J Clin Hypertens (Greenwich). 2006 Aug; 8(8):571-81; quiz 582-3. PMID: 16896273; PMCID: PMC8109721.
      Citations: 17     Fields:    Translation:Humans
    739. Sowers JR, Neutel JM, Saunders E, Bakris GL, Cushman WC, Ferdinand KC, Ofili EO, Weber MA, INCLUSIVE Investigators. Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich). 2006 Jul; 8(7):470-80. PMID: 16849900; PMCID: PMC8109400.
      Citations: 16     Fields:    Translation:Humans
    740. Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension. 2006 Aug; 48(2):219-24. PMID: 16801488.
      Citations: 121     Fields:    Translation:Humans
    741. Sarafidis PA, Bakris GL. Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease. Nephrol Dial Transplant. 2006 Sep; 21(9):2366-74. PMID: 16782993.
      Citations: 30     Fields:    Translation:Humans
    742. Jones-Burton C, Mishra SI, Fink JC, Brown J, Gossa W, Bakris GL, Weir MR. An in-depth review of the evidence linking dietary salt intake and progression of chronic kidney disease. Am J Nephrol. 2006; 26(3):268-75. PMID: 16763384.
      Citations: 46     Fields:    Translation:Humans
    743. Sarafidis PA, Bakris GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM. 2006 Jul; 99(7):431-6. PMID: 16766516.
      Citations: 22     Fields:    Translation:Humans
    744. Milchak JL, Carter BL, Ardery G, Black HR, Bakris GL, Jones DW, Kreiter CD. Development of explicit criteria to measure adherence to hypertension guidelines. J Hum Hypertens. 2006 Jun; 20(6):426-33. PMID: 16543909; PMCID: PMC1513124.
      Citations: 16     Fields:    Translation:Humans
    745. Sarafidis PA, McFarlane SI, Bakris GL. Gender disparity in outcomes of care and management for diabetes and the metabolic syndrome. Curr Diab Rep. 2006 Jun; 6(3):219-24. PMID: 16898575.
      Citations: 17     Fields:    Translation:Humans
    746. Bakris GL, Ruilope L, Locatelli F, Ptaszynska A, Pieske B, Raz I, Voors AA, Dechamplain J, Weber MA. Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: the IMPROVE trial. J Hum Hypertens. 2006 Sep; 20(9):693-700. PMID: 16710287.
      Citations: 1     Fields:    Translation:Humans
    747. Sarafidis PA, Bakris GL. Antihypertensive therapy and the risk of new-onset diabetes. Diabetes Care. 2006 May; 29(5):1167-9. PMID: 16644658.
      Citations: 9     Fields:    Translation:Humans
    748. Sarafidis PA, Bakris GL. Do the metabolic effects of beta blockers make them leading or supporting antihypertensive agents in the treatment of hypertension? J Clin Hypertens (Greenwich). 2006 May; 8(5):351-6; quiz 357-8. PMID: 16687944; PMCID: PMC8109409.
      Citations: 10     Fields:    Translation:Humans
    749. Sarafidis PA, Bakris GL. Are beta blockers passé for the treatment of hypertension? J Clin Hypertens (Greenwich). 2006 Apr; 8(4):239-40. PMID: 16596025; PMCID: PMC8109535.
      Citations: 3     Fields:    Translation:Humans
    750. Weber MA, White WB, Giles TD, Bakris GL, Neutel JM, Smith DH, Davidai G. An effectiveness study comparing algorithm-based antihypertensive therapy with previous treatments using conventional and ambulatory blood pressure measurements. J Clin Hypertens (Greenwich). 2006 Apr; 8(4):241-50; quiz 251-2. PMID: 16596026; PMCID: PMC8109716.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    751. Ofili EO, Ferdinand KC, Saunders E, Neutel JM, Bakris GL, Cushman WC, Sowers JR, Weber MA. Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy. J Natl Med Assoc. 2006 Apr; 98(4):618-26. PMID: 16623075; PMCID: PMC2569215.
      Citations: 11     Fields:    Translation:Humans
    752. Sarafidis PA, Bakris GL. Level of kidney function determines cardiovascular fate after coronary bypass graft surgery. Circulation. 2006 Feb 28; 113(8):1046-7. PMID: 16505186.
      Citations: 3     Fields:    Translation:Humans
    753. Lim HS, MacFadyen RJ, Bakris G, Lip GY. The role of hyperglycaemia and the hypercoagulable state in the pathogenesis of cardiovascular events in diabetes mellitus: implications for hypertension management. Curr Pharm Des. 2006; 12(13):1567-79. PMID: 16729870.
      Citations: 2     Fields:    Translation:Humans
    754. White WB, Giles T, Bakris GL, Neutel JM, Davidai G, Weber MA. Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. Am Heart J. 2006 Jan; 151(1):176-84. PMID: 16368314.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    755. Bogojevic Z, Bakris GL. Albuminuria and cardiovascular risk. Heart Fail Clin. 2006 Jan; 2(1):53-9. PMID: 17386876.
      Citations: 1     Fields:    Translation:Humans
    756. Sarafidis PA, Whaley-Connell A, Sowers JR, Bakris GL. Cardiometabolic syndrome and chronic kidney disease: what is the link? J Cardiometab Syndr. 2006; 1(1):58-65. PMID: 17675896.
      Citations: 17     Fields:    Translation:Humans
    757. Sarafidis PA, Bakris GL. Insulin resistance, hyperinsulinemia, and hypertension: an epidemiologic approach. J Cardiometab Syndr. 2006; 1(5):334-42; quiz 343. PMID: 17679789.
      Citations: 5     Fields:    Translation:HumansPHPublic Health
    758. Whaley-Connell A, Pavey BS, Afroze A, Bakris GL. Obesity and insulin resistance as risk factors for chronic kidney disease. J Cardiometab Syndr. 2006; 1(3):209-14; quiz 215-6. PMID: 17679819.
      Citations: 11     Fields:    Translation:Humans
    759. Khosla N, Bakris G. Lessons learned from recent hypertension trials about kidney disease. Clin J Am Soc Nephrol. 2006 Mar; 1(2):229-35. PMID: 17699211.
      Citations: 4     Fields:    Translation:Humans
    760. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli F, Phillips RA, Raskin P, Wright JT, Waterhouse B, Lukas MA, Anderson KM, Bell DS, GEMINI Investigators. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension. 2005 Dec; 46(6):1309-15. PMID: 16286578.
      Citations: 14     Fields:    Translation:Humans
    761. Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care. 2005 Nov; 28(11):2686-90. PMID: 16249540.
      Citations: 85     Fields:    Translation:HumansCTClinical Trials
    762. Mishra SI, Jones-Burton C, Fink JC, Brown J, Bakris GL, Weir MR. Does dietary salt increase the risk for progression of kidney disease? Curr Hypertens Rep. 2005 Oct; 7(5):385-91. PMID: 16157084.
      Citations: 1     Fields:    Translation:HumansAnimals
    763. Neutel JM, Saunders E, Bakris GL, Cushman WC, Ferdinand KC, Ofili EO, Sowers JR, Weber MA, INCLUSIVE Investigators. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich). 2005 Oct; 7(10):578-86. PMID: 16227760; PMCID: PMC8109614.
      Citations: 31     Fields:    Translation:Humans
    764. Bakris GL, Smith DH, Giles TD, White WB, Davidai G, Weber MA. Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients. J Clin Hypertens (Greenwich). 2005 Oct; 7(10):587-95; quiz 596-7. PMID: 16227761; PMCID: PMC8109501.
      Citations: 7     Fields:    Translation:Humans
    765. Bakris G. Clinical trials report. Proteinuria and blood pressure reduction: are they of equal importance to preserve kidney function? Curr Hypertens Rep. 2005 Oct; 7(5):357-8. PMID: 16157077.
      Citations:    Fields:    
    766. Bakris G. Clinical trials report. Combination drug treatment for hypertension with nondiabetic renal disease. Curr Hypertens Rep. 2005 Oct; 7(5):358-9. PMID: 16157078.
      Citations:    Fields:    
    767. Nathan S, Pepine CJ, Bakris GL. Calcium antagonists: effects on cardio-renal risk in hypertensive patients. Hypertension. 2005 Oct; 46(4):637-42. PMID: 16172420.
      Citations: 15     Fields:    Translation:Humans
    768. Bakris G. Proteinuria: a link to understanding changes in vascular compliance? Hypertension. 2005 Sep; 46(3):473-4. PMID: 16116045.
      Citations: 4     Fields:    Translation:Humans
    769. Russo CJ, Melista E, Cui J, DeStefano AL, Bakris GL, Manolis AJ, Gavras H, Baldwin CT. Association of NEDD4L ubiquitin ligase with essential hypertension. Hypertension. 2005 Sep; 46(3):488-91. PMID: 16103266.
      Citations: 34     Fields:    Translation:Humans
    770. Garg JP, Ellis R, Elliott WJ, Hasabou N, Chua D, Chertow GM, Bakris GL. Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study. Am J Nephrol. 2005 Jul-Aug; 25(4):393-9. PMID: 16088080.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    771. Choi KL, Bakris GL. Hypertension treatment guidelines: practical implications. Semin Nephrol. 2005 Jul; 25(4):198-209. PMID: 16202692.
      Citations: 3     Fields:    Translation:Humans
    772. Preston RA, White WB, Pitt B, Bakris G, Norris PM, Hanes V. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens. 2005 Jun; 18(6):797-804. PMID: 15925739.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    773. White WB, Weber MA, Davidai G, Neutel JM, Bakris GL, Giles T. Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 Trial. Blood Press Monit. 2005 Jun; 10(3):157-63. PMID: 15923818.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    774. Khosla N, Chua DY, Elliott WJ, Bakris GL. Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications? J Clin Hypertens (Greenwich). 2005 Jun; 7(6):354-6. PMID: 16088299.
      Citations: 18     Fields:    Translation:Humans
    775. Bakris G. Is ethnicity a factor in choice of antihypertensive drug? Postgrad Med. 2005 May; 117(5):40. PMID: 15948367.
      Citations:    Fields:    Translation:Humans
    776. Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, Rostand SG, Miller E, Smith W, Bakris GL. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med. 2005 Apr 25; 165(8):947-53. PMID: 15851648.
      Citations: 86     Fields:    Translation:HumansCTClinical Trials
    777. El-Achkar TM, Ohmit SE, McCullough PA, Crook ED, Brown WW, Grimm R, Bakris GL, Keane WF, Flack JM, Kidney Early Evaluation Program. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. Kidney Int. 2005 Apr; 67(4):1483-8. PMID: 15780101.
      Citations: 54     Fields:    Translation:Humans
    778. Bakris GL. Preventing hypertensive kidney disease: the critical role of combination therapy. Am J Hypertens. 2005 Apr; 18(4 Pt 2):93S-94S. PMID: 15837550.
      Citations: 2     Fields:    Translation:Humans
    779. Bakris GL. Protecting renal function in the hypertensive patient: clinical guidelines. Am J Hypertens. 2005 Apr; 18(4 Pt 2):112S-119S. PMID: 15837554.
      Citations: 6     Fields:    Translation:Humans
    780. Bakris G. George Bakris, MD: researching ways to combat hypertension. Interview by Mike Mitka. JAMA. 2005 Mar 23; 293(12):1439. PMID: 15784853.
      Citations:    Fields:    Translation:Humans
    781. Bakris GL, Bell DS, Fonseca V, Katholi R, McGill J, Phillips R, Raskin P, Wright JT, Iyengar M, Holeslaw T, Anderson KM, GEMINI Investigators. The rationale and design of the Glycemic Effects in Diabetes Mellitus Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial. J Diabetes Complications. 2005 Mar-Apr; 19(2):74-9. PMID: 15745836.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    782. Bakris GL, Toto RD, McCullough PA. Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. J Hum Hypertens. 2005 Feb; 19(2):139-44. PMID: 15457206.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    783. McFarlane SI, Castro J, Kaur J, Shin JJ, Kelling D, Farag A, Simon N, El-Atat F, Sacerdote A, Basta E, Flack J, Bakris G, Sowers JR. Control of blood pressure and other cardiovascular risk factors at different practice settings: outcomes of care provided to diabetic women compared to men. J Clin Hypertens (Greenwich). 2005 Feb; 7(2):73-80. PMID: 15722651; PMCID: PMC8109560.
      Citations: 15     Fields:    Translation:Humans
    784. Bakris GL. ACE inhibitor for a diabetic patient with normal blood pressure? Postgrad Med. 2005 Jan; 117(1):6. PMID: 15672885.
      Citations:    Fields:    Translation:Humans
    785. Ruilope LM, Rosei EA, Bakris GL, Mancia G, Poulter NR, Taddei S, Unger T, Volpe M, Waeber B, Zannad F. Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood Press. 2005; 14(4):196-209. PMID: 16126553.
      Citations: 13     Fields:    Translation:Humans
    786. Winer N, Folker A, Murphy JA, Hung E, Bard M, Perkelvald A, Sowers JR, Bakris GL. Effect of fixed-dose ACE-inhibitor/calcium channel blocker combination therapy vs. ACE-inhibitor monotherapy on arterial compliance in hypertensive patients with type 2 diabetes. Prev Cardiol. 2005; 8(2):87-92. PMID: 15860983.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    787. Drexler AJ, Nesto RW, Abrahamson MJ, Bakris G, Bell D, Brunzell J, Dandona P, Davidson J, Fonseca V, Fowler M, Frye R, Giles T, Haffner S, Hollenberg N, Hsueh W, Law R, Plutzky J, Ratner R, Reusch J, Selwyn A, Sowers J, Wyne K, Young LH. Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes in relation to the metabolic syndrome. Metab Syndr Relat Disord. 2005; 3(2):147-73. PMID: 18370723.
      Citations:    Fields:    
    788. Bakris GL, Bank AJ, Kass DA, Neutel JM, Preston RA, Oparil S. Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process. Am J Hypertens. 2004 Dec; 17(12 Pt 2):23S-30S. PMID: 15607432.
      Citations: 57     Fields:    Translation:HumansAnimals
    789. Abbott KC, Trespalacios FC, Agodoa LY, Taylor AJ, Bakris GL. beta-Blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Arch Intern Med. 2004 Dec 13-27; 164(22):2465-71. PMID: 15596637.
      Citations: 41     Fields:    Translation:Humans
    790. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT, Oakes R, Lukas MA, Anderson KM, Bell DS, GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004 Nov 10; 292(18):2227-36. PMID: 15536109.
      Citations: 191     Fields:    Translation:HumansCTClinical Trials
    791. Busby DE, Bakris GL. Comparison of commonly used assays for the detection of microalbuminuria. J Clin Hypertens (Greenwich). 2004 Nov; 6(11 Suppl 3):8-12. PMID: 15538105; PMCID: PMC8109456.
      Citations: 12     Fields:    Translation:Humans
    792. Bakris GL. Implications of albuminuria on kidney disease progression. J Clin Hypertens (Greenwich). 2004 Nov; 6(11 Suppl 3):18-22. PMID: 15538107; PMCID: PMC8109517.
      Citations: 5     Fields:    Translation:Humans
    793. Bakris G. Inclusion of albuminuria in hypertension and heart guidelines. Kidney Int Suppl. 2004 Nov; (92):S124-5. PMID: 15485406.
      Citations: 3     Fields:    Translation:Humans
    794. Bakris GL. Clinical importance of microalbuminuria in diabetes and hypertension. Curr Hypertens Rep. 2004 Oct; 6(5):352-6. PMID: 15341686.
      Citations: 12     Fields:    Translation:HumansPHPublic Health
    795. Bakris GL, Gaxiola E, Messerli FH, Mancia G, Erdine S, Cooper-DeHoff R, Pepine CJ, INVEST Investigators. Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. Hypertension. 2004 Nov; 44(5):637-42. PMID: 15381674.
      Citations: 39     Fields:    Translation:Humans
    796. Jamerson KA, Bakris GL, Wun CC, Lefkowitz M, Manfreda S, Pitt B, Velazquez EJ, Weber MA, Dahlöf B. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens. 2004 Sep; 17(9):793-801. PMID: 15363822.
      Citations: 32     Fields:    Translation:Humans
    797. Fox JC, Leight K, Sutradhar SC, Demopoulos LA, Gleim GW, Lewin AJ, Bakris GL. The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy. J Clin Hypertens (Greenwich). 2004 Aug; 6(8):437-42; quiz 443-4. PMID: 15308882; PMCID: PMC8109344.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    798. McCullough PA, Bakris GL, Owen WF, Klassen PS, Califf RM. Slowing the progression of diabetic nephropathy and its cardiovascular consequences. Am Heart J. 2004 Aug; 148(2):243-51. PMID: 15308993.
      Citations: 9     Fields:    Translation:Humans
    799. Hart PD, Bakris GL. Hypertension control rates: time for translation of guidelines into clinical practice. Am J Med. 2004 Jul 01; 117(1):62-4. PMID: 15210392.
      Citations: 5     Fields:    Translation:Humans
    800. Chrysant SG, Bakris GL. Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy. Am J Hypertens. 2004 Jul; 17(7):590-6. PMID: 15233978.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    801. Khosla N, Hart P, Bakris GL. Management of hypertension in the cardiometabolic syndrome and diabetes. Curr Diab Rep. 2004 Jun; 4(3):199-205. PMID: 15132885.
      Citations:    Fields:    Translation:Humans
    802. Bakris GL, Weir MR, Secic M, Campbell B, Weis-McNulty A. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004 Jun; 65(6):1991-2002. PMID: 15149313.
      Citations: 53     Fields:    Translation:HumansAnimals
    803. Chua DC, Bakris GL. Is proteinuria a plausible target of therapy? Curr Hypertens Rep. 2004 Jun; 6(3):177-81. PMID: 15128468.
      Citations: 3     Fields:    Translation:Humans
    804. Bakris G. How to adjust ACE inhibitors and ARBs in diabetes? Postgrad Med. 2004 May; 115(5):9-10. PMID: 15171073.
      Citations:    Fields:    Translation:Humans
    805. Davidson MB, Bazargan M, Bakris G, Peters Harmel A, Campese V, Basta E. ImmunoDip: an improved screening method for microalbuminuria. Am J Nephrol. 2004 May-Jun; 24(3):284-8. PMID: 15087587.
      Citations: 2     Fields:    Translation:Humans
    806. Abbott K, Basta E, Bakris GL. Blood pressure control and nephroprotection in diabetes. J Clin Pharmacol. 2004 Apr; 44(4):431-8. PMID: 15051752.
      Citations: 8     Fields:    Translation:Humans
    807. Bakris GL, Sowers JR. When does new onset diabetes resulting from antihypertensive therapy increase cardiovascular risk. Hypertension. 2004 May; 43(5):941-2. PMID: 15037556.
      Citations: 4     Fields:    Translation:Humans
    808. Bakris GL. The importance of blood pressure control in the patient with diabetes. Am J Med. 2004 Mar 08; 116 Suppl 5A:30S-38S. PMID: 15019861.
      Citations: 21     Fields:    Translation:Humans
    809. Gashti CN, Bakris GL. The role of calcium antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens. 2004 Mar; 13(2):155-61. PMID: 15202609.
      Citations: 9     Fields:    Translation:Humans
    810. Mangrum AJ, Bakris GL. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues. Semin Nephrol. 2004 Mar; 24(2):168-75. PMID: 15017529.
      Citations: 14     Fields:    Translation:Humans
    811. Izhar M, Alausa T, Folker A, Hung E, Bakris GL. Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. Hypertension. 2004 Mar; 43(3):573-7. PMID: 14744921.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    812. Chua DY, Bakris GL. Clinical implications of blockade of the renin-angiotensin system in management of hypertension. Contrib Nephrol. 2004; 143:105-16. PMID: 15248359.
      Citations: 1     Fields:    Translation:Humans
    813. Chua DY, Bakris GL. Diabetes and chronic kidney disease: tragedy and challenge. Blood Purif. 2004; 22(1):130-5. PMID: 14732821.
      Citations: 2     Fields:    Translation:Humans
    814. Abbott KC, Bakris GL. What have we learned from the current trials? Med Clin North Am. 2004 Jan; 88(1):189-207. PMID: 14871059.
      Citations: 8     Fields:    Translation:Humans
    815. Ruilope LM, Usan L, Bakris GL, Segura J. Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResión Arterial en DIabéticos tipo Dos) study. J Hypertens. 2004 Jan; 22(1):217-22. PMID: 15106814.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    816. Bakris GL. Hypertension and nephropathy. Am J Med. 2003 Dec 08; 115 Suppl 8A:49S-54S. PMID: 14678866.
      Citations: 2     Fields:    Translation:Humans
    817. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW, INVEST Investigators, Cangiano JL. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003 Dec 03; 290(21):2805-16. PMID: 14657064.
      Citations: 336     Fields:    Translation:HumansCTClinical Trials
    818. Garg J, Bakris GL. Are antihypertensive drugs used to maximally reduce cardiovascular risk in dialysis patients? Am J Kidney Dis. 2003 Dec; 42(6):1301-4. PMID: 14655205.
      Citations:    Fields:    Translation:Humans
    819. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure., National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003 Dec; 42(6):1206-52. PMID: 14656957.
      Citations: 4106     Fields:    Translation:Humans
    820. Abbott KC, Bakris GL. Cardiology patient page. Kidney failure and cardiovascular disease. Circulation. 2003 Oct 21; 108(16):e114-5. PMID: 14568888.
      Citations: 2     Fields:    Translation:Humans
    821. Eknoyan G, Hostetter T, Bakris GL, Hebert L, Levey AS, Parving HH, Steffes MW, Toto R. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis. 2003 Oct; 42(4):617-22. PMID: 14520612.
      Citations: 128     Fields:    Translation:Humans
    822. Weinberg MS, Kaperonis N, Bakris GL. How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy? Curr Hypertens Rep. 2003 Oct; 5(5):418-25. PMID: 12948435.
      Citations: 5     Fields:    Translation:Humans
    823. Bakris GL. Role for beta-blockers in the management of diabetic kidney disease. Am J Hypertens. 2003 Sep; 16(9 Pt 2):7S-12S. PMID: 14511896.
      Citations: 5     Fields:    Translation:Humans
    824. Weber MA, Bakris GL, Neutel JM, Davidai G, Giles TD. Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker. J Clin Hypertens (Greenwich). 2003 Sep-Oct; 5(5):322-9. PMID: 14564132; PMCID: PMC8101801.
      Citations: 4     Fields:    Translation:Humans
    825. Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM, RENAAL Study Group. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med. 2003 Jul 14; 163(13):1555-65. PMID: 12860578.
      Citations: 123     Fields:    Translation:HumansCTClinical Trials
    826. Bakris GL. Who should be treated with combination therapy as initial treatment for hypertension? J Clin Hypertens (Greenwich). 2003 Jul-Aug; 5(4 Suppl 3):21-8. PMID: 12941994; PMCID: PMC8099288.
      Citations: 1     Fields:    Translation:Humans
    827. Gassman JJ, Greene T, Wright JT, Agodoa L, Bakris G, Beck GJ, Douglas J, Jamerson K, Lewis J, Kutner M, Randall OS, Wang SR. Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol. 2003 Jul; 14(7 Suppl 2):S154-65. PMID: 12819322; PMCID: PMC1417393.
      Citations: 59     Fields:    Translation:HumansCTClinical Trials
    828. Appel LJ, Middleton J, Miller ER, Lipkowitz M, Norris K, Agodoa LY, Bakris G, Douglas JG, Charleston J, Gassman J, Greene T, Jamerson K, Kusek JW, Lewis JA, Phillips RA, Rostand SG, Wright JT. The rationale and design of the AASK cohort study. J Am Soc Nephrol. 2003 Jul; 14(7 Suppl 2):S166-72. PMID: 12819323.
      Citations: 59     Fields:    Translation:Humans
    829. Bakris GL. Achieving blood pressure goals: is fixed-dose combination therapy the answer? J Clin Hypertens (Greenwich). 2003 Jul-Aug; 5(4 Suppl 3):2-3. PMID: 12941991; PMCID: PMC8099300.
      Citations:    Fields:    Translation:Humans
    830. Trespalacios FC, Taylor AJ, Agodoa LY, Bakris GL, Abbott KC. Heart failure as a cause for hospitalization in chronic dialysis patients. Am J Kidney Dis. 2003 Jun; 41(6):1267-77. PMID: 12776280.
      Citations: 34     Fields:    Translation:Humans
    831. Giles TD, Bakris GL, Smith DH, Davidai G, Weber MA. Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial. Am J Hypertens. 2003 Jun; 16(6):460-6. PMID: 12799094.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    832. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluat, National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 21; 289(19):2560-72. PMID: 12748199.
      Citations: 5968     Fields:    Translation:Humans
    833. Bakris GL, Weir MR, Study of Hypertension and the Efficacy of Lotrel in Diabetes (SHIELD) Investigators. Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens (Greenwich). 2003 May-Jun; 5(3):202-9. PMID: 12826783; PMCID: PMC8101800.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    834. Bakris GL. The evolution of treatment guidelines for diabetic nephropathy. Strategies integrate JNC VI, more recent protocols. Postgrad Med. 2003 May; 113(5):35-40, 43-4, 50. PMID: 12764895.
      Citations:    Fields:    Translation:Humans
    835. Douglas JG, Bakris GL, Epstein M, Ferdinand KC, Ferrario C, Flack JM, Jamerson KA, Jones WE, Haywood J, Maxey R, Ofili EO, Saunders E, Schiffrin EL, Sica DA, Sowers JR, Vidt DG, Hypertension in African Americans Working Group of the International Society on Hypertension in Blac. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003 Mar 10; 163(5):525-41. PMID: 12622600.
      Citations: 141     Fields:    Translation:Humans
    836. Bakris G. When to refer patients to a nephrologist? Postgrad Med. 2003 Feb; 113(2):11. PMID: 12611111.
      Citations:    Fields:    Translation:Humans
    837. Bakris GL, Mensah GA. Pathogenesis and clinical physiology of hypertension. Curr Probl Cardiol. 2003 Feb; 28(2):137-55. PMID: 12806314.
      Citations:    Fields:    
    838. Kaperonis N, Bakris G. Blood pressure, antihypertensive therapy and risk for renal injury in African-Americans. Curr Opin Nephrol Hypertens. 2003 Jan; 12(1):79-84. PMID: 12496670.
      Citations: 2     Fields:    Translation:Humans
    839. Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens. 2003 Jan; 17(1):7-12. PMID: 12571611.
      Citations: 52     Fields:    Translation:HumansCTClinical Trials
    840. Garg J, Bakris GL. Treatment of hypertension in patients with renal disease. Cardiovasc Drugs Ther. 2002 Dec; 16(6):503-10. PMID: 12766383.
      Citations: 1     Fields:    Translation:Humans
    841. Wright JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG, Wright JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG, African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002 Nov 20; 288(19):2421-31. PMID: 12435255.
      Citations: 624     Fields:    Translation:HumansCTClinical Trials
    842. Bakris GL, Weir M, Bakris GL, Weir M. ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence. J Clin Hypertens (Greenwich). 2002 Nov-Dec; 4(6):420-3. PMID: 12461306; PMCID: PMC8101879.
      Citations: 5     Fields:    Translation:Humans
    843. Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma I, Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma I, orlistat and resistant hypertension investigators. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens. 2002 Nov; 20(11):2257-67. PMID: 12409965.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    844. Douglas JG, Ferdinand KC, Bakris GL, Sowers JR, Douglas JG, Ferdinand KC, Bakris GL, Sowers JR. Barriers to blood pressure control in African Americans. Overcoming obstacles is challenging, but target goals can be attained. Postgrad Med. 2002 Oct; 112(4):51-2, 55, 59-62 passim. PMID: 12400149.
      Citations: 10     Fields:    Translation:Humans
    845. Bakris GL, Ferdinand KC, Douglas JG, Sowers JR, Bakris GL, Ferdinand KC, Douglas JG, Sowers JR. Optimal treatment of hypertension in African Americans. Reaching and maintaining target blood pressure goals. Postgrad Med. 2002 Oct; 112(4):73-4, 77-80, 83-4. PMID: 12400150.
      Citations: 1     Fields:    Translation:Humans
    846. Sowers JR, Ferdinand KC, Bakris GL, Douglas JG, Sowers JR, Ferdinand KC, Bakris GL, Douglas JG. Hypertension-related disease in African Americans. Factors underlying disparities in illness and its outcome. Postgrad Med. 2002 Oct; 112(4):24-6, 29-30, 33-4 passim. PMID: 12405099.
      Citations: 12     Fields:    Translation:HumansPHPublic Health
    847. Bakris GL, Bakris GL. Hypertension and diabetes: family physicians' pivotal role. Am Fam Physician. 2002 Oct 01; 66(7):1151-2. PMID: 12387427.
      Citations:    Fields:    Translation:Humans
    848. Bakris G. Comparison of telmisartan vs. valsartan in the treatment of mild to moderate hypertension using ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2002 Jul-Aug; 4(4 Suppl 1):26-31. PMID: 12147926; PMCID: PMC8101901.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    849. Bakris GL, Sowers JR. Microalbuminuria in diabetes: focus on cardiovascular and renal risk reduction. Curr Diab Rep. 2002 Jun; 2(3):258-62. PMID: 12643182.
      Citations: 2     Fields:    Translation:Humans
    850. Garg J, Bakris GL. Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes. Curr Hypertens Rep. 2002 Jun; 4(3):185-90. PMID: 12003699.
      Citations: 2     Fields:    Translation:Humans
    851. Garg J, Messerli AW, Bakris GL. Evaluation and treatment of patients with systemic hypertension. Circulation. 2002 May 28; 105(21):2458-61. PMID: 12034648.
      Citations:    Fields:    Translation:Humans
    852. Moser M, Bakris GL, Black H, Moser M, Bakris GL, Black H. Roundtable discussion: problems in the management of hypertension. J Clin Hypertens (Greenwich). 2002 May-Jun; 4(3):207-13. PMID: 12068826; PMCID: PMC8099200.
      Citations:    Fields:    Translation:Humans
    853. Bakris GL, Mensah GA. Pathogenesis and clinical physiology of hypertension. Cardiol Clin. 2002 May; 20(2):195-206, v. PMID: 12119796.
      Citations: 3     Fields:    Translation:Humans
    854. Russo LM, Bakris GL, Comper WD, Russo LM, Bakris GL, Comper WD. Renal handling of albumin: a critical review of basic concepts and perspective. Am J Kidney Dis. 2002 May; 39(5):899-919. PMID: 11979334.
      Citations: 43     Fields:    Translation:HumansAnimals
    855. Bakris GL, Smith AC, Richardson DJ, Hung E, Preston R, Goldberg R, Epstein M. Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomised, multi-centre pilot study. J Hum Hypertens. 2002 Mar; 16(3):185-91. PMID: 11896508.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    856. Garg JP, Bakris GL. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med. 2002 Feb; 7(1):35-43. PMID: 12083733.
      Citations: 67     Fields:    Translation:HumansAnimals
    857. Hogan TJ, Elliott WJ, Seto AH, Bakris GL. Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics. 2002; 20(1):37-47. PMID: 11817991.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    858. Sica DA, Bakris GL, Sica DA, Bakris GL. Type 2 diabetes: RENAAL and IDNT--the emergence of new treatment options. J Clin Hypertens (Greenwich). 2002 Jan-Feb; 4(1):52-7. PMID: 11821641; PMCID: PMC8099376.
      Citations: 7     Fields:    Translation:Humans
    859. Abbott KC, Bakris GL, Abbott KC, Bakris GL. Treatment of the diabetic patient: focus on cardiovascular and renal risk reduction. Prog Brain Res. 2002; 139:289-98. PMID: 12436944.
      Citations: 10     Fields:    Translation:Humans
    860. Bakris G, Sica D, Ram V, Fagan T, Vaitkus PT, Anders RJ, Bakris G, Sica D, Ram V, Fagan T, Vaitkus PT, Anders RJ. A comparative trial of controlled-onset, extended-release verapamil, enalapril, and losartan on blood pressure and heart rate changes. Am J Hypertens. 2002 Jan; 15(1 Pt 1):53-7. PMID: 11824861.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    861. Bakris GL. A practical approach to achieving recommended blood pressure goals in diabetic patients. Arch Intern Med. 2001 Dec 10-24; 161(22):2661-7. PMID: 11732930.
      Citations: 28     Fields:    Translation:Humans
    862. Basta E, Bakris G. Choices and goals in the treatment of the diabetic hypertensive patient. Curr Hypertens Rep. 2001 Oct; 3(5):387-91. PMID: 11551372.
      Citations: 1     Fields:    Translation:Humans
    863. Bakris GL, Bakris GL. Angiotensin-converting enzyme inhibition to enhance vascular health--clinical and research models. Am J Hypertens. 2001 Aug; 14(8 Pt 2):264S-269S. PMID: 11497207.
      Citations: 5     Fields:    Translation:Humans
    864. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER, Norris K, O'Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT, Xu S, Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER, Norris K, O'Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT, Xu S, African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001 Jun 06; 285(21):2719-28. PMID: 11386927.
      Citations: 256     Fields:    Translation:HumansCTClinical Trials
    865. Griffin KA, Picken M, Bakris GL, Bidani AK. Comparative effects of selective T- and L-type calcium channel blockers in the remnant kidney model. Hypertension. 2001 May; 37(5):1268-72. PMID: 11358939.
      Citations: 18     Fields:    Translation:Animals
    866. Bakris GL. Microalbuminuria: what is it? Why is it important? What should be done about it? J Clin Hypertens (Greenwich). 2001 Mar-Apr; 3(2):99-102. PMID: 11416691; PMCID: PMC8101897.
      Citations: 9     Fields:    Translation:Humans
    867. Griffin KA, Picken MM, Bakris G, Bidani AK. Relative antihypertensive and glomeruloprotective efficacies of enalapril and candesartan cilexetil in the remnant kidney model. J Renin Angiotensin Aldosterone Syst. 2001 Mar; 2(1_suppl):S191-S195. PMID: 28095249.
      Citations: 1     Fields:    
    868. Bakris GL. Treatment of stage I hypertension and development of renal dysfunction. J Hum Hypertens. 2001 Feb; 15(2):81-4. PMID: 11317184.
      Citations:    Fields:    Translation:Humans
    869. Bakris G, Gradman A, Reif M, Wofford M, Munger M, Harris S, Vendetti J, Michelson EL, Wang R, CLAIM Study Investigators. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. J Clin Hypertens (Greenwich). 2001 Jan-Feb; 3(1):16-21. PMID: 11416677; PMCID: PMC8101876.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    870. Bakris GL, Siomos M, Richardson D, Janssen I, Bolton WK, Hebert L, Agarwal R, Catanzaro D. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int. 2000 Nov; 58(5):2084-92. PMID: 11044229.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    871. Vora JP, Ibrahim HA, Bakris GL. Responding to the challenge of diabetic nephropathy: the historic evolution of detection, prevention and management. J Hum Hypertens. 2000 Oct-Nov; 14(10-11):667-85. PMID: 11095158.
      Citations: 2     Fields:    Translation:HumansPHPublic Health
    872. Tarif N, Bakris G. The place for calcium channel blockers in the treatment of hypertension in patients with diabetes mellitus. Saudi J Kidney Dis Transpl. 2000 Oct-Dec; 11(4):531-6. PMID: 18209340.
      Citations:    Fields:    
    873. Odama U, Bakris G. Target Organ Damage in Hypertension. J Clin Hypertens (Greenwich). 2000 Oct; 2(5):312-318. PMID: 11416667.
      Citations: 2     Fields:    
    874. Basta E, Bakris GL. Evolution of drugs that preserve renal function. J Clin Pharmacol. 2000 Sep; 40(9):978-89. PMID: 10975069.
      Citations:    Fields:    Translation:Humans
    875. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000 Sep; 36(3):646-61. PMID: 10977801.
      Citations: 308     Fields:    Translation:Humans
    876. Bakris GL, Whelton P, Weir M, Mimran A, Keane W, Schiffrin E. The future of clinical trials in chronic renal disease: outcome of an NIH/FDA/Physician Specialist Conference. Evaluation of Clinical Trial Endpoints in Chronic Renal Disease Study Group. J Clin Pharmacol. 2000 Aug; 40(8):815-25. PMID: 10934665.
      Citations: 5     Fields:    Translation:Humans
    877. Bakris G. Oral antidiabetic agents safe with renal disease? Postgrad Med. 2000 Jun; 107(7):66. PMID: 10887446.
      Citations:    Fields:    Translation:Humans
    878. Koshy S, Bakris GL. Therapeutic approaches to achieve desired blood pressure goals: focus on calcium channel blockers. Cardiovasc Drugs Ther. 2000 Jun; 14(3):295-301. PMID: 10935151.
      Citations: 14     Fields:    Translation:Humans
    879. Bidani AK, Griffin KA, Bakris G, Picken MM. Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation. Kidney Int. 2000 Apr; 57(4):1651-61. PMID: 10760100.
      Citations: 22     Fields:    Translation:Animals
    880. Sowers JR, Williams M, Epstein M, Bakris G. Hypertension in patients with diabetes. Strategies for drug therapy to reduce complications. Postgrad Med. 2000 Apr; 107(4):47-54, 60. PMID: 10778410.
      Citations: 5     Fields:    Translation:Humans
    881. Sowers JR, Bakris GL. Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med. 2000 Mar 30; 342(13):969-70. PMID: 10738057.
      Citations: 30     Fields:    Translation:Humans
    882. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000 Mar 13; 160(5):685-93. PMID: 10724055.
      Citations: 169     Fields:    Translation:Humans
    883. Elliott WJ, Maddy R, Toto R, Bakris G. Hypertension in patients with diabetes. Overcoming barriers to effective control. Postgrad Med. 2000 Mar; 107(3):29-32, 35-6, 38. PMID: 10728133.
      Citations: 20     Fields:    Translation:Humans
    884. Weir MR, Maibach EW, Bakris GL, Black HR, Chawla P, Messerli FH, Neutel JM, Weber MA. Implications of a health lifestyle and medication analysis for improving hypertension control. Arch Intern Med. 2000 Feb 28; 160(4):481-90. PMID: 10695688.
      Citations: 23     Fields:    Translation:Humans
    885. Bakris G, Sowers J, Epstein M, Williams M. Hypertension in patients with diabetes. Why is aggressive treatment essential? Postgrad Med. 2000 Feb; 107(2):53-6, 61-4. PMID: 10689408.
      Citations: 1     Fields:    Translation:Humans
    886. Swan S, Elliott WJ, Bakris G. "Clinical pharmacology studies in patients with renal impairment: past experience and regulatory perspectives". J Clin Pharmacol. 2000 Jan; 40(1):7-10. PMID: 10631617.
      Citations:    Fields:    Translation:Humans
    887. Bakris GL. Maximizing Cardiorenal Benefit in the Management of Hypertension: Achieve Blood Pressure Goals. J Clin Hypertens (Greenwich). 1999 Oct; 1(2):141-147. PMID: 11416606.
      Citations: 12     Fields:    
    888. 35th Annual Meeting of the European Association for the Study of Diabetes : Brussels, Belgium, 28 September-2 October 1999. Diabetologia. 1999 Aug; 42(Suppl 1):A1-A330. PMID: 27770183.
      Citations: 9     Fields:    
    889. Sheinfeld GR, Bakris GL. Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients. Am J Hypertens. 1999 Aug; 12(8 Pt 2):80S-85S. PMID: 10478701.
      Citations: 3     Fields:    Translation:Humans
    890. Bakris GL, Lass NA, Glock D. Renal hemodynamics in radiocontrast medium-induced renal dysfunction: A role for dopamine-1 receptors. Kidney Int. 1999 Jul; 56(1):206-10. PMID: 10411694.
      Citations: 20     Fields:    Translation:Animals
    891. Bakris GL. When to discontinue ACE inhibitors for nephropathy. Postgrad Med. 1999 Jul; 106(1):29. PMID: 10418570.
      Citations:    Fields:    Translation:Humans
    892. Griffin KA, Picken MM, Bakris GL, Bidani AK. Class differences in the effects of calcium channel blockers in the rat remnant kidney model. Kidney Int. 1999 May; 55(5):1849-60. PMID: 10231447.
      Citations: 20     Fields:    Translation:Animals
    893. Bakris GL. Assessing kidneys that may be fragile. Postgrad Med. 1998 Nov; 104(5):31. PMID: 9823380.
      Citations:    Fields:    Translation:Humans
    894. Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. 1998 Oct; 54(4):1283-9. PMID: 9767545.
      Citations: 47     Fields:    Translation:HumansCTClinical Trials
    895. Bakris GL. The role of combination antihypertensive therapy and the progression of renal disease hypertension: looking toward the next millennium. Am J Hypertens. 1998 Oct; 11(10):158S-162S. PMID: 9799050.
      Citations: 5     Fields:    Translation:Humans
    896. Bakris GL. Risks for renal involvement in diabetes. Postgrad Med. 1998 Sep; 104(3):33. PMID: 9742900.
      Citations:    Fields:    Translation:Humans
    897. Smith AC, Toto R, Bakris GL. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int. 1998 Sep; 54(3):889-96. PMID: 9734613.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    898. Villarosa IP, Bakris GL. The Appropriate Blood Pressure Control in Diabetes (ABCD) Trial. J Hum Hypertens. 1998 Sep; 12(9):653-5. PMID: 9783501.
      Citations: 2     Fields:    Translation:Humans
    899. Bakris GL. Angiotensin II receptor blockers in hypertension and renal disease. Hosp Pract (1995). 1998 Apr 15; 33(4):19-22. PMID: 9562828.
      Citations: 1     Fields:    Translation:Humans
    900. Bakris GL. Progression of diabetic nephropathy. A focus on arterial pressure level and methods of reduction. Diabetes Res Clin Pract. 1998 Apr; 39 Suppl:S35-42. PMID: 9649958.
      Citations: 5     Fields:    Translation:Humans
    901. Makrilakis K, Bakris G. Diabetic hypertensive patients: improving their prognosis. J Cardiovasc Pharmacol. 1998; 31 Suppl 2:S34-40. PMID: 9605600.
      Citations:    Fields:    Translation:Humans
    902. Rabelink TJ, Bakris GL. The renin-angiotensin system in diabetic nephropathy: the endothelial connection. Miner Electrolyte Metab. 1998; 24(6):381-8. PMID: 9930377.
      Citations: 6     Fields:    Translation:HumansAnimals
    903. Tarif N, Bakris GL. Angiotensin II receptor blockade and progression of nondiabetic-mediated renal disease. Kidney Int Suppl. 1997 Dec; 63:S67-70. PMID: 9407425.
      Citations: 5     Fields:    Translation:HumansAnimals
    904. Tarif N, Bakris GL. Preservation of renal function: the spectrum of effects by calcium-channel blockers. Nephrol Dial Transplant. 1997 Nov; 12(11):2244-50. PMID: 9394306.
      Citations: 15     Fields:    Translation:HumansAnimals
    905. Mangrum A, Bakris GL. Predictors of renal and cardiovascular mortality in patients with non-insulin-dependent diabetes: a brief overview of microalbuminuria and insulin resistance. J Diabetes Complications. 1997 Nov-Dec; 11(6):352-7. PMID: 9365878.
      Citations: 2     Fields:    Translation:HumansAnimals
    906. Bakris GL, Griffin KA, Picken MM, Bidani AK. Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury. J Hypertens. 1997 Oct; 15(10):1181-5. PMID: 9350593.
      Citations: 6     Fields:    Translation:Animals
    907. Bakris GL, Kusmirek SL, Smith AC, Gavras I, Gavras H. Calcium antagonism abolishes the antipressor action of vasopressin (V1) receptor antagonism. Am J Hypertens. 1997 Oct; 10(10 Pt 1):1153-8. PMID: 9370387.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    908. Tarif N, Bakris GL. Renal components of the hypertensive syndrome. J Cardiovasc Risk. 1997 Aug; 4(4):271-7. PMID: 9477205.
      Citations: 1     Fields:    Translation:HumansAnimals
    909. Bakris G, Bursztyn M, Gavras I, Bresnahan M, Gavras H. Role of vasopressin in essential hypertension: racial differences. J Hypertens. 1997 May; 15(5):545-50. PMID: 9170008.
      Citations: 29     Fields:    Translation:Humans
    910. Silverman M, Bakris GL. Treatment of renal failure and blood pressure. Curr Opin Nephrol Hypertens. 1997 May; 6(3):237-42. PMID: 9263666.
      Citations:    Fields:    Translation:Humans
    911. Bakris GL, Mangrum A, Copley JB, Vicknair N, Sadler R. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension. 1997 Mar; 29(3):744-50. PMID: 9052890.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    912. Kilaru P, Bakris GL. Renal mortality associated with non-insulin-dependent diabetes mellitus. J Diabetes Complications. 1997 Mar-Apr; 11(2):104-11. PMID: 9101396.
      Citations:    Fields:    Translation:Humans
    913. Simeon G, Bakris GL. Socioeconomic impact of diabetic nephropathy: can we improve the outcome? J Hypertens Suppl. 1997 Mar; 15(2):S77-82. PMID: 9218203.
      Citations: 2     Fields:    Translation:Humans
    914. Bakris G, White D. Effects of an ACE inhibitor combined with a calcium channel blocker on progression of diabetic nephropathy. J Hum Hypertens. 1997 Jan; 11(1):35-8. PMID: 9111155.
      Citations: 2     Fields:    Translation:HumansAnimals
    915. Bakris GL, Messerli FH. The Lanai Symposium: hypertensive patient profiles: approaches to management and disease prevention. J Hum Hypertens. 1997 Jan; 11(1):7-8. PMID: 9111150.
      Citations:    Fields:    Translation:Humans
    916. Bakris GL. Is the level of arterial pressure reduction important for preservation of renal function. Nephrol Dial Transplant. 1996 Dec; 11(12):2383-4. PMID: 9017605.
      Citations:    Fields:    Translation:HumansAnimals
    917. Bakris GL, Weir MR. Salt intake and reductions in arterial pressure and proteinuria. Is there a direct link? Am J Hypertens. 1996 Dec; 9(12 Pt 2):200S-206S. PMID: 8968435.
      Citations: 6     Fields:    Translation:Humans
    918. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996 Nov; 50(5):1641-50. PMID: 8914031.
      Citations: 64     Fields:    Translation:HumansCTClinical Trials
    919. Bakris GL, Weir MR, Sowers JR. Therapeutic challenges in the obese diabetic patient with hypertension. Am J Med. 1996 Sep 30; 101(3A):33S-46S. PMID: 8876473.
      Citations: 5     Fields:    Translation:Humans
    920. Epstein M, Bakris G. Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Arch Intern Med. 1996 Sep 23; 156(17):1969-78. PMID: 8823150.
      Citations: 32     Fields:    Translation:Humans
    921. Bakris GL, Smith A. Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. Ann Intern Med. 1996 Aug 01; 125(3):201-4. PMID: 8686978.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    922. Cziraky MJ, Mehra IV, Wilson MD, Bakris GL. Current issues in treating the hypertensive patient with diabetes: focus on diabetic nephropathy. Ann Pharmacother. 1996 Jul-Aug; 30(7-8):791-801. PMID: 8826564.
      Citations: 2     Fields:    Translation:Humans
    923. Bakris GL. Microalbuminuria: prognostic implications. Curr Opin Nephrol Hypertens. 1996 May; 5(3):219-23. PMID: 8737856.
      Citations: 14     Fields:    Translation:Humans
    924. Abbott K, Smith A, Bakris GL. Effects of dihydropyridine calcium antagonists on albuminuria in patients with diabetes. J Clin Pharmacol. 1996 Mar; 36(3):274-9. PMID: 8690823.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    925. Lash JP, Bakris GL. Effects of ACE inhibitors and calcium antagonists alone or combined on progression of diabetic nephropathy. Nephrol Dial Transplant. 1995 Oct; 10 Suppl 9:56-62. PMID: 8643210.
      Citations: 1     Fields:    Translation:HumansAnimals
    926. Bakris GL, Williams B. Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ? J Hypertens Suppl. 1995 Aug; 13(2):S95-101. PMID: 8576797.
      Citations: 4     Fields:    Translation:HumansAnimals
    927. Bakris GL, Starke U, Heifets M, Polack D, Smith M, Leurgans S. Renal effects of oral prostaglandin supplementation after ibuprofen in diabetic subjects: a double-blind, placebo-controlled, multicenter trial. J Am Soc Nephrol. 1995 Mar; 5(9):1684-8. PMID: 7780057.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    928. Hoelscher DD, Weir MR, Bakris GL. Hypertension in diabetic patients: an update of interventional studies to preserve renal function. J Clin Pharmacol. 1995 Jan; 35(1):73-80. PMID: 7751415.
      Citations: 3     Fields:    Translation:HumansAnimals
    929. Kilaru P, Bakris GL. Microalbuminuria and progressive renal disease. J Hum Hypertens. 1994 Nov; 8(11):809-17. PMID: 7853323.
      Citations: 3     Fields:    Translation:Humans
    930. Gaber L, Walton C, Brown S, Bakris G. Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. Kidney Int. 1994 Jul; 46(1):161-9. PMID: 7933834.
      Citations: 13     Fields:    Translation:Animals
    931. Bakris GL, Bhandaru S, Akerstrom V, Re RN. ACE inhibitor-mediated attenuation of mesangial cell growth. A role for endothelin. Am J Hypertens. 1994 Jul; 7(7 Pt 1):583-90. PMID: 7946158.
      Citations: 2     Fields:    Translation:Humans
    932. Riley DJ, Weir M, Bakris GL. Renal adaptation to the failing heart. Avoiding a 'therapeutic misadventure'. Postgrad Med. 1994 Jun; 95(8):153-6. PMID: 8202420.
      Citations: 1     Fields:    Translation:Humans
    933. Riley DJ, Weir M, Bakris GL. Renal adaptation to the failing heart. Understanding the cascade of responses. Postgrad Med. 1994 Jun; 95(8):141-6, 149-50. PMID: 8202419.
      Citations:    Fields:    Translation:Humans
    934. Riley DJ, Weir M, Bakris GL. Renal adaptation to the failing heart. Postgrad Med. 1994 Jun; 95(8):141-150. PMID: 29211605.
      Citations:    Fields:    
    935. Riley DJ, Weir M, Bakris GL. Renal adaptation to the failing heart. Postgrad Med. 1994 Jun; 95(8):153-156. PMID: 29211606.
      Citations:    Fields:    
    936. Abbott KC, Sanders LR, Bakris GL. Microalbuminuria in non-insulin-dependent diabetes mellitus. Implications for renal survival. Arch Intern Med. 1994 Jan 24; 154(2):146-53. PMID: 8285809.
      Citations: 1     Fields:    Translation:Humans
    937. Bakris GL, Slataper R, Vicknair N, Sadler R. ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects. J Diabetes Complications. 1994 Jan-Mar; 8(1):2-6. PMID: 8167383.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    938. Hoelscher D, Bakris G. Antihypertensive therapy and progression of diabetic renal disease. J Cardiovasc Pharmacol. 1994; 23 Suppl 1:S34-8. PMID: 7519695.
      Citations: 3     Fields:    Translation:HumansAnimals
    939. Bakris GL, Talbert R. Drug dosing in patients with renal insufficiency. A simplified approach. Postgrad Med. 1993 Dec; 94(8):153-6, 159-60, 163-4. PMID: 8247992.
      Citations: 1     Fields:    Translation:Humans
    940. Bakris GL, Talbert R. Drug dosing in patients with renal insufficiency. Postgrad Med. 1993 Dec; 94(8):153-164. PMID: 29206546.
      Citations:    Fields:    
    941. Bakris G. Severe hypertension in a young patient. Hosp Pract (Off Ed). 1993 Oct 15; 28(10):57-64. PMID: 8408342.
      Citations:    Fields:    Translation:Humans
    942. Bakris GL, Stein JH. Diabetic nephropathy. Dis Mon. 1993 Aug; 39(8):573-611. PMID: 8334915.
      Citations: 1     Fields:    Translation:HumansAnimals
    943. Bakris GL, Re RN. Endothelin modulates angiotensin II-induced mitogenesis of human mesangial cells. Am J Physiol. 1993 Jun; 264(6 Pt 2):F937-42. PMID: 8322895.
      Citations: 7     Fields:    Translation:HumansCells
    944. Brown SA, Walton CL, Crawford P, Bakris GL. Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int. 1993 Jun; 43(6):1210-8. PMID: 8391095.
      Citations: 17     Fields:    Translation:Animals
    945. Abbott KC, Bakris G. Renal effects of antihypertensive medications: an overview. J Clin Pharmacol. 1993 May; 33(5):392-9. PMID: 8101193.
      Citations: 1     Fields:    Translation:Humans
    946. Slataper R, Vicknair N, Sadler R, Bakris GL. Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med. 1993 Apr 26; 153(8):973-80. PMID: 8386921.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    947. Bakris GL. Angiotensin-converting enzyme inhibitors and progression of diabetic nephropathy. Ann Intern Med. 1993 Apr 15; 118(8):643-4. PMID: 8452332.
      Citations: 5     Fields:    Translation:HumansAnimals
    948. Bakris GL. Hypertension in diabetic patients. An overview of interventional studies to preserve renal function. Am J Hypertens. 1993 Apr; 6(4):140S-147S. PMID: 8507441.
      Citations: 2     Fields:    Translation:HumansAnimals
    949. Bakris GL. Diabetic nephropathy. What you need to know to preserve kidney function. Postgrad Med. 1993 Apr; 93(5):89-90, 93-5, 99-100. PMID: 8460086.
      Citations:    Fields:    Translation:Humans
    950. Kantor GR, Lobl JK, Bakris GL. The Medical Bookshelf. Postgrad Med. 1993 Jan; 93(1):14. PMID: 27192334.
      Citations:    Fields:    
    951. Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int. 1992 Apr; 41(4):912-9. PMID: 1325010.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    952. Weir MR, Bakris GL. Risk for renal injury in diabetic hypertensive patients. The physiologic basis for blood pressure control. Postgrad Med. 1992 Feb 15; 91(3):77-80, 83-4. PMID: 1741368.
      Citations:    Fields:    Translation:Humans
    953. Weir MR, Bakris GL. Risk for renal injury in diabetic hypertensive patients. Pharmacologic approaches. Postgrad Med. 1992 Feb 15; 91(3):87-91, 94-5. PMID: 1741369.
      Citations:    Fields:    Translation:Humans
    954. Cook JL, Chen L, Bhandaru S, Bakris GL, Re RN. The use of antisense oligonucleotides to establish autocrine angiotensin growth effects in human neuroblastoma and mesangial cells. Antisense Res Dev. 1992; 2(3):199-210. PMID: 1490071.
      Citations: 1     Fields:    Translation:HumansCells
    955. Valentino VA, Wilson MD, Weart W, Bakris GL. A perspective on converting enzyme inhibitors and calcium channel antagonists in diabetic renal disease. Arch Intern Med. 1991 Dec; 151(12):2367-72. PMID: 1746992.
      Citations: 2     Fields:    Translation:HumansAnimals
    956. Bakris GL. The effects of calcium antagonists on renal hemodynamics, urinary protein excretion, and glomerular morphology in diabetic states. J Am Soc Nephrol. 1991 Aug; 2(2 Suppl 1):S21-9. PMID: 1932640.
      Citations:    Fields:    Translation:HumansAnimals
    957. Bakris GL. Renal effects of calcium antagonists in diabetes mellitus. An overview of studies in animal models and in humans. Am J Hypertens. 1991 Jul; 4(7 Pt 2):487S-493S. PMID: 1910642.
      Citations: 2     Fields:    Translation:HumansAnimals
    958. Karp S, Bakris G, Cooney A, Rubenstein D, Hou SH. Exfoliative dermatitis secondary to tobramycin sulfate. Cutis. 1991 May; 47(5):331-2. PMID: 1829999.
      Citations: 1     Fields:    Translation:Humans
    959. Bakris GL, Fairbanks R, Traish AM. Arginine vasopressin stimulates human mesangial cell production of endothelin. J Clin Invest. 1991 Apr; 87(4):1158-64. PMID: 2010532; PMCID: PMC295123.
      Citations: 6     Fields:    Translation:HumansCells
    960. Demarie BK, Bakris GL. Effects of different calcium antagonists on proteinuria associated with diabetes mellitus. Ann Intern Med. 1990 Dec 15; 113(12):987-8. PMID: 2240922.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    961. Bakris GL, Sauter ER, Hussey JL, Fisher JW, Gaber AO, Winsett R. Effects of theophylline on erythropoietin production in normal subjects and in patients with erythrocytosis after renal transplantation. N Engl J Med. 1990 Jul 12; 323(2):86-90. PMID: 2163024.
      Citations: 18     Fields:    Translation:Humans
    962. Bakris GL. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med. 1990 May 01; 112(9):707-8. PMID: 2159250.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    963. Porile JL, Bakris GL, Garella S. Acute interstitial nephritis with glomerulopathy due to nonsteroidal anti-inflammatory agents: a review of its clinical spectrum and effects of steroid therapy. J Clin Pharmacol. 1990 May; 30(5):468-75. PMID: 2189904.
      Citations: 11     Fields:    Translation:Humans
    964. Bakris GL, Gaber AO, Jones JD. Oxygen free radical involvement in urinary Tamm-Horsfall protein excretion after intrarenal injection of contrast medium. Radiology. 1990 Apr; 175(1):57-60. PMID: 2315505.
      Citations: 10     Fields:    Translation:Animals
    965. Sauter ER, Bakris GL. The effects of enalapril on urinary protein excretion in patients with idiopathic membranous nephropathy. J Clin Pharmacol. 1990 Feb; 30(2):155-8. PMID: 2312767.
      Citations:    Fields:    Translation:Humans
    966. Bakris GL, Lass N, Gaber AO, Jones JD, Burnett JC. Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol. 1990 Jan; 258(1 Pt 2):F115-20. PMID: 2301588.
      Citations: 64     Fields:    Translation:Animals
    967. Bakris GL, Frohlich ED. The evolution of antihypertensive therapy: an overview of four decades of experience. J Am Coll Cardiol. 1989 Dec; 14(7):1595-608. PMID: 2685075.
      Citations: 1     Fields:    Translation:Humans
    968. Bakris GL, Kern SR. Renal dysfunction resulting from NSAIDs. Am Fam Physician. 1989 Oct; 40(4):199-204. PMID: 2679011.
      Citations: 1     Fields:    Translation:Humans
    969. Bakris GL, Weber RR, Nelson K, Elliott WJ, Kaplan E, Murphy MB. Comparison of the effects of dopamine and fenoldopam, a selective dopamine-1 agonist, on parathyroid hormone release in man. Miner Electrolyte Metab. 1988; 14(6):343-6. PMID: 2906737.
      Citations: 1     Fields:    Translation:Humans
    970. Arend LJ, Bakris GL, Burnett JC, Megerian C, Spielman WS. Role for intrarenal adenosine in the renal hemodynamic response to contrast media. J Lab Clin Med. 1987 Oct; 110(4):406-11. PMID: 3655519.
      Citations: 24     Fields:    Translation:Animals
    971. Bakris GL, Wilson DM, Burnett JC. The renal, forearm, and hormonal responses to standing in the presence and absence of propranolol. Circulation. 1986 Nov; 74(5):1061-5. PMID: 3533311.
      Citations: 2     Fields:    Translation:Humans
    972. Bakris GL, Burnett JC. A role for calcium in radiocontrast-induced reductions in renal hemodynamics. Kidney Int. 1985 Feb; 27(2):465-8. PMID: 2581011.
      Citations: 15     Fields:    Translation:Animals
    973. Zorumski CF, Bakris GL. Choreoathetosis associated with lithium: case report and literature review. Am J Psychiatry. 1983 Dec; 140(12):1621-2. PMID: 6418012.
      Citations: 2     Fields:    Translation:Humans
    974. Bakris GL, Mulopulos GP, Korchik R, Ezdinli EZ, Ro J, Yoon BH. Pulmonary scar carcinoma. A clinicopathologic analysis. Cancer. 1983 Aug 01; 52(3):493-7. PMID: 6305476.
      Citations: 4     Fields:    Translation:HumansPHPublic Health
    975. Bakris GL, Zorumski CF. Chronic pain. A pharmacologic review and behavior modification approach. Postgrad Med. 1983 May; 73(5):119-23, 126, 128. PMID: 6133270.
      Citations:    Fields:    Translation:Humans
    976. Bakris GL, Cross PD, Hammarsten JE. Disopyramide-associated liver dysfunction. Mayo Clin Proc. 1983 Apr; 58(4):265-7. PMID: 6834895.
      Citations: 5     Fields:    Translation:Humans
    977. Petruccelli B, Bakris G, Miller T, Korpi ER, Linnoila M. A liquid chromatographic assay for 5-hydroxytryptophan, serotonin and 5-hydroxyindoleacetic acid in human body fluids. Acta Pharmacol Toxicol (Copenh). 1982 Nov; 51(5):421-7. PMID: 6187183.
      Citations: 1     Fields:    Translation:HumansAnimals
    978. Bakris GL, Cross PD, Hammarsten JE. The use of clonidine for management of opiate abstinence in a chronic pain patient. Mayo Clin Proc. 1982 Oct; 57(10):657-60. PMID: 7121072.
      Citations: 2     Fields:    Translation:Humans
    979. Bakris GL. Clonidine for opiate withdrawal in the chronic pain patient. Postgrad Med. 1982 Mar; 71(3):240-1. PMID: 6276875.
      Citations:    Fields:    Translation:Humans
    980. Bakris GL, Mulopulos GP, Tiwari S, Franklin C. An effective alternative for muscle contraction headaches. Orphenadrine citrate. IMJ Ill Med J. 1982 Feb; 161(2):106-8. PMID: 6122668.
      Citations:    Fields:    Translation:Humans
    981. Tiwari S, Bakris GL. Psychogenic vertigo: a review. Postgrad Med. 1981 Nov; 70(5):69-71, 74, 77. PMID: 7301664.
      Citations:    Fields:    Translation:Humans
    982. Bakris GL, Taylor MA, Mulopulos GP, Wawczk S. Lithium prophylaxis and the kidney. J Affect Disord. 1981 Mar; 3(1):37-42. PMID: 6455457.
      Citations:    Fields:    Translation:Humans
    983. Bakris GL, Smith DW, Tiwari S. Dermatologic manifestations of lithium: a review. Int J Psychiatry Med. 1980-1981; 10(4):327-31. PMID: 6451593.
      Citations: 1     Fields:    Translation:Humans
    Bakris's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (1006)
    Explore
    _
    Co-Authors (30)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _